tag:blogger.com,1999:blog-19520630084516836302024-02-20T11:36:34.085+01:00De genéticaBlog de Medicamentos de terapias avanzadas (MTA): de medicamentos de terapias génicas y de medicamentos de terapias celulares somáticas autorizadas por la EMA y la FDA, principalmente.
JOSE Rhttp://www.blogger.com/profile/09318104344786439010noreply@blogger.comBlogger123125tag:blogger.com,1999:blog-1952063008451683630.post-75414643256508219072020-07-05T16:33:00.007+02:002020-07-09T21:18:35.433+02:00¿Como seguir la pandemia de COVID-19?<div>9/7/20</div><div><br /></div><div><a href="https://cnecovid.isciii.es/covid19/">El Panel COVID19 del Centro Nacional de Epidemiología del Instituto Carlos III</a> también es una fuente importante para segur la pandemia en España con desagregación de datos a nivel de provincia.</div><div><br /></div><div><br /></div><div>5/7/20</div><!--[if gte mso 9]><xml>
<o:OfficeDocumentSettings>
<o:AllowPNG/>
</o:OfficeDocumentSettings>
</xml><![endif]-->
<p class="MsoNormal">Por si algún visitante no sabe dónde seguir la evolución de
la pandemia de COVID-19 - que está asolando a practicamente todo el planeta - diré que vengo visitando habitualmente un dashboard que está
en la web de la OMS (<a href="http://covid19.who.int/">http://covid19.who.int/</a>)</p><p class="MsoNormal">También sigo otro <a href="https://qap.ecdc.europa.eu/public/extensions/COVID-19/COVID-19.html">dashboard del ECDC</a>, que es la mejor fuente a nivel de países, que he encontrado.</p><p class="MsoNormal">Sobre vacunas: <a href="https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines"> Draft landscape of COVID-19 candidate vaccines</a>. Normalmente los martes se actualiza, ya hay 18 candidatos y seguimos con las cuatro españolas en fases preclínicas.</p>
<p class="MsoNormal">Fuentes de determinados Países:</p><p class="MsoNormal"></p><ul style="text-align: left;"><li> España, <a href="https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/situacionActual.htm">CENTRO DE COORDINACIÓN DE ALERTAS Y EMERGENCIAS SANITARIAS (CCAES)</a>, echo de menos datos municipales. Los gallegos solo dan datos a nivel de CCAA. Ya he dicho <a href="https://degenetica.blogspot.com/2020/05/diferentes-estrategias-informativas-de.html">mi opinión sobre este particular</a>.</li><li>Korea del Sur, el <a href="https://www.cdc.go.kr/board/board.es?mid=a30402000000&bid=0030"> Korean CDC</a></li><li>Alemania: El<a href="https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Gesamt.html"> Robert Koch Institute</a></li></ul><p></p><p class="MsoNormal"><br /></p><p class="MsoNormal"><br /></p><div class="separator" style="clear: both; text-align: center;"><br /><br /></div>JOSE Rhttp://www.blogger.com/profile/09318104344786439010noreply@blogger.com0tag:blogger.com,1999:blog-1952063008451683630.post-74551331105241568012020-06-28T14:38:00.034+02:002020-06-28T22:43:24.675+02:00Datos de casos, casos por 100.000 h, fallecidos y fallecidos por en 100.000h por COVID-19 en municipios de la provincia de Castellón<div><br /></div><div><br /></div><div><br /></div><div>En 71 municipios de la provincia de Castellón ha habido algún caso de COVID-19 según los datos publicados por la Consellería de Sanitat Universal i Salut Pública en <a href="http://coronavirus.san.gva.es/estadisticas?fbclid=IwAR1IXVAgP_Fqd0iEU8gTfw4ChtDBgtrNwx3OTGLNQII-ff6HETliu6kr0UU">este enlace</a> con datos hasta el día 26 de junio de 2020</div><div><br /></div><div>
Se presenta en esta tabla: los municipios, su número de casos, su tasa de casos por 100.000h, su número de fallecidos y su tasa de fallecidos por 100.000 habitantes.</div><div><br /></div><div><br /><table border="0" cellpadding="0" cellspacing="0" id="myTable" style="border-collapse: collapse; width: 695px;">
<colgroup>
<col style="width: 133pt;" width="100"></col>
<col style="width: 60pt;" width="80"></col>
<col style="width: 58pt;" width="77"></col>
<col style="width: 60pt;" width="80"></col>
<col style="width: 60pt;" width="80"></col>
</colgroup>
<tbody>
<tr>
<th onclick="sortTable(0)">Municipio</th>
<th onclick="sortTable(1)"> Casos</th>
<th onclick="sortTable(2)">Casos por 100.000h </th>
<th onclick="sortTable(3)">Fallecidos</th>
<th onclick="sortTable(4)">Fallecidos por 100.000h</th>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt; width: 60pt;" width="80">
Castellón
de la Plana</td>
<td class="xl64" style="width: 60pt;" width="80">428</td>
<td class="xl63" style="width: 60pt;" width="80">249</td>
<td class="xl64" style="width: 60pt;" width="80">49</td>
<td class="xl63" style="width: 60pt;" width="80">29</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Borriana</td>
<td class="xl64">294</td>
<td class="xl63">848</td>
<td class="xl64">40</td>
<td class="xl63">115</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Vila-real</td>
<td class="xl64">220</td>
<td class="xl63">432</td>
<td class="xl64">44</td>
<td class="xl63">86</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Villahermosa del Río</td>
<td class="xl64">55</td>
<td class="xl63">11.247</td>
<td class="xl64">14</td>
<td class="xl63">2.863</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Onda</td>
<td class="xl64">54</td>
<td class="xl63">217</td>
<td class="xl64">3</td>
<td class="xl63">12</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Almassora</td>
<td class="xl64">52</td>
<td class="xl63">198</td>
<td class="xl64">3</td>
<td class="xl63">11</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">La Vall d'Uixó</td>
<td class="xl64">51</td>
<td class="xl63">161</td>
<td class="xl64">4</td>
<td class="xl63">13</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Morella</td>
<td class="xl64">50</td>
<td class="xl63">2.058</td>
<td class="xl64">23</td>
<td class="xl63">947</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Segorbe</td>
<td class="xl64">49</td>
<td class="xl63">546</td>
<td class="xl64">6</td>
<td class="xl63">67</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Benicasim</td>
<td class="xl64">40</td>
<td class="xl63">220</td>
<td class="xl64">5</td>
<td class="xl63">27</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Vinaròs</td>
<td class="xl64">37</td>
<td class="xl63">129</td>
<td class="xl64">1</td>
<td class="xl63">3</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Benicarló</td>
<td class="xl64">29</td>
<td class="xl63">108</td>
<td class="xl64">3</td>
<td class="xl63">11</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Montán</td>
<td class="xl64">22</td>
<td class="xl63">5.946</td>
<td class="xl64">5</td>
<td class="xl63">1.351</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Nules</td>
<td class="xl64">21</td>
<td class="xl63">160</td>
<td class="xl64">1</td>
<td class="xl63">8</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Almenara</td>
<td class="xl64">17</td>
<td class="xl63">283</td>
<td class="xl64">3</td>
<td class="xl63">50</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Oropesa del Mar</td>
<td class="xl64">13</td>
<td class="xl63">143</td>
<td class="xl64">4</td>
<td class="xl63">44</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Alcalà de Xivert</td>
<td class="xl64">12</td>
<td class="xl63">180</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">L´Alcora</td>
<td class="xl64">11</td>
<td class="xl63">106</td>
<td class="xl64">1</td>
<td class="xl63">10</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Moncofa</td>
<td class="xl64">10</td>
<td class="xl63">153</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Les Alqueries</td>
<td class="xl64">9</td>
<td class="xl63">202</td>
<td class="xl64">1</td>
<td class="xl63">22</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">La Vilavella</td>
<td class="xl64">7</td>
<td class="xl63">222</td>
<td class="xl64">1</td>
<td class="xl63">32</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Betxí</td>
<td class="xl64">7</td>
<td class="xl63">124</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Artana</td>
<td class="xl64">6</td>
<td class="xl63">308</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Peníscola</td>
<td class="xl64">6</td>
<td class="xl63">79</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Rossell</td>
<td class="xl64">5</td>
<td class="xl63">534</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Sant Mateu</td>
<td class="xl64">5</td>
<td class="xl63">255</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Cabanes</td>
<td class="xl64">5</td>
<td class="xl63">169</td>
<td class="xl64">2</td>
<td class="xl63">68</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Altura</td>
<td class="xl64">5</td>
<td class="xl63">142</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Barracas</td>
<td class="xl64">4</td>
<td class="xl63">2.469</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">La Llosa</td>
<td class="xl64">4</td>
<td class="xl63">421</td>
<td class="xl64">3</td>
<td class="xl63">315</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Vilafamés</td>
<td class="xl64">4</td>
<td class="xl63">217</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Alcudia de Veo</td>
<td class="xl64">3</td>
<td class="xl63">1.579</td>
<td class="xl64">1</td>
<td class="xl63">526</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Portell de Morella</td>
<td class="xl64">3</td>
<td class="xl63">1.523</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Costur</td>
<td class="xl64">3</td>
<td class="xl63">573</td>
<td class="xl64">1</td>
<td class="xl63">191</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Geldo</td>
<td class="xl64">3</td>
<td class="xl63">472</td>
<td class="xl64">1</td>
<td class="xl63">157</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Xert</td>
<td class="xl64">3</td>
<td class="xl63">428</td>
<td class="xl64">1</td>
<td class="xl63">143</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Navajas</td>
<td class="xl64">3</td>
<td class="xl63">419</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Albocàsser</td>
<td class="xl64">3</td>
<td class="xl63">242</td>
<td class="xl64">1</td>
<td class="xl63">81</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Soneja</td>
<td class="xl64">3</td>
<td class="xl63">207</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Càlig</td>
<td class="xl64">3</td>
<td class="xl63">154</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Xilxes</td>
<td class="xl64">3</td>
<td class="xl63">112</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Torreblanca</td>
<td class="xl64">3</td>
<td class="xl63">54</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Cinctorres</td>
<td class="xl64">2</td>
<td class="xl63">512</td>
<td class="xl64">1</td>
<td class="xl63">256</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">San Rafael del Río</td>
<td class="xl64">2</td>
<td class="xl63">426</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Alfondeguilla</td>
<td class="xl64">2</td>
<td class="xl63">231</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Castellnovo</td>
<td class="xl64">2</td>
<td class="xl63">218</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Ribesalbes</td>
<td class="xl64">2</td>
<td class="xl63">170</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">La Pobla Tornesa</td>
<td class="xl64">2</td>
<td class="xl63">165</td>
<td class="xl64">2</td>
<td class="xl63">165</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Viver</td>
<td class="xl64">2</td>
<td class="xl63">130</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Borriol</td>
<td class="xl64">2</td>
<td class="xl63">37</td>
<td class="xl64">1</td>
<td class="xl63">19</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Villamalur</td>
<td class="xl64">1</td>
<td class="xl63">1.613</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Toga</td>
<td class="xl64">1</td>
<td class="xl63">1.000</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Todolella</td>
<td class="xl64">1</td>
<td class="xl63">645</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Gaibiel</td>
<td class="xl64">1</td>
<td class="xl63">532</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Cirat</td>
<td class="xl64">1</td>
<td class="xl63">498</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Vall de Almonacid</td>
<td class="xl64">1</td>
<td class="xl63">372</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Azuébar</td>
<td class="xl64">1</td>
<td class="xl63">317</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Tírig</td>
<td class="xl64">1</td>
<td class="xl63">239</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Figueroles</td>
<td class="xl64">1</td>
<td class="xl63">191</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Sueras/Suera</td>
<td class="xl64">1</td>
<td class="xl63">190</td>
<td class="xl64">1</td>
<td class="xl63">190</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Cervera del Maestre</td>
<td class="xl64">1</td>
<td class="xl63">174</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Vilanova d'Alcolea</td>
<td class="xl64">1</td>
<td class="xl63">171</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">La Jana</td>
<td class="xl64">1</td>
<td class="xl63">148</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">La Salzadella</td>
<td class="xl64">1</td>
<td class="xl63">142</td>
<td class="xl64">1</td>
<td class="xl63">142</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Santa Magdalena de Pulpis</td>
<td class="xl64">1</td>
<td class="xl63">130</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Tales</td>
<td class="xl64">1</td>
<td class="xl63">121</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Sierra Engarcerán</td>
<td class="xl64">1</td>
<td class="xl63">102</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Llucena/Lucena del Cid </td>
<td class="xl64">1</td>
<td class="xl63">77</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Jérica</td>
<td class="xl64">1</td>
<td class="xl63">65</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Vall d'Alba</td>
<td class="xl64">1</td>
<td class="xl63">36</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl64" height="20" style="height: 15.0pt;">Sant Joan de Moró</td>
<td class="xl64">1</td>
<td class="xl63">32</td>
<td class="xl64">0</td>
<td class="xl63">0</td>
</tr></tbody></table></div><div><br /></div><div>Los abultados números de las tasas de casos y de fallecimientos de Villahermosa, Montán y Morella se deben a brotes en residencias de tercera edad.</div>
<script>
function sortTable(n) {
var table, rows, switching, i, x, y, shouldSwitch, dir, switchcount = 0;
table = document.getElementById("myTable");
switching = true;
// Set the sorting direction to ascending:
dir = "asc";
/* Make a loop that will continue until
no switching has been done: */
while (switching) {
// Start by saying: no switching is done:
switching = false;
rows = table.rows;
/* Loop through all table rows (except the
first, which contains table headers): */
for (i = 1; i < (rows.length - 1); i++) {
// Start by saying there should be no switching:
shouldSwitch = false;
/* Get the two elements you want to compare,
one from current row and one from the next: */
x = rows[i].getElementsByTagName("TD")[n];
y = rows[i + 1].getElementsByTagName("TD")[n];
/* Check if the two rows should switch place,
based on the direction, asc or desc: */
if (dir == "asc") {
if (x.innerHTML.toLowerCase() > y.innerHTML.toLowerCase()) {
// If so, mark as a switch and break the loop:
shouldSwitch = true;
break;
}
} else if (dir == "desc") {
if (x.innerHTML.toLowerCase() < y.innerHTML.toLowerCase()) {
// If so, mark as a switch and break the loop:
shouldSwitch = true;
break;
}
}
}
if (shouldSwitch) {
/* If a switch has been marked, make the switch
and mark that a switch has been done: */
rows[i].parentNode.insertBefore(rows[i + 1], rows[i]);
switching = true;
// Each time a switch is done, increase this count by 1:
switchcount ++;
} else {
/* If no switching has been done AND the direction is "asc",
set the direction to "desc" and run the while loop again. */
if (switchcount == 0 && dir == "asc") {
dir = "desc";
switching = true;
}
}
}
}
</script>
JOSE Rhttp://www.blogger.com/profile/09318104344786439010noreply@blogger.com0tag:blogger.com,1999:blog-1952063008451683630.post-5787088197382622472020-05-21T21:36:00.001+02:002020-05-21T21:36:41.768+02:00Tasas de incidencia en los estados miembros de la UE a día 19 de mayo de 2020<div><br /></div>Tasas de incidencia por 100.000 habitantes a día 19/5/20 en los estados miembros de la UE. Nos dice donde estamos y nos compara con los otros. Datos obtenidos en la web de ECDC ( casos por día y país y calculadas las tasas a partir de la población también dada).<div><br /></div><div><div><br /></div><div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; text-align: center; width: 365px;">
<colgroup><col style="width: 173pt;" width="230"></col>
<col style="width: 101pt;" width="135"></col>
</colgroup><tbody><tr height="20" style="height: 15pt;">
<td height="20" style="height: 15pt; width: 173pt;" width="230">Países</td>
<td class="xl63" style="width: 101pt;" width="135">tasa por 100.000h </td>
</tr>
<tr height="20" style="height: 15pt;">
<td height="20" style="height: 15pt;">Luxembourg</td>
<td class="xl64">649,47</td>
</tr>
<tr height="20" style="height: 15pt;">
<td height="20" style="height: 15pt;">Ireland</td>
<td class="xl64">498,61</td>
</tr>
<tr height="20" style="height: 15pt;">
<td height="20" style="height: 15pt;">Spain</td>
<td class="xl64">497,03</td>
</tr>
<tr height="20" style="height: 15pt;">
<td height="20" style="height: 15pt;">Belgium</td>
<td class="xl64">486,42</td>
</tr>
<tr height="20" style="height: 15pt;">
<td height="20" style="height: 15pt;">Italy</td>
<td class="xl64">373,79</td>
</tr>
<tr height="20" style="height: 15pt;">
<td height="20" style="height: 15pt;">United_Kingdom</td>
<td class="xl64">370,60</td>
</tr>
<tr height="20" style="height: 15pt;">
<td height="20" style="height: 15pt;">Sweden</td>
<td class="xl64">298,31</td>
</tr>
<tr height="20" style="height: 15pt;">
<td height="20" style="height: 15pt;">Portugal</td>
<td class="xl64">284,09</td>
</tr>
<tr height="20" style="height: 15pt;">
<td height="20" style="height: 15pt;">Netherlands</td>
<td class="xl64">256,17</td>
</tr>
<tr height="20" style="height: 15pt;">
<td height="20" style="height: 15pt;">France</td>
<td class="xl64">213,33</td>
</tr>
<tr height="20" style="height: 15pt;">
<td height="20" style="height: 15pt;">Germany</td>
<td class="xl64">211,28</td>
</tr>
<tr height="20" style="height: 15pt;">
<td height="20" style="height: 15pt;">Denmark</td>
<td class="xl64">189,19</td>
</tr>
<tr height="20" style="height: 15pt;">
<td height="20" style="height: 15pt;">Austria</td>
<td class="xl64">182,87</td>
</tr>
<tr height="20" style="height: 15pt;">
<td height="20" style="height: 15pt;">Estonia</td>
<td class="xl64">135,06</td>
</tr>
<tr height="20" style="height: 15pt;">
<td height="20" style="height: 15pt;">Finland</td>
<td class="xl64">115,62</td>
</tr>
<tr height="20" style="height: 15pt;">
<td height="20" style="height: 15pt;">Malta</td>
<td class="xl64">115,40</td>
</tr>
<tr height="20" style="height: 15pt;">
<td height="20" style="height: 15pt;">Romania</td>
<td class="xl64">87,48</td>
</tr>
<tr height="20" style="height: 15pt;">
<td height="20" style="height: 15pt;">Czechia</td>
<td class="xl64">80,80</td>
</tr>
<tr height="20" style="height: 15pt;">
<td height="20" style="height: 15pt;">Cyprus</td>
<td class="xl64">77,11</td>
</tr>
<tr height="20" style="height: 15pt;">
<td height="20" style="height: 15pt;">Slovenia</td>
<td class="xl64">70,91</td>
</tr>
<tr height="20" style="height: 15pt;">
<td height="20" style="height: 15pt;">Lithuania</td>
<td class="xl64">55,46</td>
</tr>
<tr height="20" style="height: 15pt;">
<td height="20" style="height: 15pt;">Croatia</td>
<td class="xl64">54,48</td>
</tr>
<tr height="20" style="height: 15pt;">
<td height="20" style="height: 15pt;">Latvia</td>
<td class="xl64">52,37</td>
</tr>
<tr height="20" style="height: 15pt;">
<td height="20" style="height: 15pt;">Poland</td>
<td class="xl64">49,73</td>
</tr>
<tr height="20" style="height: 15pt;">
<td height="20" style="height: 15pt;">Hungary</td>
<td class="xl64">36,40</td>
</tr>
<tr height="20" style="height: 15pt;">
<td height="20" style="height: 15pt;">Bulgaria</td>
<td class="xl64">32,16</td>
</tr>
<tr height="20" style="height: 15pt;">
<td height="20" style="height: 15pt;">Slovakia</td>
<td class="xl64">27,45</td>
</tr>
<tr height="20" style="height: 15pt;">
<td height="20" style="height: 15pt;">Greece</td>
<td class="xl64">26,44</td>
</tr></tbody></table></div></div>JOSE Rhttp://www.blogger.com/profile/09318104344786439010noreply@blogger.com0tag:blogger.com,1999:blog-1952063008451683630.post-15020504273595969252020-05-20T18:31:00.000+02:002020-05-20T18:31:30.372+02:00Diferentes estrategias informativas de las CCAA y el Gobierno de la Nación con relación a la COVID-19<div>Diferentes estretegias informativas han seguido las CCAA en el traslado a la población la información sobre la evolución de la epidemia de COVID-19. Unas han dado información con detalle hasta nivel de municipio sobre los casos y fallecimientos habidos en sus territorios ( Madrid, Cataluña, Andalucía, País Vasco, Murcia, Asturias, Cantabria, Canarias y Baleares) y el resto no han bajado del departamento de salud o de la provincia.</div><div><br /></div><div>No entiendo qué razones puede tener un dirigente para no contar a sus administrados lo que está sucediendo con el mayor detalle, siempre que respete la privacidad de los enfermos, y ayude a que se conozca lo que nos ha estado enfermando y haciendo morir. Varias comunidades no han dado cifras en municipios menores de 200 habitantes, por salvar la privacidad de los pacientes. Quiero ver una actitud paternalista, pero creo que la información de lo que sucede, es el mejor antídoto contra las tan de actualidad "fake news".</div><div><br /></div><div>Habló el gobierno de España de una total transparencia informativa en los indicadores que iban a permitir conducir la desescalada, pero se está produciendo en medio de situaciones de importantes divergencias entre gobiernos de CCAA y el del Estado por no haberse publicitado los indicadores y los rangos sobre los que basarse, por lo que no se podido entender el fundamento de las decisiones.</div><div><br /></div><div>Tal vez los próximos congresos de especialistas en epidemiología, como el de la <a href="https://www.seepidemiologia.es/">Sociedad Española de Epidemiología (SEE) </a> en los que los profesionales que han lidiado esta grave situación desde el punto de vista epidemiológico, aporten información que permitan completar <a href="https://www.elmundo.es/ciencia-y-salud/salud/2020/05/18/5ec26bc2fc6c83bf178b4612.html">el mapa que publica el diario El Mundo.</a></div><div><br /></div><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjyBLCfISgdvwIR2xE7afVy_aotYMFLv187V8qx7ZXVTpJpAauRQ40WxJyWDCCOqsjFcafdqNYVA8E6_PNITMUg31GKQ7NARDx-NkVWJLKbn61EYqY81A35cE4UmN7X3kuBaOyVrsnnBXNx/" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="630" data-original-width="1295" height="312" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjyBLCfISgdvwIR2xE7afVy_aotYMFLv187V8qx7ZXVTpJpAauRQ40WxJyWDCCOqsjFcafdqNYVA8E6_PNITMUg31GKQ7NARDx-NkVWJLKbn61EYqY81A35cE4UmN7X3kuBaOyVrsnnBXNx/w640-h312/informacion+por+Municipio+COVID-19+El+Mundo+16_5_20.gif" width="640" /></a></div><div><br /></div><div></div><div><br /></div><div>Otra aproximación a lo que aún estamos sufriendo la da el <a href="https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_PRIMERA_RONDA_INFORME_PRELIMINAR.pdf" target="_blank">ESTUDIO ENE-COVID19: PRIMERA RONDA ESTUDIO NACIONAL DE SERO-EPIDEMIOLOGÍA DE LA INFECCIÓN POR SARS-COV-2 EN ESPAÑA. INFORME PRELIMINAR 13 DE MAYO DE 2020</a></div><div><br /></div><div><br /></div><div><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjlDdpJToBP2xe8u_0goRNKfXNj1a42nIfp4dAWJAdRAWrRouff-RLJxKaQhq3utJk7UBTqzFsF24ayJe_LwOlGa4IqciRf2YtI5mtK8QkDMOf1-R9JYrNo4s81q3NzbRoOxGJa6isCJ54R/" style="margin-left: 1em; margin-right: 1em; text-align: center;"><img border="0" data-original-height="728" data-original-width="843" height="552" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjlDdpJToBP2xe8u_0goRNKfXNj1a42nIfp4dAWJAdRAWrRouff-RLJxKaQhq3utJk7UBTqzFsF24ayJe_LwOlGa4IqciRf2YtI5mtK8QkDMOf1-R9JYrNo4s81q3NzbRoOxGJa6isCJ54R/w640-h552/Mapa+provincial+de+IgG+anti+SARS-Cov2_Primera+ronda.gif" width="640" /></a></div><div><br /><br /></div><div><br /></div><div><br /></div><div><br /></div>JOSE Rhttp://www.blogger.com/profile/09318104344786439010noreply@blogger.com0tag:blogger.com,1999:blog-1952063008451683630.post-72578570247469308982020-05-16T15:53:00.015+02:002020-06-03T20:35:26.011+02:00¿Como van los ensayos clínicos sobre las vacunas contra la COVID-19?<div>3/6/20</div>
<div><br /></div>
<div>
Desde ayer son ya <a href="https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-195513b88a53a54fbb914c90ed9064f395.pdf?sfvrsn=c457438f_8&download=true">10 las vacunas candidatas en fase clínica y 123 el total</a>.
</div>
<div><br /></div>
<div>
La de la Universidad de Oxford estaría en fase 2b/3 y con ensayos clínicos del
registro europeo:
</div>
<div>
<table class="NormalTable">
<tbody>
<tr>
<td width="300">
<span class="fontstyle0">Phase2b/3 </span><span class="fontstyle0" style="color: #0563c1;">2020-001228-32<br /></span><span class="fontstyle0">Phase 1/2 </span><span class="fontstyle0" style="color: #0563c1;">2020-001072-15</span>
</td>
</tr>
</tbody>
</table>
<br style="font-variant-east-asian: normal; font-variant-numeric: normal; line-height: normal; text-align: -webkit-auto; text-size-adjust: auto;" />
</div>
<div>Estas son las dos nuevas:</div>
<div><br /></div>
<div>
<table class="NormalTable">
<tbody>
<tr>
<td width="200">
<span class="fontstyle0">Protein<br />Subunit</span>
</td>
<td width="200">
<span class="fontstyle0">Full length<br />recombinant<br />SARS CoV-2<br />glycoprotein<br />nanoparticle<br />vaccine<br />adjuvanted
with<br />Matrix M</span>
</td>
<td width="200"><span class="fontstyle0">Novavax </span></td>
<td width="200"><span class="fontstyle0">SARS-CoV2 </span></td>
<td width="200">
<span class="fontstyle0">Phase 1/2<br /></span><span class="fontstyle0" style="color: #0563c1;">NCT04368988</span>
</td>
<td width="200">
<span class="fontstyle0">RSV; CCHF, HPV,<br />VZV, EBOV</span>
</td>
</tr>
</tbody>
</table>
<table class="NormalTable">
<tbody>
<tr>
<td width="200"><span class="fontstyle0">Inactivated </span></td>
<td width="200"><span class="fontstyle0">Inactivated </span></td>
<td width="200">
<span class="fontstyle0">Institute of Medical Biology<br />, Chinese Academy of<br />Medical
Sciences</span>
</td>
<td width="200"><span class="fontstyle0">SARS-CoV2 </span></td>
<td width="200"><span class="fontstyle0">Phase 1</span></td>
</tr>
</tbody>
</table>
<br style="font-variant-east-asian: normal; font-variant-numeric: normal; line-height: normal; text-align: -webkit-auto; text-size-adjust: auto;" />
</div>
<div>Y dos candidatas más españolas del IDIBAPS:</div>
<div><br /></div>
<div>
<table class="NormalTable">
<tbody>
<tr>
<td width="200">
<span class="fontstyle0">Non<br />replicating<br />viral vector</span>
</td>
<td width="200"><span class="fontstyle0">MVA-S </span></td>
<td width="200">
<span class="fontstyle0">IDIBAPS-Hospital Clinic, Spain </span>
</td>
<td width="200"><span class="fontstyle0">SARS-CoV2 </span></td>
<td width="200"><span class="fontstyle0">Pre-clinical</span></td>
</tr>
</tbody>
</table>
<br style="font-variant-east-asian: normal; font-variant-numeric: normal; line-height: normal; text-align: -webkit-auto; text-size-adjust: auto;" />
</div>
<div>
<table class="NormalTable">
<tbody>
<tr>
<td width="200"><span class="fontstyle0">RNA </span></td>
<td width="200"><span class="fontstyle0">mRNA </span></td>
<td width="200">
<span class="fontstyle0">IDIBAPS-Hospital Clinic, Spain </span>
</td>
<td width="200"><span class="fontstyle0">SARS-CoV2 </span></td>
<td width="200"><span class="fontstyle0">Pre-Clinical</span></td>
</tr>
</tbody>
</table>
<br style="font-variant-east-asian: normal; font-variant-numeric: normal; line-height: normal; text-align: -webkit-auto; text-size-adjust: auto;" />
</div>
<div><br /></div>
<div><br /></div>
<div><br /></div>
<div>1/6/20</div>
<div>
The Lancet publica
<a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31208-3/fulltext">Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5
vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised,
first-in-human trial</a> sobre la candidata de Cansino (primera en la tabla abajo). También en
Clinicaltrials.gov hay información sobre el ensayo clínico
<a href="https://clinicaltrials.gov/ct2/show/NCT04313127">https://clinicaltrials.gov/ct2/show/NCT04313127</a>
</div>
<div><br /></div>
<div>
<div>
Otros dos ensayos clínicos se recoge en ClinicalTrials.gov al preguntar por
COVID y Cansino:
</div>
<div>
<a href="https://www.clinicaltrials.gov/ct2/show/NCT04398147">https://www.clinicaltrials.gov/ct2/show/NCT04398147</a>
</div>
<div>
Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine
(Adenovirus Type 5 Vector) in Canada<span style="white-space: pre;"> </span>
</div>
<div>
<a href="https://www.clinicaltrials.gov/ct2/show/NCT04341389">https://www.clinicaltrials.gov/ct2/show/NCT04341389</a> A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for
COVID-19 (Adenovirus Vector)<span style="white-space: pre;"> </span>
</div>
<div><br /></div>
<div>16/5/20</div>
</div>
Publicaba los pasado días 16 y 19 de marzo una entrada y una actualización,
respectivamente, sobre <a href="https://degenetica.blogspot.com/2020/03/cts-de-vacunas-para-el-covid-19.html" target="_blank">CT´s de vacunas para el COVID-19</a>.
<div><br /></div>
<div>
Hoy veo que la OMS tine un <a href="https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines" target="_blank">Draft landscape of COVID-19 candidate vaccines</a> en el que se incluye 8 que están en fase clínica
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhFtOsAdTJhKDXWYujjXQxrSI2o2dBYhQb6SdH_2xTeb5YPAHZam4Lyx4yXz7b9v6qPHZnGboyJCClzLjQU9Lqpk9i33nVM1L8Kzx-BOADigmGhSDNhnT1Cmrdwex4sZ3NNqBVnieU7OB-L/" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="509" data-original-width="534" height="610" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhFtOsAdTJhKDXWYujjXQxrSI2o2dBYhQb6SdH_2xTeb5YPAHZam4Lyx4yXz7b9v6qPHZnGboyJCClzLjQU9Lqpk9i33nVM1L8Kzx-BOADigmGhSDNhnT1Cmrdwex4sZ3NNqBVnieU7OB-L/w640-h610/draf+vaccines+OMS+15+mayo+2020.gif" width="640" /></a>
</div>
</div>
<div class="separator" style="clear: both; text-align: center;">
Cuatro de las vacunas están promovidas por centros de China (1,3,4 y 5)
y una quinta (7) tiene participación de.un laboratorio chino. Dos estaría
promovidas por centros de US (2 y 8), una es de inglesa (6) y otra
alemana (7).
</div>
<div class="separator" style="clear: both; text-align: center;"><br /></div>
<div class="separator" style="clear: both; text-align: center;">
En relación con la vacuna de la Universidad de Oxford (6) en <a href="https://www.biorxiv.org/content/10.1101/2020.05.13.093195v1.full.pdf" target="_blank">ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus
macaques</a> hay un reciente artículo sobre el resultado en macacos.
</div>
<div class="separator" style="clear: both; text-align: center;"><br /></div>
<div class="separator" style="clear: both; text-align: center;">
El mismo enlace lleva a un listado de 110 vacunas en fases preclínicas, entre
las que se incluye dos españolas del CNB-CSIC:
</div>
<div class="separator" style="clear: both; text-align: center;"><br /></div>
<div class="separator" style="clear: both; text-align: center;">
<table class="NormalTable">
<tbody>
<tr>
<td width="200">
<span class="fontstyle0">Non<br />Replicating<br />Viral Vector</span>
</td>
<td width="200">
<span class="fontstyle0">MVA expressing<br />structural proteins</span>
</td>
<td width="200">
<span class="fontstyle0">Centro Nacional Biotecnología<br />(CNB-CSIC), Spain</span>
</td>
<td width="200"><span class="fontstyle0">SARS-CoV2 </span></td>
<td width="200"><span class="fontstyle0">Pre-Clinical </span></td>
<td width="200">
<span class="fontstyle0">Multiple<br />candidate</span>
</td>
</tr>
</tbody>
</table>
<br style="font-variant-east-asian: normal; font-variant-numeric: normal; line-height: normal; text-align: -webkit-auto; text-size-adjust: auto;" />
</div>
<div class="separator" style="clear: both; text-align: center;"><br /></div>
<div class="separator" style="clear: both; text-align: center;">
<table class="NormalTable">
<tbody>
<tr>
<td width="200"><span class="fontstyle0">RNA </span></td>
<td width="200">
<span class="fontstyle0">Replicating<br />Defective SARS-CoV-<br />2 derived RNAs</span>
</td>
<td width="200">
<span class="fontstyle0">Centro Nacional Biotecnología<br />(CNB-CSIC), Spain</span>
</td>
<td width="200"><span class="fontstyle0">SARS-CoV2 </span></td>
<td width="200"><span class="fontstyle0">Pre-Clinical</span></td>
</tr>
</tbody>
</table>
<br style="font-variant-east-asian: normal; font-variant-numeric: normal; line-height: normal; text-align: -webkit-auto; text-size-adjust: auto;" />
</div>
<div class="separator" style="clear: both; text-align: center;">
<div class="separator" style="clear: both; text-align: center;"><br /></div>
<div class="separator" style="clear: both; text-align: center;"><br /></div>
<div class="separator" style="clear: both; text-align: center;">
ChAdOx1 and ChAdOx2
</div>
<div class="separator" style="clear: both; text-align: center;">
https://www.vaccitech.co.uk/technology/
</div>
</div>
JOSE Rhttp://www.blogger.com/profile/09318104344786439010noreply@blogger.com0tag:blogger.com,1999:blog-1952063008451683630.post-34713475548988646512020-04-04T07:01:00.003+02:002020-05-31T20:39:52.581+02:00Informe favorable del CHMP de la EMA sobre Zolgensma y EPAR<div><br /></div><div>31/5/20</div><div><br /></div><div><a href="https://www.ema.europa.eu/en/medicines/human/EPAR/zolgensma">Zolgensma ya tiene EPAR con condiciones desde el día 27 de mayo de 2020</a> </div><div><br /></div><div><br /></div><div>4/4/20</div><div><br /></div>En su reunión del 26 Marzo de 2020, <a href="https://www.ema.europa.eu/en/medicines/human/summaries-opinion/zolgensma">el Comité de Productos Medicinales para uso Humano (CHMP) adoptó una opinión positiva,</a> recomendando la emisión de la autorización de comercialización de Zolgensma, que va dirigido al tratamiento de niños y jóvenes con Atrofia Muscular Espinal (SMA en inglés) del que nos hemos ocupado en varias ocasiones en este blog:<br />
<ul>
<li><a href="https://degenetica.blogspot.com/2019/03/zolgensma-de-novartis-posible-para-mayo.html">Zolgensma, de Novartis, posible para mayo en la FDA</a></li>
<li><a href="https://degenetica.blogspot.com/2019/05/informe-final-de-icer-sobre-zolgensma.html">Informe final de ICER sobre Zolgensma</a></li>
<li><a href="https://degenetica.blogspot.com/2019/05/aprobado-zolgensma-por-la-fda-su-precio.html">Aprobado Zolgensma por la FDA. Su precio USD 2.1M </a></li>
<li><a href="https://degenetica.blogspot.com/2019/09/the-centers-for-medicare-medicaid.html">T</a> <a href="https://degenetica.blogspot.com/2019/09/cigna-asume-el-pago-de-luxturna-y.html">Cigna asume el pago de Luxturna y Zolgensma</a></li>
<li><a href="https://degenetica.blogspot.com/2019/10/resultados-economicos-de-las-cart-hasta.html">Resultados económicos de las CART hasta Q3 del 2019, y sobre Zolgensma y sus circunstancias.</a></li>
</ul>
<div>
Las indicaciones serán: </div>
<div>
<br /></div>
<div>
<i>Zolgensma is indicated for the treatment of: </i></div>
<div>
<i>- patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a
clinical diagnosis of SMA Type 1, or</i></div>
<div>
<i>- patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2
gene.</i></div>
<div>
<br />
<br />
The applicant for Zolgensma is<a href="https://www.avexis.com/"> AveXis EU Limited</a>.
<br />
<br />
Las bases de la autorización son:<br />
<br /></div>
<div>
<i>The clinical trial providing the main body of data for the assessment of Zolgensma was conducted in 22 patients who were less than six months of age at the time of the gene replacement therapy with Zolgensma. The trial assessed the percentage of patients who had improvement in their survival (i.e. without the need to be permanently on a ventilator) and motor milestones, such as head control, crawling, sitting, standing and walking (with or without assistance).</i><br />
<i>The survival of patients treated with Zolgensma exceeded what can be expected from untreated patients with severe SMA. Out of 22 patients enrolled in the trial, 20 patients (91%) were alive and did not need permanent ventilatory support at 14 months of age. The experience with this disease shows that at 14 months of age only 25% of patients are still alive. These patients also achieved motor milestones, which are usually not achieved in the natural history of the disease. 14 patients (64%) reached the milestone of independent sitting before 18 months of age. One patient (4%) reached the milestone of walking unassisted before reaching 16 months of age. Patients with less motor deterioration appeared to benefit the most from the treatment with Zolgensma.
</i></div>
<div>
<br /></div>
<div>
El paso siguiente será la publicación del EPAR.</div>
<div>
Han pasado varios meses desde la ultima autorización de comercialización de un MTA: <a href="https://degenetica.blogspot.com/2019/06/autorizado-un-nuevo-atmp-zynteglo.html">Autorizado un nuevo ATMP: ZYNTEGLO</a> en junio de 2019.</div>
JOSE Rhttp://www.blogger.com/profile/09318104344786439010noreply@blogger.com0tag:blogger.com,1999:blog-1952063008451683630.post-44799954482532258302020-03-22T08:56:00.000+01:002020-03-24T18:30:19.708+01:00¿Y si Alemania ya hubiera tocado techo de casos de COVID-19?24/3/20<br />
<br />
He visto cual ha sido mi error al pensar que Alemania podía estar tocando techo.<br />
La gráfica representa los casos por su fecha de inicio de síntomas o de diagnóstico, no de declaración. Es decir, un caso que se declara hoy pudo ser diagnosticado o haber iniciado sus síntomas días atrás, por lo que no se reflejará como de hoy sino del día en que se diagnosticara o iniciaran sus síntomas.<br />
En estas gráficas se producen unos estratos más recientes que parece que vayan disminuyendo, pero lo que sucede es que en estos días hay una ausencia de información, ya que los casos iniciados estos días se declararán más adelante.<br />
He visto mi error al ver en un informe del CCAES una forma similar y que también se produjo en uno de los primeros estudios sobre lo habido en Wuhan. Seguiremos aprendiendo.<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhtu4RHaLBzOgMWUpzr74t9_zZSpLFo7KLZ3UkjLH3H0WHuB2bv9Q5fn3hgsGrU80H8XgC8KCGoDrBCd2N4JeQQQWb-Gq9AsFIPoanehE_9hj5PvQdn1kKpm1Iv-dRCsQ6Qqv-fOTZMZBA4/s1600/Alemania+COVID+24_3_20.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="701" data-original-width="956" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhtu4RHaLBzOgMWUpzr74t9_zZSpLFo7KLZ3UkjLH3H0WHuB2bv9Q5fn3hgsGrU80H8XgC8KCGoDrBCd2N4JeQQQWb-Gq9AsFIPoanehE_9hj5PvQdn1kKpm1Iv-dRCsQ6Qqv-fOTZMZBA4/s1600/Alemania+COVID+24_3_20.gif" /></a></div>
<br />
No obstante, se ha producido una estabilización y disminución de casos declarados en los días de mi error, que también ha coincidido con el fin de semana y una posible disminución en la calidad de las rutinas de comunicación de casos.<br />
<br />
23/3/20<br />
Mi gozo en un pozo: Alemania comunica 4.078 casos y se coloca en 22.672.
<br />
<br />
22/3/20<br />
<br />
Tras las informaciones e interpretaciones de por qué del bajo número de fallecimientos en Alemania por COVID-19, veo que la fuente a seguir es el Robert Koch-Institut que tiene <a href="https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Gesamt.html">un enlace para el último informe</a> y otro enlace para el <a href="https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Archiv.html">archivo de informes</a> que echo de menos en la página de nuestro <a href="https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/home.htm">CENTRO DE COORDINACIÓN DE ALERTAS Y EMERGENCIAS SANITARIAS (CCAES)</a>, yo no lo he encontrado.<br />
<br />
Tienen a su vez un <a href="https://experience.arcgis.com/experience/478220a4c454480e823b17327b2bf1d4">tablero/dashboard</a> del que obtengo una imagen, que me hace pensar, que si la cosa no se tuerce, Alemania estaría de bajada del brote. Hay que considerar que hoy es domingo, y el fin de semana puede influir en la calidad de la puntualidad en la transmisión de datos, como puede haberles pasado los días 7 y 14, sábados y 15 y 22, domingos.<br />
<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhSPOsaEBz9XTPsPEc7x-FreLRZcEtGaAi6URRn0pFmcl7FH8THiI7Gm0HzEfCS-mJWZkF9g7yb-ZzO-OLie_ZwmoGfBA2zIROtp6OSSxIuKPtXmkh20lXcCjFotgwQpqPOS8D6YtrzwwyI/s1600/Alemania+COVID+22_3_20.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="639" data-original-width="1317" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhSPOsaEBz9XTPsPEc7x-FreLRZcEtGaAi6URRn0pFmcl7FH8THiI7Gm0HzEfCS-mJWZkF9g7yb-ZzO-OLie_ZwmoGfBA2zIROtp6OSSxIuKPtXmkh20lXcCjFotgwQpqPOS8D6YtrzwwyI/s1600/Alemania+COVID+22_3_20.gif" /></a></div>
<br />
<br />
Pero con esta gráfica, el miércoles 18/3/20 , Alemania podría haber tocado techo. Si me equivoco agradeceré que me lo hagan ver. No sé si soy víctima de mi propensión a dar buenas en lugar de malas noticias, pero me parecen datos esperanzadores.<br />
<br />
Sobre la baja mortalidad, he visto un artículo en EL PAIS: <a href="https://elpais.com/sociedad/2020/03/20/actualidad/1584729408_422864.html?rel=lom">La baja letalidad del coronavirus en Alemania: una excepción que podría dejar de serlo</a>, que recomiendo<br />
<br />
<br />
<br />
<br />JOSE Rhttp://www.blogger.com/profile/09318104344786439010noreply@blogger.com0tag:blogger.com,1999:blog-1952063008451683630.post-7626880419819126352020-03-18T20:39:00.000+01:002020-03-22T10:55:22.812+01:00Korea es el ejemplo de futuro en la resolución de brotes epidémicos tras su éxito con el COVID1921/3/20<br />
<br />
17h<br />
<br />
En otra actualización del <a href="https://www.cdc.go.kr/board/board.es?mid=a30402000000&bid=0030&act=view&list_no=366616&tag=&nPage=1">día 21 de marzo de 2020</a> se presenta esta tabla que dice el vínculo del <span style="color: #555555; font-family: "맑은 고딕"; font-size: 14.6667px;">80.7% </span> los casos con anteriores casos. Sencillamente genial, a mi parecer. Que se puede hacer si se tiene un potente dispositivo de detección de casos y contactos como el descrito más abajo.<br />
<br />
<br />
<div class="0" style="background: transparent; border: 0px; margin: 0px; padding: 0px; text-align: center;">
<span style="background: transparent; border: 0px; font-family: "맑은 고딕"; font-size: 11pt; font-weight: bold; letter-spacing: 0pt; margin: 0px; padding: 0px;">[Table 2. Regional distribution and epidemiological links of the confirmed cases]</span></div>
<div class="0" style="background: transparent; border: 0px; margin: 0px; padding: 0px; text-align: center;">
<span style="background: transparent; border: 0px; font-family: "맑은 고딕"; font-size: 11pt; font-weight: bold; letter-spacing: 0pt; margin: 0px; padding: 0px;"><br style="margin: 0px; padding: 0px;" /></span></div>
<span style="border: 0px; color: #555555; font-family: "맑은 고딕"; font-size: 11pt; letter-spacing: 0pt; margin: 0px; padding: 0px;"></span><span style="color: #555555; font-family: "noto sans kr" , sans-serif; font-size: 15px;"></span><br />
<table style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-bottom-color: black; border-bottom-style: none; border-collapse: collapse; border-image: initial; border-left-color: black; border-left-style: none; border-right-color: black; border-right-style: none; border-spacing: 0px; border-top-color: initial; border-top-style: initial; border-width: 0px medium medium; color: #555555; font-family: "Noto Sans KR", sans-serif; font-size: 15px; height: 1041px; left: 7px; margin: 0px; padding: 0px; top: 796.86px; width: 941px;"><tbody style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;">
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td rowspan="2" style="background: rgb(230, 238, 247); border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 2px 2px 1px medium; height: 51px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 95px;"><div class="0" style="background: transparent; border: 0px; font-weight: bold; letter-spacing: 0pt; line-height: 19.5px; padding: 0px; text-align: center; word-break: keep-all;">
<span style="background: transparent; border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">Region</span></div>
</td><td rowspan="2" style="background: rgb(230, 238, 247); border-color: rgb(0, 0, 0); border-image: initial; border-style: solid; border-width: 2px 2px 1px; height: 51px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 80px;"><div class="0" style="background: transparent; border: 0px; font-weight: bold; letter-spacing: 0pt; line-height: 19.5px; padding: 0px; text-align: center; word-break: keep-all;">
<span style="background: transparent; border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">Sub-</span></div>
<div class="0" style="background: transparent; border: 0px; font-weight: bold; letter-spacing: 0pt; line-height: 19.5px; padding: 0px; text-align: center; word-break: keep-all;">
<span style="background: transparent; border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">total</span></div>
</td><td colspan="3" style="background: rgb(230, 238, 247); border-color: rgb(0, 0, 0); border-image: initial; border-style: solid; border-width: 2px 1px 1px 2px; height: 25px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 498px;"><div class="0" style="background: transparent; border: 0px; font-weight: bold; letter-spacing: 0pt; line-height: 19.5px; padding: 0px; text-align: center; word-break: keep-all;">
<span style="background: transparent; border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">Epidemiological links</span></div>
</td><td colspan="2" rowspan="2" style="background: rgb(230, 238, 247); border-color: rgb(0, 0, 0); border-image: initial; border-style: solid; border-width: 2px 2px 1px 1px; height: 51px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 149px;"><div class="0" style="background: transparent; border: 0px; font-weight: bold; letter-spacing: 0pt; line-height: 19.5px; padding: 0px; text-align: center; vertical-align: super; word-break: keep-all;">
<span style="background: transparent; border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">Others</span><span style="background: transparent; border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px; vertical-align: super;">*</span></div>
</td><td rowspan="2" style="background: rgb(230, 238, 247); border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 2px medium 1px 2px; height: 51px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 109px;"><div class="0" style="background: transparent; border: 0px; font-weight: bold; line-height: 19.5px; padding: 0px; text-align: center; vertical-align: super; word-break: keep-all;">
<span style="background: transparent; border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">Newly confirmed</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td style="background: rgb(230, 238, 247); border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 25px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 68px;"><div class="0" style="background: transparent; border: 0px; font-weight: bold; letter-spacing: 0pt; line-height: 19.5px; padding: 0px; text-align: right; word-break: keep-all;">
<span style="background: transparent; border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">n</span></div>
</td><td style="background: rgb(230, 238, 247); border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 25px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background: transparent; border: 0px; font-weight: bold; letter-spacing: 0pt; line-height: 19.5px; padding: 0px;">
<span style="background: transparent; border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">(%)</span></div>
</td><td style="background: rgb(230, 238, 247); border: 1px solid rgb(0, 0, 0); height: 25px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 348px;"><div class="0" style="background: transparent; border: 0px; font-weight: bold; letter-spacing: 0pt; line-height: 19.5px; padding: 0px; text-align: center; word-break: keep-all;">
<span style="background: transparent; border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">Details</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 70px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 96px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Seoul</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0); border-image: initial; border-style: solid; border-width: 1px 2px; height: 70px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">314</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 70px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 68px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">223</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 70px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.2pt; padding: 0px; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.2pt; margin: 0px; padding: 0px;">(71.0%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 1px solid rgb(0, 0, 0); height: 70px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 348px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.6pt; line-height: 15.6px; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; font-weight: bold; letter-spacing: -0.6pt; margin: 0px; padding: 0px;">Guro-gu call center (92), </span><span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.6pt; margin: 0px; padding: 0px;">Dongan Church-PC Cafe (20), Eunpyeong St Mary’s Hospital (14), Seongdong-gu Apartments (13), Jongno-gu (10), Shincheonji (6), Seongnam Grace River Church (4) etc.</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 70px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 67px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">91</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 70px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 82px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.1pt; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.1pt; margin: 0px; padding: 0px;">(29.0%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 70px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 110px;"><div class="1" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">15</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 56px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 96px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Busan</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0); border-image: initial; border-style: solid; border-width: 1px 2px; height: 56px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">108</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 56px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 68px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">78</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 56px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.2pt; padding: 0px; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.2pt; margin: 0px; padding: 0px;">(72.2%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 1px solid rgb(0, 0, 0); height: 56px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 348px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -1pt; line-height: 15.6px; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -1pt; margin: 0px; padding: 0px;">Onchun Church (32), Shincheonji (11), Suyeong-gu Kindergarten (5), Haeundae-gu Jangsan Catholic Church (4), Jin-gu private academy (4), Daenam Hospital (1), etc.</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 56px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 67px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">30</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 56px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 82px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.1pt; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.1pt; margin: 0px; padding: 0px;">(27.8%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 56px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 110px;"><div class="1" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">0</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 74px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 96px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Daegu</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0); border-image: initial; border-style: solid; border-width: 1px 2px; height: 74px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">6,344</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 74px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 68px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: -1.9pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: -1.9pt; margin: 0px; padding: 0px;">5,242</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 74px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.2pt; padding: 0px; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.2pt; margin: 0px; padding: 0px;">(82.6%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 1px solid rgb(0, 0, 0); height: 74px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 348px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.9pt; line-height: 15.6px; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.9pt; margin: 0px; padding: 0px;">Shincheonji (4,369), contacts of confirmed cases (683), Hansarang Convalescent Hospital (75), </span><span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; font-weight: bold; letter-spacing: -0.9pt; margin: 0px; padding: 0px;">Daesil Convalescent Hospital (64),</span><span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.9pt; margin: 0px; padding: 0px;"> </span><span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.9pt; margin: 0px; padding: 0px;">KimSin Recuperation Hospital (26), Kwak’s Hospital (15), Baesung Hospital (8), etc.</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 74px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 67px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: -2.1pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: -2.1pt; margin: 0px; padding: 0px;">1,102</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 74px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 82px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.1pt; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.1pt; margin: 0px; padding: 0px;">(17.4%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 74px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 110px;"><div class="1" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">69</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 56px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 96px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Incheon</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0); border-image: initial; border-style: solid; border-width: 1px 2px; height: 56px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">40</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 56px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 68px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">32</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 56px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.2pt; padding: 0px; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.2pt; margin: 0px; padding: 0px;">(80.0%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 1px solid rgb(0, 0, 0); height: 56px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 348px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; line-height: 15.6px; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; font-weight: bold; letter-spacing: 0pt; margin: 0px; padding: 0px;">Guro-gu call center (20),</span><span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; margin: 0px; padding: 0px;"> </span><span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">contacts of confirmed cases (6), Seocho-gu company related (3), Shincheonji (2), existing imported cases (1)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 56px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 67px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">8</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 56px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 82px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.1pt; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.1pt; margin: 0px; padding: 0px;">(20.0%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 56px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 110px;"><div class="1" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">4</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 96px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Gwangju</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0); border-image: initial; border-style: solid; border-width: 1px 2px; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">18</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 68px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">15</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.2pt; padding: 0px; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.2pt; margin: 0px; padding: 0px;">(83.3%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 1px solid rgb(0, 0, 0); height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 348px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; line-height: 15.6px; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Shincheonji (9), contacts of confirmed cases (5), existing imported cases (1)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 67px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">3</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 82px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.1pt; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.1pt; margin: 0px; padding: 0px;">(16.7%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 110px;"><div class="1" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">0</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 96px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Daejeon</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0); border-image: initial; border-style: solid; border-width: 1px 2px; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">22</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 68px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">12</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.2pt; padding: 0px; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.2pt; margin: 0px; padding: 0px;">(54.5%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 1px solid rgb(0, 0, 0); height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 348px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; line-height: 15.6px; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">contacts of confirmed cases (8), Shincheonji (2), Seosan research center (2)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 67px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">10</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 82px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.1pt; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.1pt; margin: 0px; padding: 0px;">(45.5%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 110px;"><div class="1" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">0</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 23px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 96px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Ulsan</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0); border-image: initial; border-style: solid; border-width: 1px 2px; height: 23px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">36</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 23px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 68px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">26</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 23px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.2pt; padding: 0px; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.2pt; margin: 0px; padding: 0px;">(72.2%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 1px solid rgb(0, 0, 0); height: 23px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 348px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; line-height: 15.6px; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Shincheonji (16), contacts of confirmed cases (10)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 23px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 67px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">10</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 23px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 82px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.1pt; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.1pt; margin: 0px; padding: 0px;">(27.8%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 23px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 110px;"><div class="1" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">0</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 96px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Sejong</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0); border-image: initial; border-style: solid; border-width: 1px 2px; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">41</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 68px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">38</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.2pt; padding: 0px; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.2pt; margin: 0px; padding: 0px;">(92.7%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 1px solid rgb(0, 0, 0); height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 348px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; line-height: 15.6px; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Ministry of Oceans and Fisheries (29), gym facilities (8), Shincheonji (1)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 67px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">3</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 82px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.1pt; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.1pt; margin: 0px; padding: 0px;">(7.3%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 110px;"><div class="1" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">0</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 87px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 96px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.3pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.3pt; margin: 0px; padding: 0px;">Gyeonggi</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0); border-image: initial; border-style: solid; border-width: 1px 2px; height: 87px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">321</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 87px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 68px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">262</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 87px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.2pt; padding: 0px; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.2pt; margin: 0px; padding: 0px;">(81.6%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 1px solid rgb(0, 0, 0); height: 87px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 348px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; line-height: 15.6px; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Seongnam Grace River Church (60), Guro-gu call center-Bucheon SaengMyeongSu Church (36),</span><span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; font-weight: bold; margin: 0px; padding: 0px;"> </span><span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; font-weight: bold; letter-spacing: 0pt; margin: 0px; padding: 0px;">Bundang Je-saeng Hospital (38)</span><span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">, Shincheonji (29), Suwon SaengMyeongSaem Church (12), </span><span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; font-weight: bold; letter-spacing: 0pt; margin: 0px; padding: 0px;">Gunpo Hyo Sarang Nursing Home (5)</span><span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; margin: 0px; padding: 0px;"> </span><span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">etc.</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 87px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 67px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">59</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 87px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 82px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.1pt; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.1pt; margin: 0px; padding: 0px;">(18.4%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 87px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 110px;"><div class="1" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">12</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 25px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 96px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.2pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.2pt; margin: 0px; padding: 0px;">Gangwon</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0); border-image: initial; border-style: solid; border-width: 1px 2px; height: 25px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">30</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 25px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 68px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">21</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 25px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.2pt; line-height: 16.8px; padding: 0px; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.2pt; margin: 0px; padding: 0px;">(70.0%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 1px solid rgb(0, 0, 0); height: 25px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 348px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; line-height: 15.6px; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Shincheonji (20), gym facilities in Cheonan (1)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 25px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 67px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">9</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 25px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 82px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.1pt; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.1pt; margin: 0px; padding: 0px;">(30.0%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 25px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 110px;"><div class="1" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">0</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 96px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Chung-</span><br />
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">buk</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0); border-image: initial; border-style: solid; border-width: 1px 2px; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">34</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 68px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">28</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.2pt; padding: 0px; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.2pt; margin: 0px; padding: 0px;">(82.4%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 1px solid rgb(0, 0, 0); height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 348px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; line-height: 15.6px; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Shincheonji (11), Goesan-gun Jangyeon-myeon (11), contacts of confirmed cases (6)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 67px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">6</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 82px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.1pt; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.1pt; margin: 0px; padding: 0px;">(17.6%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 110px;"><div class="1" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">1</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 96px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Chung-</span><br />
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">nam</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0); border-image: initial; border-style: solid; border-width: 1px 2px; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">119</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 68px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">112</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.2pt; padding: 0px; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.2pt; margin: 0px; padding: 0px;">(94.1%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 1px solid rgb(0, 0, 0); height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 348px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; line-height: 15.6px; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Gym facilities in Cheonan (103), Seosan research center (8), Seongnam Grace River Church (1)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 67px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">7</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 82px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.1pt; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.1pt; margin: 0px; padding: 0px;">(5.9%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 110px;"><div class="1" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">0</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 96px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Jeon-buk</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0); border-image: initial; border-style: solid; border-width: 1px 2px; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">10</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 68px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">4</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.2pt; padding: 0px; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.2pt; margin: 0px; padding: 0px;">(40.0%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 1px solid rgb(0, 0, 0); height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 348px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; line-height: 15.6px; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Contacts of confirmed cases (2), existing imported cases (1), Shincheonji (1)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 67px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">6</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 82px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.1pt; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.1pt; margin: 0px; padding: 0px;">(60.0%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 110px;"><div class="1" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">0</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 96px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Jeon-</span><br />
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">nam</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0); border-image: initial; border-style: solid; border-width: 1px 2px; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">5</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 68px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">4</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.2pt; padding: 0px; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.2pt; margin: 0px; padding: 0px;">(80.0%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 1px solid rgb(0, 0, 0); height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 348px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; line-height: 15.6px; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Shincheonji (1), existing imported cases (1), contacts of confirmed cases (2)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 67px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">1</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 82px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.1pt; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.1pt; margin: 0px; padding: 0px;">(20.0%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 42px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 110px;"><div class="1" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">0</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 87px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 96px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Gyeong-</span><br />
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">buk</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0); border-image: initial; border-style: solid; border-width: 1px 2px; height: 87px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">1,243</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 87px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 68px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">910</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 87px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.2pt; padding: 0px; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.2pt; margin: 0px; padding: 0px;">(73.2%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 1px solid rgb(0, 0, 0); height: 87px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 348px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.9pt; line-height: 15.6px; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.9pt; margin: 0px; padding: 0px;">Shincheonji (527), Cheongdo Daenam Hospital (120), Bonghwa Pureun Nursing Home (68), pilgrimage to Israel (49), </span><span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; font-weight: bold; letter-spacing: -0.9pt; margin: 0px; padding: 0px;">Gyeongsan Seo Convalescent Hospital (30),</span><span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.9pt; margin: 0px; padding: 0px;"> </span><span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.9pt; margin: 0px; padding: 0px;">Milal Shelter (27), Gyeongsan Seorin Nursing Home (25), Gyeongsan Cham Joeun Community Center (18), etc.</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 87px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 67px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">333</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 87px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 82px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.1pt; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.1pt; margin: 0px; padding: 0px;">(26.8%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 87px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 110px;"><div class="1" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">40</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 81px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 96px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Gyeong-</span><br />
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">nam</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0); border-image: initial; border-style: solid; border-width: 1px 2px; height: 81px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">87</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 81px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 68px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">70</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 81px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.2pt; padding: 0px; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.2pt; margin: 0px; padding: 0px;">(80.5%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 1px solid rgb(0, 0, 0); height: 81px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 348px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; line-height: 15.6px; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Shincheonji (32), Geochang Church (10), Geochang Woongyang-myeon (8), Hanmaeum Changwon Hospital (7), Changyeong coin karaoke (7), contacts of confirmed cases (4), Busan Oncheon Church (2)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 81px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 67px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">17</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 81px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 82px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.1pt; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.1pt; margin: 0px; padding: 0px;">(19.5%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 81px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 110px;"><div class="1" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">0</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 23px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 96px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Jeju</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0); border-image: initial; border-style: solid; border-width: 1px 2px; height: 23px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">4</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 23px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 68px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">-</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 23px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.2pt; padding: 0px; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.2pt; margin: 0px; padding: 0px;">-</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 1px solid rgb(0, 0, 0); height: 23px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 348px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; line-height: 15.6px; padding: 0px;">
<br /></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 23px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 67px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">4</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 1px medium; height: 23px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 82px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.1pt; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.1pt; margin: 0px; padding: 0px;">(100%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 2px; height: 23px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 110px;"><div class="1" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">0</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 2px medium; height: 25px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 96px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Airport</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0); border-image: initial; border-style: solid; border-width: 1px 2px 2px; height: 24px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">23</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 2px 2px; height: 24px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 68px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">23</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 2px medium; height: 25px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.7pt; padding: 0px; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.7pt; margin: 0px; padding: 0px;">(100%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0); border-image: initial; border-style: solid; border-width: 1px 1px 2px; height: 25px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 348px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; line-height: 15.6px; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Imported cases (23)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 2px 1px; height: 24px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 67px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">-</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 2px 2px medium; height: 25px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 82px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -0.1pt; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -0.1pt; margin: 0px; padding: 0px;"> -</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 2px 2px; height: 24px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 110px;"><div class="1" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">6</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 2px 2px 2px medium; height: 25px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 95px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Total</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 2px solid rgb(0, 0, 0); height: 25px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 80px;"><div class="1" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-weight: bold; letter-spacing: 0pt; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">8,799</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 2px medium 2px 2px; height: 25px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 67px;"><div class="1" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: -2pt; padding: 0px; text-align: right;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 10pt; letter-spacing: -2pt; margin: 0px; padding: 0px;">7,100</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 2px 1px 2px medium; height: 25px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 80px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -1.4pt; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -1.4pt; margin: 0px; padding: 0px;">(80.7%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0); border-image: initial; border-style: solid; border-width: 2px 1px; height: 25px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 347px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; line-height: 19.5px; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">Shincheonji related cases 5,037 (57.2%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 2px medium 2px 1px; height: 25px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 66px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: -2.1pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: -2.1pt; margin: 0px; padding: 0px;">1,699</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 2px 2px 2px medium; height: 25px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 81px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -2.3pt; padding: 0px;">
<span style="border: 0px; font-family: "맑은 고딕"; font-size: 9pt; letter-spacing: -2.4pt; margin: 0px; padding: 0px;"> (19.3%)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 2px medium 2px 2px; height: 25px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 109px;"><div class="1" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center;">
<span style="border: 0px; font-family: "맑은 고딕"; letter-spacing: 0pt; margin: 0px; padding: 0px;">147</span></div>
</td></tr>
</tbody></table>
<br />
También tiene una gráfica de casos importados por semanas en la que quince casos repartidos en las semanas 4 ( 3 casos), 5(5 casos) y 6 (7 casos) serían el origen todo el brote. En la S12 tienen 52 importados. No acabo de ver que tan pocos casos hayan provocado todo el brote de Korea, aunque siempre empieza todo en un único caso.<br />
<br />
<br />
7h<br />
<br />
Tomado de la <a href="https://www.cdc.go.kr/board/board.es?mid=a30402000000&bid=0030&act=view&list_no=366615&tag=&nPage=1">actualización del día 21 del KCDC</a> una tabla de distribución por edad y sexo de casos. Datos que ya quisiéramos para España: 102 fallecidos, en España más de 1000. Obsérvese que no hay ningún fallecido con edad inferior a 40 años. Tasa de mortalidad que se incrementa con la edad.<br />
<br />
<br />
<div class="0" style="background: transparent; border: 0px; letter-spacing: 0pt; margin: 0px 0px 0px 21px; padding: 0px; text-indent: -15.8pt;">
<strong style="background: transparent; border: 0px; font-weight: normal; margin: 0px; padding: 0px;"><span style="background: transparent; border: 0px; font-family: "맑은 고딕"; font-size: 11pt; font-weight: bold; letter-spacing: 0pt; margin: 0px; padding: 0px;">Case distribution by gender and age group:</span></strong></div>
<span style="border: 0px; color: #555555; font-family: "맑은 고딕"; font-size: 11pt; letter-spacing: 0pt; margin: 0px; padding: 0px;"></span><span style="border: 0px; color: #555555; font-family: "맑은 고딕"; font-size: 14.6667px; margin: 0px; padding: 0px;"></span><span style="border: 0px; color: #555555; font-family: "맑은 고딕"; font-size: 14.6667px; margin: 0px; padding: 0px;"></span><span style="border: 0px; color: #555555; font-family: "맑은 고딕"; font-size: 14.6667px; margin: 0px; padding: 0px;"></span><span style="border: 0px; color: #555555; font-family: "맑은 고딕"; font-size: 14.6667px; margin: 0px; padding: 0px;"></span><span style="border: 0px; color: #555555; font-family: "맑은 고딕"; font-size: 14.6667px; margin: 0px; padding: 0px;"></span><span style="border: 0px; color: #555555; font-family: "맑은 고딕"; font-size: 14.6667px; margin: 0px; padding: 0px;"></span><span style="border: 0px; color: #555555; font-family: "맑은 고딕"; font-size: 14.6667px; margin: 0px; padding: 0px;"></span><span style="border: 0px; color: #555555; font-family: "맑은 고딕"; font-size: 14.6667px; margin: 0px; padding: 0px;"></span><span style="border: 0px; color: #555555; font-family: "맑은 고딕"; font-size: 14.6667px; margin: 0px; padding: 0px;"></span><span style="color: #555555; font-family: "맑은 고딕"; font-size: 14.6667px;"></span><br />
<table style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-bottom-color: black; border-bottom-style: none; border-collapse: collapse; border-image: initial; border-left-color: black; border-left-style: none; border-right-color: black; border-right-style: none; border-spacing: 0px; border-top-color: initial; border-top-style: initial; border-width: 0px medium medium; color: #555555; font-family: "맑은 고딕"; font-size: 14.6667px; height: 371px; left: 7px; margin: 0px; padding: 0px; top: 1695.53px; width: 784px;"><tbody style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;">
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td colspan="2" style="background: rgb(223, 234, 245); border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 2px 1px 2px medium; height: 40px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 209px;"><span style="background: transparent; border: 0px; margin: 0px; padding: 0px;"></span><br />
<div class="0" style="background: transparent; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px;">
<span style="background: transparent; border: 0px; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Classification</span></div>
</td><td style="background: rgb(223, 234, 245); border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 2px medium 2px 1px; height: 40px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 113px;"><span style="background: transparent; border: 0px; margin: 0px; padding: 0px;"></span><br />
<div class="0" style="background: transparent; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="background: transparent; border: 0px; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Confirmed Cases</span></div>
</td><td style="background: rgb(223, 234, 245); border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 2px 1px 2px medium; height: 40px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 101px;"><span style="background: transparent; border: 0px; margin: 0px; padding: 0px;"></span><br />
<div class="0" style="background: transparent; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px;">
<span style="background: transparent; border: 0px; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">(%)</span></div>
</td><td style="background: rgb(223, 234, 245); border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 2px medium 2px 1px; height: 40px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 98px;"><span style="background: transparent; border: 0px; margin: 0px; padding: 0px;"></span><br />
<div class="0" style="background: transparent; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px; text-align: right; word-break: keep-all;">
<span style="background: transparent; border: 0px; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Deaths</span></div>
</td><td style="background: rgb(223, 234, 245); border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 2px 1px 2px medium; height: 40px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 108px;"><span style="background: transparent; border: 0px; margin: 0px; padding: 0px;"></span><br />
<div class="0" style="background: transparent; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px;">
<span style="background: transparent; border: 0px; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">(%)</span></div>
</td><td style="background: rgb(223, 234, 245); border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 2px medium 2px 1px; height: 40px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 144px;"><span style="background: transparent; border: 0px; margin: 0px; padding: 0px;"></span><br />
<div class="0" style="background: transparent; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px; text-align: center; word-break: keep-all;">
<span style="background: transparent; border: 0px; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Fatality rate (%)</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td colspan="2" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 2px 1px 2px medium; height: 24px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 209px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -1.2pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-family: 한양중고딕; font-size: 9pt; letter-spacing: -1.2pt; margin: 0px; padding: 0px;">Total</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 2px medium 2px 1px; height: 24px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 113px;"><div class="4" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px; text-align: right;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">8,799</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 2px 1px 2px medium; height: 24px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 101px;"><div class="3" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">(100)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 2px medium 2px 1px; height: 24px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 98px;"><div class="4" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px; text-align: right;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">102</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 2px 1px 2px medium; height: 24px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 108px;"><div class="3" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">(100)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 2px medium 2px 1px; height: 24px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 144px;"><div class="5" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px; text-align: center;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">1.16</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td rowspan="2" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 2px 1px 2px medium; height: 51px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 76px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -1.2pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-family: 한양중고딕; font-size: 9pt; letter-spacing: -1.2pt; margin: 0px; padding: 0px;">Sex</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0); border-image: initial; border-style: solid; border-width: 2px 1px 1px; height: 24px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 130px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Male</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 2px medium 1px 1px; height: 24px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 113px;"><div class="7" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px; text-align: right;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">3,387</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 2px 1px 1px medium; height: 24px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 101px;"><div class="3" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">(38.49)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 2px medium 1px 1px; height: 24px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 98px;"><div class="7" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px; text-align: right;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">54</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 2px 1px 1px medium; height: 24px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 108px;"><div class="3" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">(52.94)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 2px medium 1px 1px; height: 24px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 144px;"><div class="5" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px; text-align: center;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">1.59</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0); border-image: initial; border-style: solid; border-width: 1px 1px 2px; height: 27px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 131px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">Female</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 2px 1px; height: 27px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 114px;"><div class="7" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px; text-align: right;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">5,412</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 2px medium; height: 27px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 102px;"><div class="3" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">(61.51)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 2px 1px; height: 27px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 99px;"><div class="7" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px; text-align: right;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">48</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 2px medium; height: 27px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 109px;"><div class="3" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">(47.06)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 2px 1px; height: 27px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 145px;"><div class="8" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px; text-align: center;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">0.89</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td rowspan="9" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 2px 1px 2px medium; height: 245px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 76px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: -1.2pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-family: 한양중고딕; font-size: 9pt; letter-spacing: -1.2pt; margin: 0px; padding: 0px;">Age</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0); border-image: initial; border-style: solid; border-width: 2px 1px 1px; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: bottom; width: 130px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">80 and above</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 2px medium 1px 1px; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 113px;"><div class="2" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px; text-align: right;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">381</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 2px 1px 1px medium; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 101px;"><div class="3" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">(4.33)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 2px medium 1px 1px; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 98px;"><div class="7" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px; text-align: right;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">39</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 2px 1px 1px medium; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 108px;"><div class="3" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">(38.24)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 2px medium 1px 1px; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 144px;"><div class="9" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; margin: 0px; padding: 0px;">10.24</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 1px solid rgb(0, 0, 0); height: 26px; margin: 0px; padding: 1px 6px; vertical-align: bottom; width: 131px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">70-79</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 114px;"><div class="2" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px; text-align: right;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">589</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 102px;"><div class="3" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">(6.69)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 99px;"><div class="1" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px; text-align: right;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">37</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 109px;"><div class="3" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">(36.27)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 145px;"><div class="9" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; margin: 0px; padding: 0px;">6.28</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 1px solid rgb(0, 0, 0); height: 26px; margin: 0px; padding: 1px 6px; vertical-align: bottom; width: 131px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">60-69</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 114px;"><div class="2" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px; text-align: right;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">1,118</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 102px;"><div class="3" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">(12.71)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 99px;"><div class="1" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px; text-align: right;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">17</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 109px;"><div class="3" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">(16.67)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 145px;"><div class="9" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; margin: 0px; padding: 0px;">1.52</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 1px solid rgb(0, 0, 0); height: 26px; margin: 0px; padding: 1px 6px; vertical-align: bottom; width: 131px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">50-59</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 114px;"><div class="2" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px; text-align: right;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">1,672</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 102px;"><div class="3" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">(19.00)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 99px;"><div class="2" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px; text-align: right;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">7</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 109px;"><div class="3" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">(6.86)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 145px;"><div class="9" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; margin: 0px; padding: 0px;">0.42</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 1px solid rgb(0, 0, 0); height: 26px; margin: 0px; padding: 1px 6px; vertical-align: bottom; width: 131px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">40-49</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 114px;"><div class="2" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px; text-align: right;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">1,203</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 102px;"><div class="3" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">(13.67)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 99px;"><div class="2" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px; text-align: right;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">1</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 109px;"><div class="3" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">(0.98)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 145px;"><div class="9" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; margin: 0px; padding: 0px;">0.08</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 1px solid rgb(0, 0, 0); height: 26px; margin: 0px; padding: 1px 6px; vertical-align: bottom; width: 131px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">30-39</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 114px;"><div class="2" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px; text-align: right;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">900</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 102px;"><div class="3" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">(10.23)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 99px;"><div class="2" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px; text-align: right;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">1</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 109px;"><div class="3" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">(0.98)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 145px;"><div class="9" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; margin: 0px; padding: 0px;">0.11</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 1px solid rgb(0, 0, 0); height: 26px; margin: 0px; padding: 1px 6px; vertical-align: bottom; width: 131px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">20-29</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 114px;"><div class="2" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px; text-align: right;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">2,380</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 102px;"><div class="3" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">(27.05)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 99px;"><div class="7" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px; text-align: right;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">0</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 109px;"><div class="3" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">(0.00)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 145px;"><div class="9" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; margin: 0px; padding: 0px;">-</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 1px solid rgb(0, 0, 0); height: 26px; margin: 0px; padding: 1px 6px; vertical-align: bottom; width: 131px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">10-19</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 114px;"><div class="2" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px; text-align: right;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">457</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 102px;"><div class="3" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">(5.19)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 99px;"><div class="7" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px; text-align: right;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">0</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 1px medium; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 109px;"><div class="3" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">(0.00)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 1px 1px; height: 26px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 145px;"><div class="9" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; margin: 0px; padding: 0px;">-</span></div>
</td></tr>
<tr style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; margin: 0px; padding: 0px;"><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0); border-image: initial; border-style: solid; border-width: 1px 1px 2px; height: 29px; margin: 0px; padding: 1px 6px; vertical-align: bottom; width: 131px;"><div class="0" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 9pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">0-9</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 2px 1px; height: 29px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 114px;"><div class="2" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px; text-align: right;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">99</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 2px medium; height: 29px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 102px;"><div class="3" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">(1.13)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 2px 1px; height: 29px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 99px;"><div class="7" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px; text-align: right;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">0</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0) black; border-image: initial; border-style: solid solid solid none; border-width: 1px 1px 2px medium; height: 29px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 109px;"><div class="3" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; padding: 0px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; font-size: 10pt; letter-spacing: 0pt; margin: 0px; padding: 0px;">(0.00)</span></div>
</td><td style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-color: rgb(0, 0, 0) black rgb(0, 0, 0) rgb(0, 0, 0); border-image: initial; border-style: solid none solid solid; border-width: 1px medium 2px 1px; height: 29px; margin: 0px; padding: 1px 6px; vertical-align: middle; width: 145px;"><div class="9" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; padding: 0px; text-align: center;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; letter-spacing: 0pt; margin: 0px; padding: 0px;">-</span></div>
</td></tr>
</tbody></table>
<br />
<br />
20/3/20<br />
En este enlace <a href="http://ncov.mohw.go.kr/en/baroView.do?brdId=11&brdGubun=111&dataGubun=&ncvContSeq=&contSeq=&board_id=">Quarantine System</a> <a href="http://ncov.mohw.go.kr/en/baroView.do?brdId=11&brdGubun=111&dataGubun=&ncvContSeq=&contSeq=&board_id=">Korean Government’s Response System(as of February 25, 2020)</a> de la web del ministerio de salud y bienestar de Korea, hay una descripción sobre lo que han llamado Sistema de cuarentena, donde describen algunos de sus procedimientos para atacar el brote.<br />
Todo el texto me parece muy interesante, aunque pego unos fragmentos me parecen a destacar.<br />
<br />
<i>Testing and diagnosis</i><br />
<i>There are currently 118 locations – 23 public facilities, 81 healthcare facilities, and 14 commercial laboratories - that provide testing and diagnosis services. As of March, approval for five diagnosis tests have been fast-tracked.
Since scaling the use of diagnosis tests at testing facilities and obtaining fast-track approval, the maximum daily testing capacity increased from 3,000 people (February 7) to approximately 15,000 people in March.</i><br />
<i><br /></i>
<i><br /><b>Preventing COVID-19 spread using epidemiologic surveys and isolating people who have come in contact with a patient</b></i><br />
<i>Epidemiologic survey</i><br />
<i>When cases are confirmed, the central and local governments promptly conduct epidemiological investigations to track infection sources and screen contacts.</i><br />
<i> The Korean government thoroughly identifies the whereabouts of confirmed cases based on their credit card use history, CCTV, and mobile phone location information and disclose the information transparently to prevent additional infections and help people learn whether they are contacts themselves.</i><br />
<i> To rapidly complete epidemiological investigations, the preliminary investigations of individual cases are conducted by local governments. For outbreaks within healthcare institutions and group facilities, the central immediate response teams are providing support to prevent further spread</i><br />
<i><br /></i>
<i> Isolation</i><br />
<i> A clinic that first becomes aware of a confirmed case shall conduct a contact trace following directions provided by the city/provincial epidemiologic survey task force. After the confirmed case has been identified, persons who have had contact with the patient, including family members or roommates shall be self-quarantined</i><br />
<i> Contacts identified through epidemiological investigations are all put under self-isolation and thoroughly managed on a one-on-one basis by the Ministry of the Interior and Safety and local governments. Those put under self-isolation are banned from leaving the nation regardless of whether or not they develop symptoms. Those violating self-isolation will be imposed with a fine of KRW 10 million or less or imprisonment with labor of one year or less. </i><br />
<br />
19/3/20<br />
<br />
Siguiendo con Korea, parece que un importante índice de su bolsa, el Kospi Seul, no es tan optimista como yo en mi entrada de ayer. Lleva 5 días bajando con una pérdida del 21% (desde 1911 a 1589) y la importante bajada de ayer (4,8%) se relacionaría un repunte de 192 casos casos desde los 74 que tuvieron el día 16 de marzo, mínimo por el momento.<br />
<br />
Datos de bolsa en <a href="https://www.elmundo.es/economia/bolsa/indices/kospiseul_I.SL.html">Kospi Seul</a><br />
<br />
Datos de casos de COVID19 en <a href="https://www.cdc.go.kr/board/board.es?mid=a30402000000&bid=0030">Updates on COVID-19 in Republic of Korea. 19 March, 2020</a><br />
<br />
<br />
<br />
18/3/20<br />
<br />
Korea del sur, en adelante Korea, es un país similar a España en alguna de sus magnitudes como puede verse en la tabla (población y renta algo mayor en Korea y densidad muy superior)<br />
<br />
<table border="1" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 706px;">
<colgroup><col style="mso-width-alt: 3986; mso-width-source: userset; width: 82pt;" width="109"></col>
<col style="mso-width-alt: 3803; mso-width-source: userset; width: 78pt;" width="104"></col>
<col style="mso-width-alt: 4132; mso-width-source: userset; width: 85pt;" width="113"></col>
<col style="width: 60pt;" width="80"></col>
</colgroup><tbody>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt; width: 82pt;" width="109">país</td>
<td style="width: 78pt;" width="104">Censo población</td>
<td style="width: 85pt;" width="113">Densidad población</td>
<td style="width: 60pt;" width="80">Renta per cápita</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;">Korea del sur</td>
<td class="xl63">51 446 201</td>
<td class="xl63">507 hab./km²</td>
<td class="xl64">32.775$</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;">España</td>
<td class="xl63">47 100 000</td>
<td class="xl63">93,09 hab./km²</td>
<td class="xl63">29.661$</td>
</tr>
</tbody></table>
<br />
Tanto Korea como España estamos sufriendo la pandemia por el COVID-19. Korea empezó antes, el 20 de enero tuvo su primer caso, coherentemente con su proximidad a China, y fue casi un mes después cuando el brote fue tomando mayor intensidad. Llegaron a los 909 casos por día el día 29 de febrero, alcanzando los 8000 casos. A día de hoy tienen el brote muy controlado.<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj40OsLyuZrMfq51mqRKKRYbo-IFsIO3Dh8eoZNIlYh_3uphJ8pVUHq-Dkpm8oIHfaKIOfdMo2TlEYIz0k0pX5fnWLEwUwPmdcwIIqj7qrarsX88RoaOZzzh0b2zJsSUHRsqf90T1BF7qlz/s1600/Covid-19+Korea+13_3_20.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="650" data-original-width="767" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj40OsLyuZrMfq51mqRKKRYbo-IFsIO3Dh8eoZNIlYh_3uphJ8pVUHq-Dkpm8oIHfaKIOfdMo2TlEYIz0k0pX5fnWLEwUwPmdcwIIqj7qrarsX88RoaOZzzh0b2zJsSUHRsqf90T1BF7qlz/s1600/Covid-19+Korea+13_3_20.gif" /></a></div>
<br />
<br />
En España el brote comenzó a tomar intensidad a finales de febrero y a día 16 de marzo de 2020 estábamos en más de 9000 casos con días de más de 2.000 casos. En España tendremos muchos más casos que en Korea.<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhjEz8rVYNFkhRyoC0Vf9Ykgzs93mOh3PYEoDOxLYvi9zVmCZu1UsCcQFVbFzl0DMfcsuHWzSRCTEWVnY9rGovrKQ6fhlQE45PTzOc17ATxFcHECMzrRAFIk0T4a-Pk_uYE3csmQyMjMT5y/s1600/Covid-19+Espa%25C3%25B1a+16_3_20.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="539" data-original-width="692" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhjEz8rVYNFkhRyoC0Vf9Ykgzs93mOh3PYEoDOxLYvi9zVmCZu1UsCcQFVbFzl0DMfcsuHWzSRCTEWVnY9rGovrKQ6fhlQE45PTzOc17ATxFcHECMzrRAFIk0T4a-Pk_uYE3csmQyMjMT5y/s1600/Covid-19+Espa%25C3%25B1a+16_3_20.gif" /></a></div>
<br />
Una importante razón de la diferente evolución de las curvas epidémicas es la experiencia de Korea en el padecimiento del MERS en 2015. Dice Denis Normile en el interesante artículo <a href="https://www.sciencemag.org/news/2020/03/coronavirus-cases-have-dropped-sharply-south-korea-whats-secret-its-success">Coronavirus cases have dropped sharply in South Korea. What’s the secret to its success?</a> :<br />
<br />
<i>South Korea learned the importance of preparedness the hard way. In 2015, a South Korean businessman came down with Middle East respiratory syndrome (MERS) after returning from a visit to three Middle Eastern countries. He was treated at three South Korean health facilities before he was diagnosed with MERS and isolated. By then, he had set off a chain of transmission that infected 186 and killed 36, including many patients hospitalized for other ailments, visitors, and hospital staff. Tracing, testing, and quarantining nearly 17,000 people quashed the outbreak after 2 months. The specter of a runaway epidemic alarmed the nation and dented the economy.</i><br />
<br />
A partir de dicha experiencia han hecho más de 270.000 tests para detectar los casos y se han apoyado en la tecnología para depurar la información sobre los recorridos de los enfermos y poder aislarlos. En el artículo del Korea Centers for Disease Control and Prevention: <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045882/pdf/ophrp-11-60.pdf">Contact Transmission of COVID-19 in South Korea: Novel Investigation Techniques for Tracing Contacts</a> cuentan los procedimientos utilizados, que resumen es esta gráfica.<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEggnZhfNfWPsNtO8p9ZMGjh3_IFSlCVSpxOFIn2ESpqjXK6g_Edr9ALv1C0sS8jZa81h666ibgsjkZNutC0svND54VnvKx3DYt9ompRoE4NRlKELEdiseiRCOoLyWYuwdPk477Zy8_199Lh/s1600/Korea+CDC+contact+transmission.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="486" data-original-width="889" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEggnZhfNfWPsNtO8p9ZMGjh3_IFSlCVSpxOFIn2ESpqjXK6g_Edr9ALv1C0sS8jZa81h666ibgsjkZNutC0svND54VnvKx3DYt9ompRoE4NRlKELEdiseiRCOoLyWYuwdPk477Zy8_199Lh/s1600/Korea+CDC+contact+transmission.gif" /></a></div>
Han utilizado información procedente de los registros hospitalarios, de geolocalización de los teléfonos móviles, del uso de tarjetas bancarias y de las cámaras de televisión que hay por todo el país.<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgryTDxLVISbyUFry54cO4BZ99gwySjQE0vpj7TiA-4YQDGDFpvDtgt6Gs_cTpg79au6UkJrgDAtrf5e2odmSozbAwmxLh1dEswmOsnsgmJV6TR1H9chdWOe0s8qhhKZPSVkz7sq5gUHEUi/s1600/Korea+CDC+contact+transmission_fuentes.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="566" data-original-width="658" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgryTDxLVISbyUFry54cO4BZ99gwySjQE0vpj7TiA-4YQDGDFpvDtgt6Gs_cTpg79au6UkJrgDAtrf5e2odmSozbAwmxLh1dEswmOsnsgmJV6TR1H9chdWOe0s8qhhKZPSVkz7sq5gUHEUi/s1600/Korea+CDC+contact+transmission_fuentes.gif" /></a></div>
<br />
<br />
Con todo ello han podido reconstruir las rutas de los enfermos, identificar los contactos, someterlos a los tests y si ha sido necesario aislarlos. Han publicado las rutas de los enfermos para que otras personas enriquecieran la información procurando respetar la intimidad de los enfermos.<br />
<br />
No parece hayan utilizado Big Data ya que hablan de lo laborioso de ver las bases de datos médicas, de los datos de GPS, de la información de los cajeros, de las imágenes de TV. Toda esta información también existe en España solo, que no es poco, falta que la autoridad entienda que es bueno para el conjunto de la población poder cruzarla y la población también lo entendamos.<br />
<br />
Esta epidemia de COVID19 la pasaremos como podamos, con mucho esfuerzo de toda la población, profesionales sanitarios, etc etc con una gran merma en términos de riqueza del país, pero espero que aprendamos, para cuando llegue la próxima que posiblemente llegará.JOSE Rhttp://www.blogger.com/profile/09318104344786439010noreply@blogger.com0tag:blogger.com,1999:blog-1952063008451683630.post-32117881157560075862020-03-16T06:58:00.000+01:002020-03-19T12:45:30.768+01:00CT´s de vacunas para el COVID-1919/3/20<br />
<br />
Continuando con los ensayos clínicos de vacunas para el COVID-19. He buscado en el<a href="http://www.chictr.org.cn/"> Chinese Clinical Trial Registry</a> (ChiCTR) y tras cacharrear un poco para entender como funciona, con la búsqueda "Public title = coronavirus" y "Scientific title = vaccine" , se obtiene 3 Resultados<br />
<div>
<br /></div>
<table border="1" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 913px;">
<colgroup><col style="mso-width-alt: 4425; mso-width-source: userset; width: 91pt;" width="121"></col>
<col style="mso-width-alt: 20370; mso-width-source: userset; width: 418pt;" width="557"></col>
<col style="mso-width-alt: 5668; mso-width-source: userset; width: 116pt;" width="155"></col>
<col style="width: 60pt;" width="80"></col>
</colgroup><tbody>
<tr height="33" style="height: 24.75pt;">
<td class="xl64" height="33" style="height: 24.75pt; width: 91pt;" width="121"><b>Registration
number</b></td>
<td class="xl64" style="border-left: none; width: 418pt;" width="557"><b>Public title</b></td>
<td class="xl64" style="border-left: none; width: 116pt;" width="155"><b>Type</b></td>
<td class="xl64" style="border-left: none; width: 60pt;" width="80"><b>Registration time</b></td>
</tr>
<tr height="40" style="height: 30.0pt;">
<td class="xl66" height="61" rowspan="2" style="border-bottom: 1.0pt solid #CCCCCC; border-top: none; height: 45.75pt; line-height: 18px; margin-right: 0px; padding-bottom: 5px; padding-top: 5px; width: 91pt;" width="121">ChiCTR2000030950</td>
<td class="xl67" style="border-left: none; border-top: none; line-height: 18px; margin-right: 0px; padding-bottom: 5px; padding-top: 5px; width: 418pt;" width="557"><a href="http://www.chictr.org.cn/showprojen.aspx?proj=51272" style="margin-right: 0px; padding-bottom: 0px; padding-top: 0px;">Study for novel coronavirus pneumonia
(COVID-19) patients etiology and immune response and guidance for vaccine
design</a></td>
<td class="xl66" rowspan="2" style="border-bottom: 1.0pt solid #CCCCCC; border-top: none; line-height: 18px; margin-right: 0px; padding-bottom: 5px; padding-top: 5px; width: 116pt;" width="155"></td>
<td class="xl68" rowspan="2" style="border-bottom: 1.0pt solid #CCCCCC; border-top: none; line-height: 18px; margin-right: 0px; padding-bottom: 5px; padding-top: 5px; width: 60pt;" width="80">19/03/2020</td>
</tr>
<tr height="21" style="height: 15.75pt;">
<td class="xl69" height="21" style="border-left: none; height: 15.75pt; width: 418pt;" width="557">West China Hospital of Sichuan University</td>
</tr>
<tr height="40" style="height: 30.0pt;">
<td class="xl71" height="61" rowspan="2" style="border-bottom: 1.0pt solid #CCCCCC; border-top: none; height: 45.75pt; line-height: 18px; margin-right: 0px; padding-bottom: 5px; padding-top: 5px; width: 91pt;" width="121">ChiCTR2000030934</td>
<td class="xl72" style="border-left: none; border-top: none; line-height: 18px; margin-right: 0px; padding-bottom: 5px; padding-top: 5px; width: 418pt;" width="557"><a href="http://www.chictr.org.cn/showprojen.aspx?proj=51160" style="margin-right: 0px; padding-bottom: 0px; padding-top: 0px;">A Platform for Rapid Immuno-detection
and Emergency Vaccine Development of Novel Coronavirus (2019-COV)</a></td>
<td class="xl71" rowspan="2" style="border-bottom: 1.0pt solid #CCCCCC; border-top: none; line-height: 18px; margin-right: 0px; padding-bottom: 5px; padding-top: 5px; width: 116pt;" width="155">Observational</td>
<td class="xl73" rowspan="2" style="border-bottom: 1.0pt solid #CCCCCC; border-top: none; line-height: 18px; margin-right: 0px; padding-bottom: 5px; padding-top: 5px; width: 60pt;" width="80">18/03/2020</td>
</tr>
<tr height="21" style="height: 15.75pt;">
<td class="xl74" height="21" style="border-left: none; height: 15.75pt; width: 418pt;" width="557">The Fifth Affiliated Hospital of Sun Yat-sen University</td>
</tr>
<tr height="40" style="height: 30.0pt;">
<td class="xl76" height="61" rowspan="2" style="border-bottom: 1.0pt solid #CCCCCC; border-top: none; height: 45.75pt; width: 91pt;" width="121">ChiCTR2000030906</td>
<td class="xl77" style="border-left: none; border-top: none; width: 418pt;" width="557"><a href="http://www.chictr.org.cn/showprojen.aspx?proj=51154" style="margin-right: 0px; padding-bottom: 0px; padding-top: 0px;">A phase I clinical trial for
recombinant novel coronavirus (2019-COV) vaccine (adenoviral vector)</a></td>
<td class="xl76" rowspan="2" style="border-bottom: 1.0pt solid #CCCCCC; border-top: none; width: 116pt;" width="155">Prevention</td>
<td class="xl78" rowspan="2" style="border-bottom: 1.0pt solid #CCCCCC; border-top: none; width: 60pt;" width="80">17/03/2020</td>
</tr>
<tr height="21" style="height: 15.75pt;">
<td class="xl79" height="21" style="border-left: none; height: 15.75pt; width: 418pt;" width="557">Jiangsu Provincial Center for Disease Control and Prevention</td>
</tr>
</tbody></table>
<br />
<br />
16/3/20<br />
<br />
Tras una búsqueda en ClinicalTrialsRegister.eu con las palabra COVID VACCINE y no obtener ningún resultado, he buscado en clinicaltrials.gov y he obtenido estos cuatro resultados.<br />
<br />
<br />
<table border="1" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 889px;">
<colgroup><col style="width: 60pt;" width="80"></col>
<col style="mso-width-alt: 29586; mso-width-source: userset; width: 607pt;" width="809"></col>
</colgroup><tbody>
<tr height="60" style="height: 45.0pt;">
<td class="xl63" height="60" style="height: 45.0pt; width: 60pt;" width="80">NCT</td>
<td class="xl64" style="width: 607pt;" width="809">Brief Summary:</td>
</tr>
<tr height="160" style="height: 120.0pt;">
<td class="xl63" height="160" style="height: 120.0pt; width: 60pt;" width="80">NCT04283461</td>
<td class="xl64" style="width: 607pt;" width="809">This is a
phase I, open-label, dose ranging clinical trial in males and non-pregnant
females, 18 to 55 years of age, inclusive, who are in good health and meet
all eligibility criteria. This clinical trial is designed to assess the
safety, reactogenicity and immunogenicity of mRNA-1273 manufactured by
ModernaTX, Inc.<b> mRNA-1273 is a novel lipid nanoparticle (LNP)-encapsulated
mRNA-based <span class="font6">vaccine</span><span class="font5"> that
encodes for a full-length, prefusion stabilized spike (S) protein of </span><span class="font6">2019-</span></b><span class="font5"><b>novel coronavirus (nCoV).
</b> Enrollment will occur at one domestic site. Forty-five subjects will be
enrolled into one of three cohorts and will receive an intramuscular (IM)
injection of mRNA-1273 on Days 1 and 29 in the deltoid muscle. Subjects will
be followed through 12 months post second </span><span class="font6">vaccination</span><span class="font5"> (Day 394). The primary objective is to evaluate the
safety and reactogenicity of a 2-dose </span><span class="font6">vaccination</span><span class="font5"> schedule of mRNA-1273, given 28 days apart, across 3
dosages in healthy adults.</span></td>
</tr>
<tr height="200" style="height: 150.0pt;">
<td class="xl63" height="200" style="height: 150.0pt; width: 60pt;" width="80">NCT04299724</td>
<td class="xl64" style="width: 607pt;" width="809">In
December <span class="font6">2019</span><span class="font5">, viral
pneumonia (Covid-19) caused by a novel beta-coronavirus (SARS-CoV-2) broke
out in Wuhan, China. Some patients rapidly progressed and suffered severe
acute respiratory failure and died, making it imperative to develop a safe
and effective </span><span class="font6">vaccine</span><span class="font5"> to treat and prevent severe Covid-19 pneumonia. <b>Based on
detailed analysis of the viral genome and search for potential immunogenic
targets, a synthetic minigene has been engineered based on conserved domains
of the viral structural proteins and a polyprotein protease.</b> The infection of
Covid-19 is mediated through binding of the Spike protein to the ACEII
receptor, and the viral replication depends on molecular mechanisms of all of
these viral proteins. <b>This trial proposes to develop universal </b></span><span class="font6"><b>vaccine</b></span><span class="font5"><b> and test innovative
Covid-19 minigenes engineered based on multiple viral genes</b>, using an
efficient lentiviral vector system (NHP/TYF) to express viral proteins and
immune modulatory genes to modify artificial antigen presenting cells (aAPC)
and to activate T cells. In this study, the safety and immune reactivity of
this aAPC </span><span class="font6">vaccine</span><span class="font5"> will
be investigated.</span></td>
</tr>
<tr height="180" style="height: 135.0pt;">
<td class="xl63" height="180" style="height: 135.0pt; width: 60pt;" width="80">NCT04276896</td>
<td class="xl64" style="width: 607pt;" width="809">In
December <span class="font6">2019</span><span class="font5">, viral
pneumonia caused by a novel beta-coronavirus (Covid-19) broke out in Wuhan,
China. Some patients rapidly progressed and suffered severe acute respiratory
failure and died, making it imperative to develop a safe and effective </span><span class="font6">vaccine</span><span class="font5"> to treat and prevent
severe Covid-19 pneumonia. <b>Based on detailed analysis of the viral genome and
search for potential immunogenic targets, a synthetic minigene has been
engineered based on conserved domains of the viral structural proteins and a polyprotein
protease</b>. The infection of Covid-19 is mediated through binding of the Spike
protein to the ACEII receptor, and the viral replication depends on molecular
mechanisms of all of these viral proteins. <b>This trial proposes to develop and
test innovative Covid-19 minigenes engineered based on multiple viral genes</b>,
using an efficient lentiviral vector system (NHP/TYF) to express viral
proteins and immune modulatory genes to modify dendritic cells (DCs) and to
activate T cells. In this study, the safety and efficacy of this LV </span><span class="font6">vaccine</span><span class="font5"> (LV-SMENP) will be
investigated.</span></td>
</tr>
<tr height="80" style="height: 60.0pt;">
<td class="xl63" height="80" style="height: 60.0pt; width: 60pt;" width="80">NCT04292340</td>
<td class="xl64" style="width: 607pt;" width="809">There is still
no effective antiviral drugs and <span class="font6">vaccines</span><span class="font5"> against SARS-CoV-2 yet now. This is an obsevational
study, the investigators collected the clinical information and clinical
outcomes of the COVID-19 patients using anti-</span><span class="font6">2019-</span><span class="font5">nCoV inactivated convalescent plasma.<b>The study is to evaluate
the efficacy and safety of anti-</b></span><span class="font6"><b>2019-</b></span><span class="font5"><b>nCoV inactivated convalescent plasma in the treatment of
COVID-19 pneumonia</b>.</span></td>
</tr>
</tbody></table>
<br />JOSE Rhttp://www.blogger.com/profile/09318104344786439010noreply@blogger.com0tag:blogger.com,1999:blog-1952063008451683630.post-406749908365407642020-03-15T06:18:00.000+01:002020-03-17T16:08:48.518+01:00Notas sobre el brote por CoviD-19 (2)17/3/20<br />
<br />
Parece que Boris Jhonson ha cambiado de opinión y propone medidas más estrictas:
<br />
<h2>
<a href="https://www.theguardian.com/world/2020/mar/16/pm-tells-britons-to-avoid-non-essential-contact-with-others?CMP=share_btn_tw">PM tells Britons to avoid non-essential travel and contact</a></h2>
15/3/20 8h<br />
<br />
En la actualización del día 9/2/20 en la entrada <a href="http://degenetica.blogspot.com/2020/02/notas-sobre-el-brote-por-2019-ncov.html">Comentarios sobre el Covid-19 (1)</a> puse un comentario que denominé "Poniendo en contexto" elaborado a partir del<a href="http://vgripe.isciii.es/documentos/20172018/InformesAnuales/Informe_Vigilancia_GRIPE_2017-2018_27julio2018.pdf"> Informe de vigilancia de la gripe en España en la temporada 2017-2018 del Instituto Carlos III del Mº de Sanidad</a>.<br />
<br />
Siguiendo en la misma línea de poner en contexto, considero interesante comentar que si nos fijamos en las incidencias acumuladas semanales en la gráfica que se acompaña, obtenida del mencionado informe, se puede ver que en cualquiera de los años ha habido alrededor de 15 semanas con incidencias superiores a los 50 casos por 100.000 habitantes, que son 23.500 casos por semana. Dato que se puede comparar con los que tenemos hasta el momento, datos a día 13 de marzo en España: 5753 casos.<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh8A6FnwMlU5jWM6HUlfkZabKPtPpl4y_REeZSygUgoEPHp_s7MCryMpk7O1W1zY4SWmEkw-yxIvh7H4KOzTLI-jA2TdZxY2DDrkxzvpjjDjJwp02qXnuCFlo0t884LYrKTP5pcLYZGt6qf/s1600/Incidencia+semanal+gripe+Espa%25C3%25B1a+2017_18+y+anteriores.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="539" data-original-width="1070" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh8A6FnwMlU5jWM6HUlfkZabKPtPpl4y_REeZSygUgoEPHp_s7MCryMpk7O1W1zY4SWmEkw-yxIvh7H4KOzTLI-jA2TdZxY2DDrkxzvpjjDjJwp02qXnuCFlo0t884LYrKTP5pcLYZGt6qf/s1600/Incidencia+semanal+gripe+Espa%25C3%25B1a+2017_18+y+anteriores.gif" /></a></div>
<br />
Pienso que China, que al principio no reaccionó con la agilidad necesaria y desconociendo qué características de morbilidad y letalidad tiene el virus, decidió que no le volvía a afear el mundo no haber reaccionado bien como sucedió en 2002-3 <a href="https://www.who.int/csr/sars/epicurve/epiindex/en/index1.html">con el brote de SARS</a> , adoptó medidas de contención tan estrictas como confinar en sus domicilios a 50 millones de personas. Medidas que se han demostrado eficaces dado que los<a href="http://www.nhc.gov.cn/xcs/yqtb/202003/8331f126d3854413b6ea323009fbbcc5.shtml"> pocos casos que tiene estos días</a> (día 13/3/20 20 casos) son importados.<br />
Ahora son los países de occidente quienes tienen que estar a la altura aplicando estrictas medidas de contención, salvo UK que de momento solo confina en su domicilio a los enfermos.<br />
<br />
6h<br />
En la madrugada del día 14 al día 15 de Marzo de 2020 se ha publicado en el Boletín Oficial del Estado del Reino de España el:<br />
<i><a href="https://www.boe.es/boe/dias/2020/03/14/pdfs/BOE-A-2020-3692.pdf">Real Decreto 463/2020, de 14 de marzo, por el que se declara el estado de alarma para la gestión de la situación de crisis sanitaria ocasionada por el COVID-19</a>,</i> cuyo articulado es el siguiente<i>:</i><br />
Artículo 1. Declaración del estado de alarma<br />
Artículo 2. Ámbito territorial<br />
Artículo 3. Duración.<br />
Artículo 4. Autoridad competente.<br />
Artículo 5. Colaboración con las autoridades competentes delegadas.<br />
Artículo 6. Gestión ordinaria de los servicios<br />
Artículo 7. Limitación de la libertad de circulación de las personas<br />
Artículo 8. Requisas temporales y prestaciones personales obligatorias.<br />
Artículo 9. Medidas de contención en el ámbito educativo y de la formación<br />
Artículo 10. Medidas de contención en el ámbito de la actividad comercial,
equipamientos culturales, establecimientos y actividades recreativos, actividades de
hostelería y restauración, y otras adicionales.<br />
Artículo 11. Medidas de contención en relación con los lugares de culto y con las
ceremonias civiles y religiosas<br />
Artículo 12. Medidas dirigidas a reforzar el Sistema Nacional de Salud en todo el
territorio nacional<br />
Artículo 13. Medidas para el aseguramiento del suministro de bienes y servicios
necesarios para la protección de la salud pública.<br />
Artículo 14. Medidas en materia de transportes.<br />
Artículo 15. Medidas para garantizar el abastecimiento alimentario.<br />
Artículo 16. Tránsito aduanero.<br />
Artículo 17. Garantía de suministro de energía eléctrica, productos derivados del
petróleo y gas natural.<br />
Artículo 18. Operadores críticos de servicios esenciales<br />
Artículo 19. Medios de comunicación de titularidad pública y privada.<br />
Artículo 20. Régimen sancionador<br />
Disposición adicional primera. Personal extranjero acreditado como miembro de las
misiones diplomáticas<br />
Disposición adicional segunda. Suspensión de plazos procesales.<br />
Disposición adicional tercera. Suspensión de plazos administrativos.<br />
Disposición adicional cuarta. Suspensión de plazos de prescripción y caducidad.<br />
Disposición adicional quinta. Carácter de agente de la autoridad de los miembros de las
Fuerzas Armadas.<br />
Disposición final primera. Ratificación de las medidas adoptadas por las autoridades
competentes de las Administraciones Públicas.<br />
Disposición final segunda. Habilitación.<br />
Disposición final tercera. Entrada en vigor.<br />
<br />
<br />JOSE Rhttp://www.blogger.com/profile/09318104344786439010noreply@blogger.com0tag:blogger.com,1999:blog-1952063008451683630.post-20012168617128588892020-02-23T07:48:00.000+01:002020-03-23T09:28:01.582+01:00Segundo aniversario de degenetica.blogspot.com y tercero del fallecimiento de Guillermo Negre (Peñeta).<br />
23/3/20<br />
<!--[if gte mso 9]><xml>
<o:OfficeDocumentSettings>
<o:AllowPNG/>
</o:OfficeDocumentSettings>
</xml><![endif]--><br />
<!--[if gte mso 9]><xml>
<w:WordDocument>
<w:View>Normal</w:View>
<w:Zoom>0</w:Zoom>
<w:TrackMoves/>
<w:TrackFormatting/>
<w:HyphenationZone>21</w:HyphenationZone>
<w:PunctuationKerning/>
<w:ValidateAgainstSchemas/>
<w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
<w:IgnoreMixedContent>false</w:IgnoreMixedContent>
<w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
<w:DoNotPromoteQF/>
<w:LidThemeOther>ES</w:LidThemeOther>
<w:LidThemeAsian>X-NONE</w:LidThemeAsian>
<w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
<w:Compatibility>
<w:BreakWrappedTables/>
<w:SnapToGridInCell/>
<w:WrapTextWithPunct/>
<w:UseAsianBreakRules/>
<w:DontGrowAutofit/>
<w:SplitPgBreakAndParaMark/>
<w:EnableOpenTypeKerning/>
<w:DontFlipMirrorIndents/>
<w:OverrideTableStyleHps/>
</w:Compatibility>
<m:mathPr>
<m:mathFont m:val="Cambria Math"/>
<m:brkBin m:val="before"/>
<m:brkBinSub m:val="--"/>
<m:smallFrac m:val="off"/>
<m:dispDef/>
<m:lMargin m:val="0"/>
<m:rMargin m:val="0"/>
<m:defJc m:val="centerGroup"/>
<m:wrapIndent m:val="1440"/>
<m:intLim m:val="subSup"/>
<m:naryLim m:val="undOvr"/>
</m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
<w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"
DefSemiHidden="true" DefQFormat="false" DefPriority="99"
LatentStyleCount="267">
<w:LsdException Locked="false" Priority="0" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Normal"/>
<w:LsdException Locked="false" Priority="9" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>
<w:LsdException Locked="false" Priority="39" Name="toc 1"/>
<w:LsdException Locked="false" Priority="39" Name="toc 2"/>
<w:LsdException Locked="false" Priority="39" Name="toc 3"/>
<w:LsdException Locked="false" Priority="39" Name="toc 4"/>
<w:LsdException Locked="false" Priority="39" Name="toc 5"/>
<w:LsdException Locked="false" Priority="39" Name="toc 6"/>
<w:LsdException Locked="false" Priority="39" Name="toc 7"/>
<w:LsdException Locked="false" Priority="39" Name="toc 8"/>
<w:LsdException Locked="false" Priority="39" Name="toc 9"/>
<w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>
<w:LsdException Locked="false" Priority="10" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Title"/>
<w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>
<w:LsdException Locked="false" Priority="11" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>
<w:LsdException Locked="false" Priority="22" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Strong"/>
<w:LsdException Locked="false" Priority="20" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>
<w:LsdException Locked="false" Priority="59" SemiHidden="false"
UnhideWhenUsed="false" Name="Table Grid"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>
<w:LsdException Locked="false" Priority="1" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 1"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 1"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 1"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>
<w:LsdException Locked="false" Priority="34" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>
<w:LsdException Locked="false" Priority="29" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Quote"/>
<w:LsdException Locked="false" Priority="30" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 1"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 1"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 2"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 2"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 2"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 2"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 2"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 3"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 3"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 3"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 3"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 3"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 4"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 4"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 4"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 4"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 4"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 5"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 5"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 5"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 5"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 5"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 6"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 6"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 6"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 6"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 6"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>
<w:LsdException Locked="false" Priority="19" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>
<w:LsdException Locked="false" Priority="21" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>
<w:LsdException Locked="false" Priority="31" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>
<w:LsdException Locked="false" Priority="32" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>
<w:LsdException Locked="false" Priority="33" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>
<w:LsdException Locked="false" Priority="37" Name="Bibliography"/>
<w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/>
</w:LatentStyles>
</xml><![endif]--><!--[if gte mso 10]>
<style>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Tabla normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:"";
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin:0cm;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:11.0pt;
font-family:"Calibri","sans-serif";
mso-ascii-font-family:Calibri;
mso-ascii-theme-font:minor-latin;
mso-hansi-font-family:Calibri;
mso-hansi-theme-font:minor-latin;
mso-fareast-language:EN-US;}
</style>
<![endif]-->
<br />
<div class="MsoNormal">
Hoy se cumple el tercer aniversario del fallecimiento de mi
hermano Guillermo. Este blog que nació como un homenaje a él, está ahora totalmente
enfocado a otro asunto, que no es su objetivo inicial y denominación: los
medicamentos de terapias avanzadas. Hoy está enfocado a un grave, y puede que
gravísimo, problema de salud pública que está afectando a todo el planeta: la pandemia por COVID19. Aunque
está claro que no afecta a todos los países del mismo modo, porque las
respuestas y preparaciones para afrontarlo, no han sido las mismas en todos los países.</div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
Xiquet em fas falta i amés acabem de perdre a José Manuel.
No és un bon mes el mes de març per mosatros.</div>
<div class="MsoNormal">
<br /></div>
<br />
<br />
23/2/20 <br />
Hoy, día 23 de febrero de 2020 se cumplen dos años desde la puesta en marcha de este blog. Dentro de un mes, el día 23 de marzo, hará 3 años del fallecimiento de <a href="http://sobreguillermonegre.blogspot.com/">mi hermano Guillermo</a>. No hay día que no lo recuerde.<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjvy3V3yNQGvZz89ibhiBLS9yQuZBvEmXraNbkVOs3bY2vHUfe7PHDgI2gkflNy711NJIltPTHcsZTRNnIU1zEQ21ZCpfJOosuePL-UHSSTULBi2_EVhZLxkvv9r-qqN-5vyjpq8NXGY3cN/s1600/Guillermo+y+yo_casa+Tia+Pe%25C3%25B1a.bmp" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="574" data-original-width="413" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjvy3V3yNQGvZz89ibhiBLS9yQuZBvEmXraNbkVOs3bY2vHUfe7PHDgI2gkflNy711NJIltPTHcsZTRNnIU1zEQ21ZCpfJOosuePL-UHSSTULBi2_EVhZLxkvv9r-qqN-5vyjpq8NXGY3cN/s1600/Guillermo+y+yo_casa+Tia+Pe%25C3%25B1a.bmp" /></a></div>
<br />
En este momento de no concesión de Autorizaciones de comercialización (MA´s) por la EMA desde junio de 2019 que<a href="https://degenetica.blogspot.com/2019/06/autorizado-un-nuevo-atmp-zynteglo.html"> concedió la de Zynteglo</a>, espero que la recién (19 a 21 de febrero de 2020) <a href="https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-19-21-february-2020-meeting_en.pdf">pasada reunión del CAT </a>haya alumbrado alguna MA<br />
<br />
Aunque no sea tema del core del blog, la actual <a href="https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)">PHEIC sobre el Covid-19</a> declarada por la OMS el pasado día 30 de enero de 2020 que también vengo siguiendo -como de algún modo seguimos todos - me ha llevado a abrir <a href="http://degenetica.blogspot.com/2020/02/notas-sobre-el-brote-por-2019-ncov.html">una entrada sobre el brote</a> que si bien descentra el blog, no me ha parecido adecuado iniciar otro blog sobre ello. Ahora son Lombardía y el Veneto, en Italia, los protagonista en la contención/resolución del problema.<br />
<br />JOSE Rhttp://www.blogger.com/profile/09318104344786439010noreply@blogger.com0tag:blogger.com,1999:blog-1952063008451683630.post-49418400323135088272020-02-12T16:12:00.000+01:002020-02-12T16:12:26.093+01:00Resultados de fase 1 del NCT03399448 de edición génica con CRISPRDe uno de los CT con edición génica que comenté en la <a href="http://degenetica.blogspot.com/2020/01/pd-1-y-ccr-5-los-objetivos-mas-deseados.html">entrada del día 27 de enero de 2020</a> <b>"Los PD-1 y CCR-5 los objetivos más deseados en los CT de edición génica"</b>, el ClinicalTrials.gov NCT03399448, se ha presentado resultados de fase 1.<br />
En el artículo:
<a href="https://science.sciencemag.org/content/early/2020/02/05/science.aba7365">CRISPR-engineered T cells in patients with refractory cancer</a> de Stadtmauer et al, y entre ellos Carl H June, se describe el procedimiento de elaboración de NY-ESO-1 transduced CRISPR 3X edited cells (NYCE) y los resultados desde el punto de vista, sobre todo, de la seguridad.<br />
El producto consiste en linfocitos T del paciente, modificados mediante CRISPR y tres gRNA para eliminar tres genes codificadores de los receptores TRAC, TRBC Y PD1. Además, mediante vector viral modifican el gen NY-ESO-1<br />
Copio del artículo:<br />
<i>Experimental design</i><br />
<i>Guide RNAs (gRNA)</i><br />
<i>The genomic gRNA target sequences with PAM in bold were: TRAC1 and TRAC2: 5’-TGTGCTAGACATGAGGTCTATGG-3’, TRBC: 5’-GGAGAATGACGAGTGGACCCAGG-3’, and PDCD1: 5’-GGCGCCCTGGCCAGTCGTCTGGG-3
</i><br />
<br />
<i>Lentiviral vector manufacturing</i><br />
<i> The 8F TCR recognizes the HLA-A*0201 SLLMWITQC epitope on NY-ESO-1 and LAGE-1. The 8F TCR was isolated from a T cell clone obtained from patient after vaccination with NY-ESO-1 peptide. The TCR sequences were cloned into a transfer plasmid that contains the EF-1α promoter, a cPPT sequence, a rev response element and a woodchuck hepatitis virus posttranscriptional regulatory element
</i><br />
<i><br /></i>
El proceso de manufactura se refleja en este gráfico<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgKhEHL9grJI5iANqoDPPLdRSBymVua1FqCXFEHaWaVY-9F-f8H4zclfQz6aAVNiT4wW019EDtIhuD82ux7vavNgwhje4F9CknBNQnhQXX_evMs7PRnx2DQQvJJGZd9vj0Sno3X3FlZQMEd/s1600/NYCE++manufacture.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="484" data-original-width="1096" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgKhEHL9grJI5iANqoDPPLdRSBymVua1FqCXFEHaWaVY-9F-f8H4zclfQz6aAVNiT4wW019EDtIhuD82ux7vavNgwhje4F9CknBNQnhQXX_evMs7PRnx2DQQvJJGZd9vj0Sno3X3FlZQMEd/s1600/NYCE++manufacture.gif" /></a></div>
<br />
<br />
Y el protocolo del CT<br />
<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgj7SeG2dy_aBSRuI688OHG2LOHl1jteqE7bKx0cefAfp3oxaXievwkavzZjly6NRw0OeMqZ-GACk5BtzkAFOvPUEhw3i170SxR8TaEZjaS8ZzJOEBIX_5Tl-S_3a8RDAsJY4JNblXEbN0o/s1600/NYCE+CT+protocolo.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="975" data-original-width="790" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgj7SeG2dy_aBSRuI688OHG2LOHl1jteqE7bKx0cefAfp3oxaXievwkavzZjly6NRw0OeMqZ-GACk5BtzkAFOvPUEhw3i170SxR8TaEZjaS8ZzJOEBIX_5Tl-S_3a8RDAsJY4JNblXEbN0o/s1600/NYCE+CT+protocolo.gif" /></a></div>
<br />
En resumen:<br />
<i>In conclusion, our phase I human pilot study has confirmed that multiplex CRISPR-Cas9 editing of the human genome is possible at clinical scale. We note that while the initial clinical results are safe, experience with more patients given infusions with higher editing efficiencies and longer observation after infusion will be required to fully assess the safety of this approach. The potential rejection of infused cells due to pre-existing immune responses to Cas9 (28, 29) does not appear to be a barrier to the application of this promising technology. Finally, it is important to note that our manufacturing was based on the reagents available in 2016, when our protocol had been reviewed by the NIH Recombinant DNA Advisory Committee and received approval. Our Investigational New Drug Application was subsequently reviewed and accepted by the U.S. FDA. There has been rapid progress in the field since that time, with the development of reagents that should increase efficiencies and decrease off-target editing using CRISPR-based technology (50).
</i><br />
<i>Of the three patients that were infused with CRISPR-Cas9 engineered T cells, two patients had refractory advanced myeloma and one patient had a refractory metastatic sarcoma not responding to multiple prior therapies
</i><br />
<br />
En una <a href="https://degenetica.blogspot.com/2018/03/los-car-t-1.html">entrada anterior mencioné a Carl H June y Emily Whitehead</a>, actores con diversos papeles en el desarrollo de las CAR-T, el primero como médico y la segunda como paciente<br />
<br />JOSE Rhttp://www.blogger.com/profile/09318104344786439010noreply@blogger.com0tag:blogger.com,1999:blog-1952063008451683630.post-60269903950911975142020-02-06T19:33:00.002+01:002020-03-15T05:48:36.687+01:00Notas sobre el brote por Covid-19 (1)<div>
14/3/20<br />
<br />
Sobre Reino Unido<br />
<br />
El 12 de marzo de 2020 el<a href="https://www.gov.uk/government/news/covid-19-government-announces-moving-out-of-contain-phase-and-into-delay"> Gobierno del Reino Unido anuncia</a><br />
<br />
<i>"COVID-19: government announces moving out of contain phase and into delay"</i><br />
Disponen que los que tengan síntomas que se auto-aislen una semana y si empeoran que contacten con el NHS. No proponen ningún tipo de medida más que lavarse con frecuencia las manos.<br />
Buscando más información sobre la estrategia seguida por el Gobierno británico, veo en <a href="https://www.cgdev.org/blog/responsible-response-examining-uk-governments-covid-19-strategy">Responsible Response: Examining the UK Government’s COVID-19 Strategy</a>, un artículo de Kalipso Chalkidou que contiene interesantes reflexiones abogando porque el Gobierno publique los modelos y datos en que basa sus decisiones.<br />
Por su parte Richard Horton editor en jefe de The Lancet está embarcado en una iniciativa <a href="https://twitter.com/richardhorton1/with_replies">para que el gobierno explique los modelos en que basa su decisión de no contener</a><br />
A su parte Matt Hancock, Secretary of State for Health & Social Care, dice que <a href="https://twitter.com/MattHancock">sus decisiones están fundamentadas en evidencias,</a> pero no publican los modelos.<br />
Chris Whitty chief medical officer for England, <a href="https://www.bmj.com/content/368/bmj.m918.full">dice </a><br />
<i>Epidemic modelling predicts that the health system will face 50% of all covid-19 cases over a three week period and 90% of cases over a nine week period, when “the NHS could have a huge pressure on it</i>.<br />
<br />
De entrada, me parecía que UK por ser una isla, podría tener más fácil la contención, pero de momento entiende el Gobierno que no toca y dicen que su decisión se basa en los modelos de enfermedad y la adoptarán más adelante si procede. Un compañero de trabajo plantea que no podemos saber qué hubiera pasado en Wuhan si no se hubieran adoptado las medidas de contención tan importantes que ha adoptado el gobierno chino. Seguiremos sin saber que hubiera pasado en Wuhan-Hubei, pero veremos qué pasa en GB si no contienen. UK está en 120 casos por día, veremos en una semana sin contención en cuantos se sitúan.<br />
<br />
13/3/20<br />
<br />
20h<br />
<br />
Datos de España. Estamos en claro incremento de casos<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiCGNA0CQDzfsrvpHbJZJlaal2eGSidCD6L9Gh9_yXs2R_MO7gH54EfihhhxNdlealkZG1jw6OHZwt6OaaIdGlufTMDe5xlQKnZhYJhBvYIueK2bTHjOkGRuP6RvLV5iCrB8odzyTfUfpXx/s1600/Covid-19+Espa%25C3%25B1a+13_3_20.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="745" data-original-width="975" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiCGNA0CQDzfsrvpHbJZJlaal2eGSidCD6L9Gh9_yXs2R_MO7gH54EfihhhxNdlealkZG1jw6OHZwt6OaaIdGlufTMDe5xlQKnZhYJhBvYIueK2bTHjOkGRuP6RvLV5iCrB8odzyTfUfpXx/s1600/Covid-19+Espa%25C3%25B1a+13_3_20.gif" /></a></div>
<br />
<br />
<br />
<br />
19h<br />
Actualizamos datos de Italia, que lleva tres días con un número de casos en torno a 2.000:<br />
<br />
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 370px;">
<colgroup><col style="mso-width-alt: 4096; mso-width-source: userset; width: 84pt;" width="112"></col>
<col style="mso-width-alt: 3584; mso-width-source: userset; width: 74pt;" width="98"></col>
<col style="width: 60pt;" width="80"></col>
<col style="width: 60pt;" width="80"></col>
</colgroup><tbody>
<tr height="20" style="height: 15.0pt;">
<td align="right" class="xl66" height="20" style="height: 15.0pt; width: 84pt;" width="112">Día</td>
<td align="right" style="width: 60pt;" width="80">casos nuevos </td>
<td align="right" class="xl65" style="width: 60pt;" width="80">T1/T0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td align="right" class="xl66" height="20" style="height: 15.0pt;">11/03/20</td>
<td align="right">2076</td>
<td align="right" class="xl65">3,92</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td align="right" class="xl66" height="20" style="height: 15.0pt;">12/03/20</td>
<td align="right">2249</td>
<td align="right" class="xl65">1,08</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td align="right" class="xl66" height="20" style="height: 15.0pt;">13/03/20</td>
<td align="right">2116</td>
<td align="right" class="xl65">0,94</td>
</tr>
</tbody></table>
<br />
El día 11 el Índice T1/T0 es muy alto, de casi 4, pero los otros dos días está alrededor de 1.<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgDIBtHfUX33IIQYpj4EPlmaRalzSDZvRvnLpqDiF1-iqRlcuPNqza1A5ocmIoMU_tc_8cXPeBVVIF54yfqABP8jER2xZtAjsdRzwqt3nwVZ56HO9ihFN-MphpOFDuns9ShUf4j3l0P9crM/s1600/Covid-19+Italia+13_3_20.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="742" data-original-width="959" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgDIBtHfUX33IIQYpj4EPlmaRalzSDZvRvnLpqDiF1-iqRlcuPNqza1A5ocmIoMU_tc_8cXPeBVVIF54yfqABP8jER2xZtAjsdRzwqt3nwVZ56HO9ihFN-MphpOFDuns9ShUf4j3l0P9crM/s1600/Covid-19+Italia+13_3_20.gif" /></a></div>
<br />
<div class="separator" style="clear: both; text-align: center;">
</div>
<br />
<div class="separator" style="clear: both; text-align: center;">
</div>
<br />
<br />
11/3/20<br />
<br />
<!--[if gte mso 9]><xml>
<w:WordDocument>
<w:View>Normal</w:View>
<w:Zoom>0</w:Zoom>
<w:TrackMoves/>
<w:TrackFormatting/>
<w:HyphenationZone>21</w:HyphenationZone>
<w:PunctuationKerning/>
<w:ValidateAgainstSchemas/>
<w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
<w:IgnoreMixedContent>false</w:IgnoreMixedContent>
<w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
<w:DoNotPromoteQF/>
<w:LidThemeOther>ES</w:LidThemeOther>
<w:LidThemeAsian>X-NONE</w:LidThemeAsian>
<w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
<w:Compatibility>
<w:BreakWrappedTables/>
<w:SnapToGridInCell/>
<w:WrapTextWithPunct/>
<w:UseAsianBreakRules/>
<w:DontGrowAutofit/>
<w:SplitPgBreakAndParaMark/>
<w:EnableOpenTypeKerning/>
<w:DontFlipMirrorIndents/>
<w:OverrideTableStyleHps/>
</w:Compatibility>
<m:mathPr>
<m:mathFont m:val="Cambria Math"/>
<m:brkBin m:val="before"/>
<m:brkBinSub m:val="--"/>
<m:smallFrac m:val="off"/>
<m:dispDef/>
<m:lMargin m:val="0"/>
<m:rMargin m:val="0"/>
<m:defJc m:val="centerGroup"/>
<m:wrapIndent m:val="1440"/>
<m:intLim m:val="subSup"/>
<m:naryLim m:val="undOvr"/>
</m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
<w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"
DefSemiHidden="true" DefQFormat="false" DefPriority="99"
LatentStyleCount="267">
<w:LsdException Locked="false" Priority="0" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Normal"/>
<w:LsdException Locked="false" Priority="9" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>
<w:LsdException Locked="false" Priority="39" Name="toc 1"/>
<w:LsdException Locked="false" Priority="39" Name="toc 2"/>
<w:LsdException Locked="false" Priority="39" Name="toc 3"/>
<w:LsdException Locked="false" Priority="39" Name="toc 4"/>
<w:LsdException Locked="false" Priority="39" Name="toc 5"/>
<w:LsdException Locked="false" Priority="39" Name="toc 6"/>
<w:LsdException Locked="false" Priority="39" Name="toc 7"/>
<w:LsdException Locked="false" Priority="39" Name="toc 8"/>
<w:LsdException Locked="false" Priority="39" Name="toc 9"/>
<w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>
<w:LsdException Locked="false" Priority="10" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Title"/>
<w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>
<w:LsdException Locked="false" Priority="11" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>
<w:LsdException Locked="false" Priority="22" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Strong"/>
<w:LsdException Locked="false" Priority="20" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>
<w:LsdException Locked="false" Priority="59" SemiHidden="false"
UnhideWhenUsed="false" Name="Table Grid"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>
<w:LsdException Locked="false" Priority="1" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 1"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 1"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 1"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>
<w:LsdException Locked="false" Priority="34" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>
<w:LsdException Locked="false" Priority="29" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Quote"/>
<w:LsdException Locked="false" Priority="30" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 1"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 1"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 2"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 2"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 2"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 2"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 2"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 3"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 3"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 3"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 3"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 3"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 4"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 4"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 4"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 4"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 4"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 5"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 5"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 5"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 5"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 5"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 6"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 6"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 6"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 6"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 6"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>
<w:LsdException Locked="false" Priority="19" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>
<w:LsdException Locked="false" Priority="21" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>
<w:LsdException Locked="false" Priority="31" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>
<w:LsdException Locked="false" Priority="32" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>
<w:LsdException Locked="false" Priority="33" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>
<w:LsdException Locked="false" Priority="37" Name="Bibliography"/>
<w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/>
</w:LatentStyles>
</xml><![endif]--><!--[if gte mso 10]>
<style>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Tabla normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:"";
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin:0cm;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:11.0pt;
font-family:"Calibri","sans-serif";
mso-ascii-font-family:Calibri;
mso-ascii-theme-font:minor-latin;
mso-hansi-font-family:Calibri;
mso-hansi-theme-font:minor-latin;
mso-fareast-language:EN-US;}
</style>
<![endif]-->
<br />
<div class="MsoNormal">
La situación en España se puede ver de modo sintético, ya
que son varias CCAA las que concentran el mayor número de casos, con la gráfica que adjuntamos. Los datos se han obtenido de los informes del <a href="https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/home.htm">CENTRO DE COORDINACIÓN DE ALERTAS Y EMERGENCIAS SANITARIAS (CCAES)</a></div>
<br />
Se presenta casos por día, casos acumulados e índice de casos del día T1 dividido por los casos del día anterior (T0)<br />
<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiMoMddFXr-N1_iahgGSPtO6mVuA4X54cO6NoeKfkwezaC-egvqoEeX3Qp9MaTriaXglf4Q852qBXKqVSfF2caMIolnXDokpVmTX3d2YOV8RwUR5CaFVeYqGZeERhMGVQaRogfB23h3l9cy/s1600/Espa%25C3%25B1a+10_3_20.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="864" data-original-width="1310" height="422" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiMoMddFXr-N1_iahgGSPtO6mVuA4X54cO6NoeKfkwezaC-egvqoEeX3Qp9MaTriaXglf4Q852qBXKqVSfF2caMIolnXDokpVmTX3d2YOV8RwUR5CaFVeYqGZeERhMGVQaRogfB23h3l9cy/s640/Espa%25C3%25B1a+10_3_20.gif" width="640" /></a></div>
<br />
<br />
1/3/20<br />
En la web de <a href="http://www.protezionecivile.gov.it/web/guest/media-comunicazione/comunicati-stampa/-/content-view/view/1220045">Proteccione Civile</a> de Italia se publica diariamente los casos nuevos confirmados y con ellos construyo la siguiente gráfica, similar a la del día 26/2/20 aunque sin los acumulados porque, siendo importantes, no dejan ver la evolución diaria del brote.<br />
El índice T2/T1 sube a 3,21 el día 27, porque los casos se triplican, pasan de 78 a 250, pero vuelve a 1 porque se mantienen en el rango de 250 los dos días siguientes.<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiGsGo5VegW1P5XqyG1scXF6Z1ndvVtWTSf4DfuAkyZlXvvnjuug4kAc0IoTD-AXYOaO6GfztHaIXFfZ5TCHL7Ub4L5yNpUn047vsGpajLyqEqb-Lg6X5XpcUGMAKbk6LZ1UA92L44QCNoN/s1600/Covid-19+Italia+29_2_20.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="525" data-original-width="684" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiGsGo5VegW1P5XqyG1scXF6Z1ndvVtWTSf4DfuAkyZlXvvnjuug4kAc0IoTD-AXYOaO6GfztHaIXFfZ5TCHL7Ub4L5yNpUn047vsGpajLyqEqb-Lg6X5XpcUGMAKbk6LZ1UA92L44QCNoN/s1600/Covid-19+Italia+29_2_20.gif" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
</div>
<br />
<br />
<br />
26/2/20<br />
Dado que en China va bien el brote <a href="https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/Actualizacion_31_COVID-19.pdf">con unos números bajos, de alrededor de 400 casos por día,</a> y la atención está en Italia presento una gráfica con datos obtenidos en la web del Ministerio de Salud de Italia<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEipz3KDJieegoGUA4Gsqbsoe30Q5qqtlHXhvn08wLGkbI7W7iWYo5pV8EwImDGv2J8AP5JIscNAjX_sNDMR5AjogEaH0SndVzFSz87h-jcSeGLb4ju4_pmZaxbgJUUq_sSthxiGXTb849vw/s1600/Covid-19+Italia+26_2_20.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="537" data-original-width="720" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEipz3KDJieegoGUA4Gsqbsoe30Q5qqtlHXhvn08wLGkbI7W7iWYo5pV8EwImDGv2J8AP5JIscNAjX_sNDMR5AjogEaH0SndVzFSz87h-jcSeGLb4ju4_pmZaxbgJUUq_sSthxiGXTb849vw/s1600/Covid-19+Italia+26_2_20.gif" /></a></div>
<br />
<br />
<br />
<br />
22/2/20<br />
Ahora que parece que China contiene el brote, es Italia quien decide tomar medidas drásticas de ordenar el confinamiento de un número importante de personas en sus domicilios a través de<a href="http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioComunicatiNuovoCoronavirus.jsp?lingua=italiano&menu=salastampa&p=comunicatistampa&id=5453"> un comunicado del Ministerio de Salud de Italia</a><br />
<br />
<i>Covid-19: “Permanenza domiciliare per chi rientra dalla Cina”</i><br />
<i>Comunicato n. 87</i><br />
<i>Data del comunicato 21 febbraio 2020</i><br />
<i><br /></i>
<i>In merito all’Ordinanza firmata oggi dal ministro della Salute si precisa che per tutti gli individui che, negli ultimi quattordici giorni, abbiano fatto ingresso in Italia dopo aver soggiornato nelle aree della Cina interessate dall’epidemia, come identificate dall’Organizzazione Mondiale della Sanità:</i><br />
<i><br /></i>
<i>- l’Autorità sanitaria territorialmente competente provvederà all’adozione della misura della permanenza domiciliare fiduciaria con sorveglianza attiva ovvero, in presenza di condizioni ostative, di misure alternative di efficacia equivalente.</i><br />
<i><br /></i>
<i>- vige l’obbligo di comunicare al Dipartimento di prevenzione dell’azienda sanitaria territorialmente competente di aver soggiornato nelle aree suddette.</i><br />
<i><br /></i>
<i>Il mancato rispetto delle misure previste costituirà una violazione dell’Ordinanza. </i><br />
<i><br /></i>
<i><br /></i>
<i>Data di pubblicazione: 21 febbraio 2020 , ultimo aggiornamento 21 febbraio 2020</i><br />
<br />
En la ciudad de Codogno, en Lombardia, y en Padua en el Veneto, ambas de Italia, hay varios casos de afectados por infecciones del Covid-2019. Hay dos muertos y ¿50.000 personas confinadas en sus domicilios.<br />
<br />
<br />
19/2/20<br />
<br />
Actualización y cambio de tipo de gráfica<br />
<br />
<a href="http://www.nhc.gov.cn/xcs/yqtb/202002/8f2cfd17f4c040d89c69a4b29e99748c.shtml">Dice el Ministerio de Salud de China que los casos nuevos confirmados del día 18 de febrero de 2020 son 1749</a>, de lo que se deriva un índice de crecimiento de 0,93. Hemos cambiado el tipo de gráfico porque nos permite ver mejor los datos de las dos series, casos nuevos confirmados e índice de crecimiento.<br />
<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj8I12Fi-FZkL3RTzxgZg5ksVsmSUEv93Aap5h2MG_BDRGtvvEpusqcJ_234ssG-fSLvQbV87jQfoIcaYuof4XlOkQsfjccFY2pWJaB2YiV_Vh_ECX9LSFuUHObFNFQ0n-uI8fJ2mCFEaok/s1600/datos+dia++18_feb_20_B.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="660" data-original-width="932" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj8I12Fi-FZkL3RTzxgZg5ksVsmSUEv93Aap5h2MG_BDRGtvvEpusqcJ_234ssG-fSLvQbV87jQfoIcaYuof4XlOkQsfjccFY2pWJaB2YiV_Vh_ECX9LSFuUHObFNFQ0n-uI8fJ2mCFEaok/s1600/datos+dia++18_feb_20_B.gif" /></a></div>
<br />
<div class="separator" style="clear: both; text-align: center;">
</div>
<br />
<br />
18/2/20<br />
Actualización gráfica y datos<br />
<br />
Dice el Ministerio de Salud Chino que el día 17 de febrero de 2020 han tenido 1880 nuevos casos confirmados, lo que da un índice de crecimiento de 0,92<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj4pFfZt-IAN9zIt37zmourv8_P3t9KPdJEH6VcGV8jjb1oqS7-xspTS0Qaw_13lvMc3rQ4RYl9YTWyB7cILGc7N_NSQDnc7FcmRv7OydbWzgoNx-mKkWg4ns0IJhgAJXWYePGeR9L9symi/s1600/datos+dia++17_feb_20.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="661" data-original-width="927" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj4pFfZt-IAN9zIt37zmourv8_P3t9KPdJEH6VcGV8jjb1oqS7-xspTS0Qaw_13lvMc3rQ4RYl9YTWyB7cILGc7N_NSQDnc7FcmRv7OydbWzgoNx-mKkWg4ns0IJhgAJXWYePGeR9L9symi/s1600/datos+dia++17_feb_20.gif" /></a></div>
<br />
<div class="separator" style="clear: both; text-align: center;">
</div>
<br />
<div class="separator" style="clear: both; text-align: center;">
</div>
17/2/90<br />
<br />
Desde el día 12 de febrero de 2020, tras al cambio de criterio en la definición de caso confirmado, el Ministerio de Salud Chino publica da día dos valores de casos acumulados. Seguiremos construyendo la serie de casos confirmados por día con el que presenta mayor número de casos.<br />
<br />
Se presenta los datos hasta el día 16 de febrero de 2020 y en la gráfica puede verse un enorme pico hemos truncado para poder ver el detalle de los datos de casos confirmados por día y del índice de incremento. Podemos ver siguen en el rango de los habidos en los días anteriores: el día 14 con 2641 casos y <span style="white-space: pre;"> </span>0,65 de índice ; el 15 con 2008 casos y 0,76, y el día 16 con 2048 casos y 1,02 de indice de crecimiento.<br />
<br />
Hay que mencionar que el incremento de casos del día 12 de febrero, parece un conjunto de casos acumulados, por lo que la reflexión de que podría deber de multiplicarse por 8 el número de casos para obtener el total de los casos confirmados hecha en este blog el pasado día 13 de febrero, no sería correcta, como vienen indicando los casos de los tres días arriba mencionados, aunque los datos correspondan a funde semana. Los próximos días iremos viendo.<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg4uJSyFKGnezlX40h2rblt7zhTmGwtrgchNWK0sZ95Kuq_j-ePdzSe4teMPmZKndIRga_TMo_sFV_ibsFHW7k_1eFbWXDIGApA7KaQSKDxIfPwSkP7C9zOcGmLGWJLj6dxXlv5rMjhcmkc/s1600/datos+dia++16_feb_20.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em; text-align: center;"><img border="0" data-original-height="496" data-original-width="684" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg4uJSyFKGnezlX40h2rblt7zhTmGwtrgchNWK0sZ95Kuq_j-ePdzSe4teMPmZKndIRga_TMo_sFV_ibsFHW7k_1eFbWXDIGApA7KaQSKDxIfPwSkP7C9zOcGmLGWJLj6dxXlv5rMjhcmkc/s1600/datos+dia++16_feb_20.gif" /></a><br />
<br />
Seguimos a la expectativa del resultado de la vuelta al trabajo sobre el número de casos.<br />
<br />
13/2/20<br />
<br />
El Ministerio de Salud de China ha cambiado la definición de caso, de modo que no se requiere la determinación analítica con PCR para calificarlo como caso confirmado, siendo suficiente la existencia de sintomas clínicos. Con ello, se produce un gran incremento en el número de personas que cumplen el nuevo criterio. <a href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200212-sitrep-23-ncov.pdf">La OMS sigue manteniendo sus definiciones y en base a ellos los casos acumulados a 12 de febrero de 2020 son 45.171</a><br />
<br />
Actualizando los datos a día 12 de febrero, mezclando los casos obtenidos con una y otra definición nos topamos con ésta artefáctica gráfica.<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhUg_JXoSl8ABHWzDB4Q-GBGQ5gw-HuW39MzjFpGv1S03uw4pzoDDNJRTUyMGilQNkGhWRP2RwIVa1yxGiKtPQErVUMTWsaTQ1rEBirlPFvhm-N5DmWtTOc3GjrLR0fOEhOVAF1UVBf8M9b/s1600/datos+dia+cambio+definicion+13_feb_20.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="459" data-original-width="684" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhUg_JXoSl8ABHWzDB4Q-GBGQ5gw-HuW39MzjFpGv1S03uw4pzoDDNJRTUyMGilQNkGhWRP2RwIVa1yxGiKtPQErVUMTWsaTQ1rEBirlPFvhm-N5DmWtTOc3GjrLR0fOEhOVAF1UVBf8M9b/s1600/datos+dia+cambio+definicion+13_feb_20.gif" /></a></div>
Tal como venía siendo el número de casos los últimos días, con la definición de caso anterior, se podría estimar que iban a ser en el entorno de los 1800 casos que se podría producir el día 12 de febrero. Acepto que es un atrevimiento decir ésto.<br />
Dado que nos dicen que son unos 15.000, con la nueva definición, se derivaría de ello un factor de corrección 8, 3 . Estimamos los valores con dicha corrección y obtenemos la curva epidémica. También obtenemos el total de casos acumulados confirmados que se habrían producido con esta definición (380.000).<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi091DqpTMaOayyDTWocdNU6Zn9mF4VWXRRT8F44vcmbFFY83YvlEBmfjcfQ2mh8WieFS_yWhlHl31hCvAHnnXoy82p2lhzlp5Ay6Alf0gUcG94sFHYi7JmJTta54asmkoTwsw-3kP0QGwO/s1600/estimados+y+acumulados+dia+cambio+dfinicion+caso+12_feb_20.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="506" data-original-width="703" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi091DqpTMaOayyDTWocdNU6Zn9mF4VWXRRT8F44vcmbFFY83YvlEBmfjcfQ2mh8WieFS_yWhlHl31hCvAHnnXoy82p2lhzlp5Ay6Alf0gUcG94sFHYi7JmJTta54asmkoTwsw-3kP0QGwO/s1600/estimados+y+acumulados+dia+cambio+dfinicion+caso+12_feb_20.gif" /></a></div>
<br />
Veremos si se confirma la tendencia a disminuir que veíamos desde el pasado día 4 de febrero y veremos como influye la vuelta al trabajo de los trabajadores chinos.<br />
<br />
<br />
12/2/20<br />
Actualización de datos a 11 de febrero. Siguen bajando los casos nuevos (2015) y con ello el % de crecimiento a un 0,85. La OMS decide que el virus causante de este brote se llame Covid-19.<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
</div>
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg_w189oiFAClsqWxvI4NSYyqAoIYLx6ZcP0a61htU2oEat76n1ZTDBhZceQM-7bUH94GuUt7cwWm2oGWw9zxf1U_1DG_0xZWPBN24n7dfomAZ3aW3HRKkJUZPwSbL_56Vehgkut1PCM9qc/s1600/nCoV+casos+dia+y+%2525+crecimiento+11_2_20.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="522" data-original-width="656" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg_w189oiFAClsqWxvI4NSYyqAoIYLx6ZcP0a61htU2oEat76n1ZTDBhZceQM-7bUH94GuUt7cwWm2oGWw9zxf1U_1DG_0xZWPBN24n7dfomAZ3aW3HRKkJUZPwSbL_56Vehgkut1PCM9qc/s1600/nCoV+casos+dia+y+%2525+crecimiento+11_2_20.gif" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
</div>
<br />
<br />
11/2/20<br />
Actualización con datos de los días 9 y 10. El 9 se incrementó el número de casos nuevos confirmados (3062) y el día 10 volvió a disminuir (2467). El porcentaje de crecimiento para el día 9 fue superior a 1 (1,16) y el día 10 fue menor a 1 (0,85). Las series ofrecen un trazado en sierra que habla de una estabilización del número de casos nuevos confirmados. Se actualiza la tabla.<br />
El Ministerio Chino publica dos datos de acumulados confirmados que parece responder a dos fuentes ¿Cuerpo de Producción y Construcción de Xinjiang y el propio Ministerio? con una pequeña diferencia en los datos. Tomamos los del Ministerio.<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjyDEnPdRZTi14ry4DkYfKkHEroJY7vH4KhrNpqv67c-H3OJ4hsR_O8zFTfXcSyIa60FJEPhmyBdgMIpMTcD0C_sJMM4J_UXyVlhsTbagcvjbXdc7VqZEBcxoniTqPdVqXIc9DrwC7jLV_Z/s1600/nCoV+casos+dia+y+%2525+crecimiento+10_2_20.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="685" data-original-width="939" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjyDEnPdRZTi14ry4DkYfKkHEroJY7vH4KhrNpqv67c-H3OJ4hsR_O8zFTfXcSyIa60FJEPhmyBdgMIpMTcD0C_sJMM4J_UXyVlhsTbagcvjbXdc7VqZEBcxoniTqPdVqXIc9DrwC7jLV_Z/s1600/nCoV+casos+dia+y+%2525+crecimiento+10_2_20.gif" /></a></div>
<br />
Dicen los medios, que <a href="https://www.lavanguardia.com/vida/20200211/473437653021/coronavirus-china-trabajadores-casos-medidas.html">las empresas reinician su actividad tras las vacaciones prolongadas como medio de cortar la cadena de transmisión mediante el aislamiento</a>, aunque <a href="https://www.europapress.es/motor/sector-00644/noticia-volkswagen-vuelve-retrasar-vuelta-trabajo-empleados-chinos-coronavirus-20200210174141.html">algunas lo posponen unos días más</a>. Veremos cómo influye ésto en el brote.<br />
<br />
<br />
<br />
9/2/20<br />
<br />
<b>Poniendo en contexto</b><br />
Por ver la dimensión del brote que está sufriendo China por el coronavirus, se me ocurre ver los datos de las campañas de gripe en España. En el<a href="http://vgripe.isciii.es/documentos/20172018/InformesAnuales/Informe_Vigilancia_GRIPE_2017-2018_27julio2018.pdf"> informe de vigilancia de la gripe en España en la temporada 2017-2018 del Instituto Carlos III del Mº de Sanidad</a> se aporta datos de esta temporada y las anteriores.<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj9yFUKxa8sN5_j3f_sYldZgV-EPgYjXCh-7IvBPRb61oXe9u-eLxH6G-UehXvYq0thyphenhyphen68E4eJtYV7xKI62SFjvdZ78NAlRahwVmeT_bel0mNzPL16S3tesZDdEn7vL3EBh8CLT4E0qdpfw/s1600/Tasa+global+de+gripe_Espa%25C3%25B1a+2009_10+hasta+2017_18.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="400" data-original-width="809" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj9yFUKxa8sN5_j3f_sYldZgV-EPgYjXCh-7IvBPRb61oXe9u-eLxH6G-UehXvYq0thyphenhyphen68E4eJtYV7xKI62SFjvdZ78NAlRahwVmeT_bel0mNzPL16S3tesZDdEn7vL3EBh8CLT4E0qdpfw/s1600/Tasa+global+de+gripe_Espa%25C3%25B1a+2009_10+hasta+2017_18.gif" /></a></div>
Vemos en esta tabla, que procede de dicho informe, la tasa global de incidencia acumulada de gripe ajustada por edad en la temporada 2017-2018, que fue de 2.313 casos por 100.000h, y en las campañas desde 2009-2010 hasta 2018-17 osciló entre unos 1.600 a .2700 casos por 100.000h, que suponen de 750.000 a 1.260.000 casos de gripe por año.<br />
<div>
En la temporada 2017-18 la tasa de hospitalización fue 23 por 100.000, es decir 10.800 personas ingresaron en relación con el brote anual de gripe (tabla 7, página 22). Y la tasa de letalidad en casos graves fue de 17,4% es decir 991 fallecimientos. Datos algo superiores a los de los años anteriores.</div>
<div>
Estos datos no nos asustan más allá de la indignación de ver las imágenes de personas en los pasillos de los hospitales en las semanas de mayor incidencia de casos.</div>
<div>
Entiendo que China se ha echado a la espalda parar este brote en un momento en que no se sabía cual era el comportamiento del virus y que hasta el momento se puede asimilar a una gripe estacional. Veremos si sigue siendo así. </div>
<br />
<br />
<b>Actualización datos</b><br />
El número de casos confirmados en el día 8 de febrero de 2020 ( 2.630) ha vuelto disminuir con respecto a los casos del día anterior (3.407) resultando un % porcentaje de crecimiento menor a 1 (0,77). No obstante, al encontrarnos en fin de semana podría suceder lo mismo que hace 15 días en el que un descenso en el número de casos el domingo día 26 de enero se acompañó de un incremento en el lunes día 27. Hipótesis no contrastada, claro.<br />
<br />
Entiendo que esta disminución de los casos podría deberse al importante número de personas confinadas en sus casas. Pero, ¿hasta cuando mantener este confinamiento? ¿Qué sucederá cuando se levante el confinamiento con los que no han tenido contacto con el virus? Habrá un gran número de personas que se habrán recuperado de la enfermedad y otras que no la habrán sufrido, pese al contacto con el virus, que harán de barrera, pero quienes no hayan tenido contacto con el virus serán susceptibles a padecer la enfermedad. Veremos.<br />
<br />
He quitado los valores de los días 17 y 18 de enero porque descuadran la gráfica y con ello parece muy diferente de las anteriores, aunque en el fondo, no lo es.<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgwYJI9MJUQqYN7E-MbxrHgExCqwL3YuMVv0k12M8FTtUoUH34xYuQq6yO6cgH8SmgqBWgTokDjKvj5dVWlKkQ2VqN3B8tLVdB3-IQY5-GfsHv6oO6ybM79-lJFUcHxQSBsk6IRTSBLjxj6/s1600/nCoV+casos+dia+y+%2525+crecimiento+8_2_20.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="494" data-original-width="671" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgwYJI9MJUQqYN7E-MbxrHgExCqwL3YuMVv0k12M8FTtUoUH34xYuQq6yO6cgH8SmgqBWgTokDjKvj5dVWlKkQ2VqN3B8tLVdB3-IQY5-GfsHv6oO6ybM79-lJFUcHxQSBsk6IRTSBLjxj6/s1600/nCoV+casos+dia+y+%2525+crecimiento+8_2_20.gif" /></a></div>
<br />
<br />
<br />
8/2/20<br />
Actualización datos<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
</div>
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhsKFrXanW8hmFwJB3lVYt75J2UizHfJA5EVUi1Lql1m7xW6yqYiqLhWa3NhWdtCtJGQrdBtFmq5CYP3cELUBBrrgtwACPsGsOHhIPAKYJwOKX3MMdN-xV0NTk-VhpVbkm4hEP3TiO2njPO/s1600/nCoV+casos+dia+y+%2525+crecimiento+7_2_20.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="517" data-original-width="709" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhsKFrXanW8hmFwJB3lVYt75J2UizHfJA5EVUi1Lql1m7xW6yqYiqLhWa3NhWdtCtJGQrdBtFmq5CYP3cELUBBrrgtwACPsGsOHhIPAKYJwOKX3MMdN-xV0NTk-VhpVbkm4hEP3TiO2njPO/s1600/nCoV+casos+dia+y+%2525+crecimiento+7_2_20.gif" /></a></div>
<br />
<br />
<br />
<br />
7/2/20<br />
<br />
Veo los datos del Ministerio de Salud chino, y en especial los confirmados a día 6 de febrero, que son 3143, inferiores a los del día 5 (3694) y día 4 (3884). Actualizo tabla y añado nueva gráfica porque me parece muy significativo. Otros actores más importantes que quien escribe ésto también hablan de la disminución de casos:<a href="https://periodicocorreo.com.mx/se-registra-una-disminucion-de-nuevos-casos-de-coronavirus/">El Director Ejecutivo (del Programa de Emergencias Sanitarias) de la OMS, Michael Ryan, informó que se registró una disminución en el número de nuevos casos de infección del coronavirus 2019-nCoV, cosa que sucede por primera vez desde su aparición informa Reuters.</a><br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgDBvIcDamYfyZeuAxe0r2PddjO2dBzvY7rrTWfO0wDiLRlhyphenhyphenwn3FTy7uFklbo7eRQvnC8554hQkoIMj24NMphb8b_IvVLooX247GRjTtq6a0DYpkIC4v26bxyh0CbJrf01Zr16pdkqFbVz/s1600/nCoV+casos+dia+y+%2525+crecimiento+6_2_20.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="517" data-original-width="709" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgDBvIcDamYfyZeuAxe0r2PddjO2dBzvY7rrTWfO0wDiLRlhyphenhyphenwn3FTy7uFklbo7eRQvnC8554hQkoIMj24NMphb8b_IvVLooX247GRjTtq6a0DYpkIC4v26bxyh0CbJrf01Zr16pdkqFbVz/s1600/nCoV+casos+dia+y+%2525+crecimiento+6_2_20.gif" /></a></div>
<br />
<br />
<br />
6/2/2020<br />
Llevo, como muchas personas, varios días siguiendo el brote de 2019-nCoV que viene aquejando, inicialmente y sobre todo a China, y ya a otros veinticinco países.<br />
Vengo pensando si descentrar un poco el blog hablando del brote, pero creo merece la pena.<br />
Bebo de varias fuentes, pero de una especialmente, del <a href="http://www.nhc.gov.cn/">Ministerio de Salud de la República de China</a> y de sus actualizaciones diarias de datos. No sé chino, pero con la ayuda del translator de Google, y que los números son los mismos los que se usa en China y los que se usan en occidente, me hace más fácil seguir las actualizaciones.<br />
Tengo una hojita de cálculo en la que voy anotando diariamente los datos y obteniendo una gráficas que me ayudan a saber dónde estamos.<br />
Los datos acumulados de casos confirmados no dejan ver el desarrollo detallado del brote, por ello presento datos de casos confirmados por día.<br />
Por otra parte, calculando el incremento de los casos sobre el día anterior (tasa de crecimiento) nos da pistas de como evoluciona el brote.<br />
En la gráfica de abajo presento dos series con ambas informaciones: Casos diarios desde el 18 de enero de 2020 en que comienza con 17 casos, hasta los 3.694 del día de ayer 5 de febrero de 2020. Datos que de confirmase hablaría de un descenso desde los 3.884 del día anterior.<br />
La tasa de crecimiento venía estando, a partir del día 29 de enero, entre 1,06 y 1,20 y en el día 5/2/20 se hace inferior a 1 (0,95) coherentemente con la disminución de casos arriba mencionada.<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
</div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgdVljRaH1Ru88fGjoGGMoZ8qmR7QWj95dly4HzCeNhaCGsXKhsmH0iwK0Kl0yOIsZGxaDvMkxEgam51wUCPKQw7B5v6teedA6BeiQrJO1I1n6htDJADrG9d1bv7p2EYV-t-TNevcB39MIo/s1600/nCoV+casos+dia+y+%2525+crecimiento+5_2_20+con+etiquetas.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="539" data-original-width="689" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgdVljRaH1Ru88fGjoGGMoZ8qmR7QWj95dly4HzCeNhaCGsXKhsmH0iwK0Kl0yOIsZGxaDvMkxEgam51wUCPKQw7B5v6teedA6BeiQrJO1I1n6htDJADrG9d1bv7p2EYV-t-TNevcB39MIo/s1600/nCoV+casos+dia+y+%2525+crecimiento+5_2_20+con+etiquetas.gif" /></a></div>
<br />
<br />
<table border="1" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 322px;">
<colgroup><col style="mso-width-alt: 5741; mso-width-source: userset; width: 118pt;" width="157"></col>
<col style="mso-width-alt: 3108; mso-width-source: userset; width: 64pt;" width="85"></col>
<col style="width: 60pt;" width="80"></col>
</colgroup><tbody>
<tr height="38" style="height: 28.5pt; mso-height-source: userset;">
<td class="xl66" height="38" style="height: 28.5pt; width: 118pt;" width="157">fecha</td>
<td class="xl70" style="width: 64pt;" width="85">casos confirmados</td>
<td class="xl67" style="width: 60pt;" width="80">T2/T1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl68" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.01.17</td>
<td class="xl66">17</td>
<td class="xl67"></td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl68" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.01.18</td>
<td class="xl66">59</td>
<td class="xl67">3,47</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl68" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.01.19</td>
<td class="xl66">77</td>
<td class="xl67">1,31</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl68" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.01.20</td>
<td class="xl66">93</td>
<td class="xl67">1,21</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl68" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.01.21</td>
<td class="xl66">149</td>
<td class="xl67">1,60</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl68" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.01.22</td>
<td class="xl66">131</td>
<td class="xl67">0,88</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl68" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.01.23</td>
<td class="xl66">259</td>
<td class="xl67">1,98</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl68" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.01.24</td>
<td class="xl66">457</td>
<td class="xl67">1,76</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl68" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.01.25</td>
<td class="xl66">688</td>
<td class="xl67">1,51</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl68" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.01.26</td>
<td class="xl66">769</td>
<td class="xl67">1,12</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl68" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.01.27</td>
<td class="xl66">1771</td>
<td class="xl67">2,30</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl68" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.01.28</td>
<td class="xl66">1459</td>
<td class="xl67">0,82</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl68" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.01.29</td>
<td class="xl66">1737</td>
<td class="xl67">1,19</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl68" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.01.30</td>
<td class="xl66">1981</td>
<td class="xl67">1,14</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl68" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.01.31</td>
<td class="xl66">2099</td>
<td class="xl67">1,06</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl69" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.02.1</td>
<td class="xl66">2589</td>
<td class="xl67">1,23</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl69" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.02.2</td>
<td class="xl66">2825</td>
<td class="xl67">1,09</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl69" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.02.3</td>
<td class="xl66">3235</td>
<td class="xl67">1,15</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl69" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.02.4</td>
<td class="xl66">3884</td>
<td class="xl67">1,20</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl69" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.02.5</td>
<td class="xl66">3694</td>
<td class="xl67">0,95</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl69" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.02.6</td>
<td class="xl66">3143</td>
<td class="xl67">0,85</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl69" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.02.7</td>
<td class="xl66">3407</td>
<td class="xl67">1,08</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl69" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.02.8</td>
<td class="xl66">2630</td>
<td class="xl67">0,77</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl69" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.02.9</td>
<td class="xl66">3062</td>
<td class="xl67">1,16</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl69" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.02.10</td>
<td class="xl66">2467</td>
<td class="xl67">0,81</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl69" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.02.11</td>
<td class="xl66">2015</td>
<td class="xl67">0,72</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl69" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.02.12</td>
<td class="xl66">15151</td>
<td class="xl67">7,52</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl69" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.02.13</td>
<td class="xl66">4047</td>
<td class="xl67">0,27</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl69" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.02.14</td>
<td class="xl66">2641</td>
<td class="xl67">0,65</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl69" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.02.15</td>
<td class="xl66">2008</td>
<td class="xl67">1,76</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl69" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.02.16</td>
<td class="xl66">2048</td>
<td class="xl67">1,02</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl69" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.02.17</td>
<td class="xl66">1888</td>
<td class="xl67">0,92</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl69" height="20" style="height: 15.0pt; width: 118pt;" width="157">2020.02.18</td>
<td class="xl66">1749</td>
<td class="xl67">0,93</td>
</tr>
</tbody></table>
<br />
<br />
Otras fuentes a seguir son:<br />
<a href="http://www.promedmail.org/">www.promedmail.org</a><br />
<a href="https://en.wikipedia.org/wiki/2019%E2%80%9320_outbreak_of_novel_coronavirus_2019-nCoV">https://en.wikipedia.org/wiki/2019%E2%80%9320_outbreak_of_novel_coronavirus_2019-nCoV</a></div>
http://virological.org/<br />
<a href="https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/home.htm">CENTRO DE COORDINACIÓN DE ALERTAS Y EMERGENCIAS SANITARIAS (CCAES)</a><br />
<br />
<div>
Agencias gubernamentales<br />
<a href="http://www.cdc.gov/">CDC</a>,<br />
<a href="http://www.ecdc.eu/">ECDC</a>,<br />
<a href="http://www.who.int/">OMS</a>,<br />
<br /></div>
JOSE Rhttp://www.blogger.com/profile/09318104344786439010noreply@blogger.com2tag:blogger.com,1999:blog-1952063008451683630.post-19725379945555352382020-02-06T15:39:00.000+01:002020-02-06T15:39:51.879+01:00Estrategia para favorecer el desarrollo de MTA en SueciaSuecia, un país de <a href="https://es.wikipedia.org/wiki/Suecia">10.171.524 hab. (2018)</a> y con una <a href="https://datosmacro.expansion.com/pib/suecia">renta per cápita (2018) de 46.310€,</a> (aunque su moneda oficial es la corona, no el euro) miembro <a href="https://elordenmundial.com/mapas/el-mapa-de-la-integracion-europea/">de la UE desde 1995</a>, nueve años después que España, tiene una estrategia para hacer llegar los MTA a sus ciudadanos, que se apoya en varias "patas":<br />
<ul>
<li><a href="https://atmpsweden.se/camp-2/camp/">Centre for Advanced Medical Products (CAMP)</a></li>
</ul>
<i>CAMP is a Vinnova funded project focussing on the science and technology required to translate ATMPs from lab to clinic, including bioprocess development, GMP production and logistics. CAMP drives collaboration between researchers, GMP competent resources, industry and hospitals</i>.<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj1MNEUn1Vq4fmZK82EUUPJSwAeMjpp1Ro8EfhS0P9ghtACXOWvDktOW00pCbgnfjbbLHv3uArZ7oyt_PArHaLdzrAPcJCGtAQqaoeGGrBxoIgFibi3qkjqzdPRQuuh3XkHzbvrfj7PWNF6/s1600/CAMP-Sweden+structure.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="428" data-original-width="777" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj1MNEUn1Vq4fmZK82EUUPJSwAeMjpp1Ro8EfhS0P9ghtACXOWvDktOW00pCbgnfjbbLHv3uArZ7oyt_PArHaLdzrAPcJCGtAQqaoeGGrBxoIgFibi3qkjqzdPRQuuh3XkHzbvrfj7PWNF6/s1600/CAMP-Sweden+structure.gif" /></a></div>
<br />
Centre Director – Jukka Lausmaa<br />
Scientific Director – Pontus Blomberg<br />
WP1 (Work packages – Process development – Stefan Scheding<br />
WP2 – Infrastructure for GMP manufacturing – Pontus Blomberg<br />
WP3 – Quality control, shelf-life and logistics – Jim Lund<br />
CCP1 (Cross cutting priorities) – Legislation, regulatory aspects and ethics – Ann Novotny<br />
CCP2 – Swedish ATMP challenges and opportunities – Kristina Kannisto<br />
Industry representatives;<br />
– Mohammad Bohlooly (AstraZeneca)<br />
– Raimund Strehl (VERIGRAFT)<br />
Coordinator – Paul Kingham<br />
Communications – Heather Main
<br />
<ul>
<li><a href="https://atmpsweden.se/swelife-atmp-2/swelife-atmp/">Swelife-ATMP</a></li>
</ul>
<i>Swelife-ATMP SDPs (SYSTEM DEVELOPMENT PROJECTS) address the systems and processes around ATMP development. </i><br />
<i>The following projects have commenced:</i><br />
<i>SDP1: The regulatory aspect for ATMP </i><br />
<i>SDP2: Road Map for setting the ethical and legal framework of stem cell based ATMP in Sweden
SDP3: Business models and health economics for ATMPs </i><br />
<i>SDP4: Opportunities and challenges for Sweden to become internationally leading in the field of gene therapy </i><br />
<i>SDP5: Sweden’s CAR T Cell Competence Network (SWECARNET)
</i><br />
<ul>
<li><a href="https://www.vinnova.se/">https://www.vinnova.se/</a></li>
</ul>
<i>Vinnova es la autoridad de innovación de Suecia. Nuestra misión es fortalecer la capacidad de innovación de Suecia y contribuir al crecimiento sostenible. Trabajamos para que Suecia sea una fuerza innovadora en un mundo sostenible. (</i>Traducido mediante translate de Google del Sueco<i>)</i><br />
Aportan<a href="https://atmpsweden.se/wp-content/uploads/2020/01/Protokoll_styrelsem%C3%B6te-nr-7_20190405.pdf"> recursos para financiar proyectos</a>, ver páginas 54 y 56.<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgA6u95_4R6879Hw-gvyGV_daegsuaOZhKdLLemL-zXVO6kTaLN-7VaHxJkz5ZOmhliYQ5b2m3PHXVRo3WpmBb1uaZSSUBndKjXK7WTWz9MaIFeG5xehRTCOtCHgs4nR5_hX2DtDaLqF1IO/s1600/CAMP+Projects+WP.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="705" data-original-width="1281" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgA6u95_4R6879Hw-gvyGV_daegsuaOZhKdLLemL-zXVO6kTaLN-7VaHxJkz5ZOmhliYQ5b2m3PHXVRo3WpmBb1uaZSSUBndKjXK7WTWz9MaIFeG5xehRTCOtCHgs4nR5_hX2DtDaLqF1IO/s1600/CAMP+Projects+WP.gif" /></a></div>
<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj2yTK4c_t7BhBb-iaR51n3PShgtCdpIdrPhttlEGKu5k7Dd2DS0spV-7m17C-S0s5w2tTSylfz1sew82xWaXQ0fyLlnifFx89vMSUTafKn0udZAR5eBAH9F0yVCsoo5IdM_2HQWSEn24PM/s1600/CAMP+SWElife+Projects+CCP.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="511" data-original-width="1219" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj2yTK4c_t7BhBb-iaR51n3PShgtCdpIdrPhttlEGKu5k7Dd2DS0spV-7m17C-S0s5w2tTSylfz1sew82xWaXQ0fyLlnifFx89vMSUTafKn0udZAR5eBAH9F0yVCsoo5IdM_2HQWSEn24PM/s1600/CAMP+SWElife+Projects+CCP.gif" /></a></div>
<br />
<br />
<br />
Tienen un <a href="https://www.google.com/maps/d/viewer?mid=1X82HDlhZO7mg2MfMe0pnX2-_FVZQlKQm&ll=60.006897060773966%2C16.131098449999968&z=5">mapa con los actores en el ámbito de los ATMP´s en Suecia</a> en que se recogen:<br />
<br />
35 ATMP Sweden partners
<br />
15 Facilities for manufacture or process development<br />
68 Clinical or pre-clinical ATMPs<br />
20 Specialist treatment clinics <br />
<br />
Total 138<br />
<br />
Tienen un resumen del proceso regulatorio de los ATMP´s elaborado por uno de sus grupos.<br />
<a href="https://atmpsweden.se/atmp-regulatory-guide/">https://atmpsweden.se/atmp-regulatory-guide/</a><br />
<div>
<br /></div>
JOSE Rhttp://www.blogger.com/profile/09318104344786439010noreply@blogger.com0tag:blogger.com,1999:blog-1952063008451683630.post-81821010321773901412020-01-27T19:39:00.000+01:002020-01-27T19:39:23.568+01:00PD-1 y CCR-5 los objetivos más deseados en los CT de edición génica<head><!-- Global site tag (gtag.js) - Google Analytics -->
<script async="" src="https://www.googletagmanager.com/gtag/js?id=UA-133555286-1"></script>
<script>
window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config', 'UA-133555286-1');
</script>
</head>
<br />
Tras varios días cacharreando con la tabla del artículo de Schaker y Seimetz, y la propia información de ClinicalTrials.gov, comparto la observación de que PD-1 y CCR-5 son los objetivos más deseados en los CT de edición génica.<br />
<br />
Nueve CT´S tienen por objetivo el gen PD-1.<br />
<br />
<table border="1" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 567px;">
<colgroup><col style="width: 119pt;" width="158"></col>
<col style="mso-width-alt: 14957; mso-width-source: userset; width: 307pt;" width="409"></col>
</colgroup><tbody>
<tr height="40" style="height: 30.0pt;">
<td class="xl68" height="40" style="height: 30.0pt; width: 119pt;" width="158"><b>NCT
Number</b></td>
<td class="xl68" style="border-left: none; width: 307pt;" width="409"><b>Title</b></td>
</tr>
<tr height="69" style="height: 51.75pt; mso-height-source: userset;">
<td class="xl67" height="69" style="height: 51.75pt; width: 119pt;" width="158">NCT03747965</td>
<td class="xl67" style="border-left: none; width: 307pt;" width="409">Study of PD-1
Gene-knocked Out Mesothelin-directed CAR-T Cells With the Conditioning of PC
in Mesothelin Positive Multiple Solid Tumors</td>
</tr>
<tr height="58" style="height: 43.5pt; mso-height-source: userset;">
<td class="xl67" height="58" style="border-top: none; height: 43.5pt; width: 119pt;" width="158">NCT03399448</td>
<td class="xl67" style="border-left: none; border-top: none; width: 307pt;" width="409">NY-ESO-1-redirected
CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)</td>
</tr>
<tr height="80" style="height: 60.0pt;">
<td class="xl67" height="80" style="border-top: none; height: 60.0pt; width: 119pt;" width="158">NCT03081715</td>
<td class="xl67" style="border-left: none; border-top: none; width: 307pt;" width="409">PD-1
Knockout Engineered T Cells for Advanced Esophageal Cancer</td>
</tr>
<tr height="100" style="height: 75.0pt;">
<td class="xl67" height="100" style="border-top: none; height: 75.0pt; width: 119pt;" width="158">NCT02793856</td>
<td class="xl67" style="border-left: none; border-top: none; width: 307pt;" width="409">PD-1
Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer</td>
</tr>
<tr height="100" style="height: 75.0pt;">
<td class="xl67" height="100" style="border-top: none; height: 75.0pt; width: 119pt;" width="158">NCT02863913</td>
<td class="xl67" style="border-left: none; border-top: none; width: 307pt;" width="409">PD-1
Knockout Engineered T Cells for Muscle-invasive Bladder Cancer</td>
</tr>
<tr height="100" style="height: 75.0pt;">
<td class="xl67" height="100" style="border-top: none; height: 75.0pt; width: 119pt;" width="158">NCT02867332</td>
<td class="xl67" style="border-left: none; border-top: none; width: 307pt;" width="409">PD-1
Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.</td>
</tr>
<tr height="80" style="height: 60.0pt;">
<td class="xl67" height="80" style="border-top: none; height: 60.0pt; width: 119pt;" width="158">NCT02867345</td>
<td class="xl67" style="border-left: none; border-top: none; width: 307pt;" width="409">PD-1
Knockout Engineered T Cells for Castration Resistant Prostate Cancer</td>
</tr>
<tr height="102" style="height: 76.5pt; mso-height-source: userset;">
<td class="xl67" height="102" style="border-top: none; height: 76.5pt; width: 119pt;" width="158">NCT03044743</td>
<td class="xl67" style="border-left: none; border-top: none; width: 307pt;" width="409">PD-1
Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated
Malignancies</td>
</tr>
<tr height="100" style="height: 76.0pt;">
<td class="xl68" height="160" style="height: 120.0pt; width: 119pt;" width="158">NCT03545815</td>
<td class="xl68" style="width: 307pt;" width="409">Study of CRISPR-Cas9 Mediated
PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients
With Mesothelin Positive Multiple Solid Tumors.</td></tr>
</tbody></table>
<br />
No obstante, los NCT02863913, NCT02867332, NCT02867345 han sido retirados<br />
<br />
La causa, entiendo que es, la importantísima función de autoregulación inmunitaria que queda reflejada en sus múltiples ubicaciones y funciones. (<a href="https://www.frontiersin.org/articles/10.3389/fimmu.2016.00550/full">The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation</a>):<br />
<i>Programed cell death 1 is expressed on activated CD4 and CD8 T cells, B cells, monocytes, natural killer (NK) cells, and dendritic cells (DCs) (23, 35, 36). PD-1 expression can also be induced on APCs, myeloid CD11c+ DCs, and monocytes (37, 38). ---</i><br />
<i>PD-1 expression is also upregulated and sustained on “exhausted” virus-specific T cells during chronic viral infection preventing their proliferation and function in clearing the virus (46, 47).</i><br />
Respecto de los ligandos:<br />
<i>PD-Ls have distinct expression patterns:</i><br />
<ul>
<li><i> PD-L1 is constitutively expressed on T and B cells, DCs, macrophages, mesenchymal stem cells and bone marrow-derived mast cells (35). In addition, PD-L1 is expressed on a wide variety of non-hematopoietic cells including lung, vascular endothelium, fibroblastic reticular cells, liver non-parenchymal cells, mesenchymal stem cells, pancreatic islets, astrocytes, neurons, and keratinocytes (36). It has also been shown to be expressed on placental syncytiotrophoblasts and functions in the placenta to induce fetal–maternal tolerance (48, 49). PD-L1 is expressed constitutively in the cornea and retinal pigmented epithelium (RPE) and PD-1–PD-L1 interaction protects the eye from activated T cells (50–53).</i></li>
<li><i>In contrast, PD-L2 expression is restricted to activated DCs, macrophages, bone marrow derived mast cells, and more than 50% of peritoneal B1 cells (54). In the thymus, PD-L1 is expressed mostly in the cortex, while PD-L2 expression is confined in medullary stromal cells (55, 56). PD-L1 expression on human T cells are induced by common γ chain cytokines IL-2, IL-7, and IL-15, whereas IL-21 can stimulate PD-L1 expression on B (CD19+) cells from peripheral blood mononuclear cells (PBMCs). LPS or BCR activation also result in induction of PD-L1 and PD-L2 in human B cells (14, 15, 28)</i><i>. ---</i></li>
</ul>
<i><b>PD-Ls are also expressed on various tumor cells. PD-Ls mediate potent inhibitory signals after ligation with PD-1, causing a detrimental effect on antitumor immunity by allowing the tumor cells to escape immunosurveillance </b>(62–64).</i><i></i><br />
<div>
<i><br /></i></div>
<i>
</i>Estas últimas frases son la razón de que sea un objetivo para tratar diversos tipos de cáncer, que se pretende mediante el Knock Out del gen PD-1, en todos estos ensayos con CRISPR/Cas9 como nucleasa.<br />
<br />
En ct.gov solo veo la información sobre el medio de "Delivery" de las herramientas a las células a modificar en el NCT03399448: <i>"NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1
Autologous T cells transduced with a lentiviral vector to express NY-ESO-1 and electroporated with CRISPR guide RNA to disrupt expression of endogenous TCRα, TCRβ and PD-1 (NYCE T Cells)."</i><br />
<i><br /></i>
Los nueve CT´s se basan en la modificiación de linfocitos T y 3 de ellos son un CART además del KO del PD-1.<br />
<i><br /></i>
<br />
<div>
<span style="color: red; mso-themecolor: dark2;"><span style="mso-spacerun: yes;"></span>Le ruego evalúe la presente entrada asignando un valor de 1 a 5, de peor a mejor valorada, usando la opción de comentarios
</span>
</div>
<div>
<br /></div>
JOSE Rhttp://www.blogger.com/profile/09318104344786439010noreply@blogger.com0tag:blogger.com,1999:blog-1952063008451683630.post-76384809312222077682020-01-17T16:06:00.000+01:002020-01-19T07:29:13.827+01:00A vueltas con los Ensayos Clínicos de edición génica en Clinicaltrials.gov<head><!-- Global site tag (gtag.js) - Google Analytics -->
<script async="" src="https://www.googletagmanager.com/gtag/js?id=UA-133555286-1"></script>
<script>
window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config', 'UA-133555286-1');
</script>
</head>
<br />
<div>
Dando vueltas a los datos de los ensayos clínicos de edición génica obtenidos de la página web de clínicaltrials.gov tras conocer del <a href="https://link.springer.com/article/10.1186/s40169-019-0244-7">trabajo de Schacker</a> entiendo que son las siguientes variables, las que definen las diversas soluciones que se vienen ensayando:<br />
<ul>
<li>Enfermedad a tratar,</li>
<li>Target (gen a modificar, eliminar, incorporar al genoma del paciente),</li>
<li>procedimiento de modificación del genoma (Modification), </li>
<li>nucleasa utilizada, </li>
<li>procedimiento de entrega (delivery), </li>
<li>tipo (In-vivo, ex-vivo).</li>
</ul>
<br />
Con relación a la enfermedad a tratar, son 21 diferentes las listadas por Sacher, que se han agrupado en 6 grupos para facilitar su tabulación, y que son los siguientes:<br />
<b>Cáncer hemático: </b><br />
<ul>
<li>Acute myeloid leukemia,</li>
<li>B cell leukemia, B cell lymphoma y</li>
<li>T cell Acute Lymphoblastic Leukemia, T cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma</li>
</ul>
<br />
<b>Cáncer no hemático: </b><br />
<ul>
<li>EBV positive advanced stage malignancies;</li>
<li>Esophageal cancer;</li>
<li>Hormone Refractory Prostate Cancer;</li>
<li>Human papillomavirus-Related malignant neoplasm;</li>
<li>Invasive Bladder Cancer Stage IV;</li>
<li>Metastatic non-small cell lung cancer;</li>
<li>Metastatic renal cell carcinoma;</li>
<li>Multiple Myeloma, Melanoma, Synovial Sarcoma, Myxoid/Round Cell Liposarcoma</li>
<li>Solid Tumor.</li>
</ul>
<br />
<b>Hemáticas</b>:<br />
<ul>
<li>Beta Thalassemia, </li>
<li>Hemophilia B</li>
<li>Sickle cell disease</li>
</ul>
<br />
<b>HIV</b><br />
<br />
<b></b>
<b>Lisosomas:</b><br />
<ul>
<li>Mucopolysaccharidosis I</li>
<li>y Mucopolysaccharidosis II</li>
</ul>
<br />
<b>Visión: </b>Leber congenital amaurosis 10<br />
<br />
Hemos cruzado las variables que nos parecen más significativas y presentamos las tablas que hemos obtenido.<br />
<br />
<table border="1" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 1270px;">
<colgroup><col style="mso-width-alt: 5851; mso-width-source: userset; width: 120pt;" width="160"></col>
<col span="6" style="width: 60pt;" width="80"></col>
<col style="mso-width-alt: 3291; mso-width-source: userset; width: 68pt;" width="90"></col>
<col span="3" style="width: 60pt;" width="80"></col>
</colgroup><tbody>
<tr height="20" style="height: 15.0pt;">
<td class="xl67" colspan="4" height="20" style="height: 15.0pt; mso-ignore: colspan; width: 300pt;" width="400"><b>CT´s por
Enfermedad (Grupo), Target y Modificación</b></td>
</tr>
<tr height="42" style="height: 31.5pt; mso-height-source: userset;">
<td class="xl68" height="42" style="height: 31.5pt;"><br /></td>
<td class="xl69" style="width: 60pt;" width="180">Allogeneic CAR T cells </td>
<td class="xl69" style="width: 60pt;" width="180">Autologous CAR T cells</td>
<td class="xl69" style="width: 60pt;" width="80">Autologous CD34+ HSPCs</td>
<td class="xl69" style="width: 60pt;" width="80">CD4 CAR T cells</td>
<td class="xl69" style="width: 60pt;" width="80">CD4+ T cells</td>
<td class="xl69" style="width: 60pt;" width="80">CTL cells</td>
<td class="xl69" style="width: 68pt;" width="90">Patient specific iHSCs</td>
<td class="xl69" style="width: 60pt;" width="80">T cells</td>
<td class="xl69" style="width: 60pt;" width="80">sin modificación (in vivo)</td>
<td class="xl69" style="width: 60pt;" width="80">Total </td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl70" height="20" style="height: 15.0pt;"><b>Cáncer hemático</b></td>
<td class="xl70"><b>3</b></td>
<td class="xl70"><b>1</b></td>
<td class="xl70"></td>
<td class="xl70"></td>
<td class="xl70"></td>
<td class="xl70"></td>
<td class="xl70"></td>
<td class="xl70"></td>
<td class="xl70"></td>
<td class="xl70"><b>4</b></td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;">CD123</td>
<td class="xl66">1</td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66">1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;">CD19 and CD20/22 </td>
<td class="xl66">1</td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66">1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;">CD19; TCR and B2-M </td>
<td class="xl66">1</td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66">1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;">CD7</td>
<td class="xl66"></td>
<td class="xl66">1</td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66">1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;"><b>Cáncer no hemático</b></td>
<td class="xl66"></td>
<td class="xl66"><b>3</b></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"><b>1</b></td>
<td class="xl66"></td>
<td class="xl66"><b>5</b></td>
<td class="xl66"><b>3</b></td>
<td class="xl66"><b>12</b></td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;">E7/E6,E7</td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66">3</td>
<td class="xl66">3</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;">NY-ESO-1; TCR and PD-1</td>
<td class="xl66"></td>
<td class="xl66">1</td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66">1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;">PD-1</td>
<td class="xl66"></td>
<td class="xl66">2</td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66">1</td>
<td class="xl66"></td>
<td class="xl66">5</td>
<td class="xl66"></td>
<td class="xl66">8</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;"><b>Hemáticas</b></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"><b>2</b></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"><b>1</b></td>
<td class="xl66"></td>
<td class="xl66"><b>1</b></td>
<td class="xl66"><b>4</b></td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl70" height="20" style="height: 15.0pt;">BCL11A</td>
<td class="xl70"></td>
<td class="xl70"></td>
<td class="xl70">2</td>
<td class="xl70"></td>
<td class="xl70"></td>
<td class="xl70"></td>
<td class="xl70"></td>
<td class="xl70"></td>
<td class="xl70"></td>
<td class="xl70">2</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;">gene of Albumin</td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66">1</td>
<td class="xl66">1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;">HBB</td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66">1</td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66">1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl70" height="20" style="height: 15.0pt;"><b>HIV</b></td>
<td class="xl70"></td>
<td class="xl70"></td>
<td class="xl70"><b>2</b></td>
<td class="xl70"><b>1</b></td>
<td class="xl70"><b>5</b></td>
<td class="xl70"></td>
<td class="xl70"></td>
<td class="xl70"></td>
<td class="xl70"></td>
<td class="xl70"><b>8</b></td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;">CCR5</td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66">2</td>
<td class="xl66">1</td>
<td class="xl66">5</td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66">8</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl70" height="20" style="height: 15.0pt;"><b>Lisosomas</b></td>
<td class="xl70"></td>
<td class="xl70"></td>
<td class="xl70"></td>
<td class="xl70"></td>
<td class="xl70"></td>
<td class="xl70"></td>
<td class="xl70"></td>
<td class="xl70"></td>
<td class="xl70"><b>2</b></td>
<td class="xl70"><b>2</b></td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;">gene of Albumin</td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66">2</td>
<td class="xl66">2</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;"><b>Visión</b></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"><b>1</b></td>
<td class="xl66"><b>1</b></td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;">CEP290</td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66">1</td>
<td class="xl66">1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl70" height="20" style="height: 15.0pt;"><b>Total general</b></td>
<td class="xl70"><b>3</b></td>
<td class="xl70"><b>4</b></td>
<td class="xl70"><b>4</b></td>
<td class="xl70"><b>1</b></td>
<td class="xl70"><b>5</b></td>
<td class="xl70"><b>1</b></td>
<td class="xl70"><b>1</b></td>
<td class="xl70"><b>5</b></td>
<td class="xl70"><b>7</b></td>
<td class="xl70"><b>31</b></td>
</tr>
</tbody></table>
</div>
<br />
<br />
<table border="1" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 400px;">
<colgroup><col style="mso-width-alt: 5851; mso-width-source: userset; width: 120pt;" width="160"></col>
<col span="3" style="width: 60pt;" width="80"></col>
</colgroup><tbody>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" colspan="3" height="20" style="height: 15.0pt; mso-ignore: colspan; width: 240pt;" width="320"><b>CT por nucleasa, Target y exvivo/invivo</b></td>
<td class="xl66" style="width: 60pt;" width="80"></td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl67" height="20" style="height: 15.0pt;"></td>
<td class="xl67">Ex vivo</td>
<td class="xl67">In vivo</td>
<td class="xl67">Total</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;"><b>CRISPR/Cas9</b></td>
<td align="right" class="xl66"><b>16</b></td>
<td align="right" class="xl66"><b>1</b></td>
<td align="right" class="xl66"><b>17</b></td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;">BCL11A</td>
<td align="right">2</td>
<td></td>
<td align="right">2</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;">CCR5</td>
<td align="right">1</td>
<td></td>
<td align="right">1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;">CD19 and CD20/22 </td>
<td align="right">1</td>
<td></td>
<td align="right">1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;">CD7</td>
<td align="right">1</td>
<td></td>
<td align="right">1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;">CEP290</td>
<td></td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;">HBB</td>
<td align="right">1</td>
<td></td>
<td align="right">1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;">PD-1</td>
<td align="right">8</td>
<td></td>
<td align="right">8</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;">NY-ESO-1;
TCR and PD-1</td>
<td align="right">1</td>
<td></td>
<td align="right">1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;">CD19; TCR and B2-M </td>
<td align="right">1</td>
<td></td>
<td align="right">1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;"><b>TALEN</b></td>
<td align="right" class="xl66"><b>1</b></td>
<td align="right" class="xl66"><b>1</b></td>
<td align="right" class="xl66"><b>2</b></td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;">CD123</td>
<td align="right">1</td>
<td></td>
<td align="right">1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;">E7/E6,E7</td>
<td></td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;"><b>TALEN CRISPR/Cas9</b></td>
<td class="xl66"></td>
<td align="right" class="xl66"><b>1</b></td>
<td align="right" class="xl66"><b>1</b></td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;">E7/E6,E7</td>
<td></td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;"><b>ZFN</b></td>
<td align="right" class="xl66"><b>7</b></td>
<td align="right" class="xl66"><b>4</b></td>
<td align="right" class="xl66"><b>11</b></td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;">CCR5</td>
<td align="right">7</td>
<td></td>
<td align="right">7</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;">gene of
Albumin</td>
<td></td>
<td align="right">3</td>
<td align="right">3</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;">E7/E6,E7</td>
<td></td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;"><b>Total</b></td>
<td align="right" class="xl66"><b>24</b></td>
<td align="right" class="xl66"><b>7</b></td>
<td align="right" class="xl66"><b>31</b></td>
</tr>
</tbody></table>
<br />
<br />
<br />
<table border="1" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 860px;">
<colgroup><col style="mso-width-alt: 5851; mso-width-source: userset; width: 120pt;" width="160"></col>
<col span="5" style="width: 60pt;" width="80"></col>
</colgroup><tbody>
<tr height="20" style="height: 15.0pt;">
<td colspan="2" height="20" style="height: 15.0pt; mso-ignore: colspan; width: 180pt;" width="240"><b>CT´s por Enf (Grupo), Nucleasa y Delivery</b></td>
<td style="width: 60pt;" width="80"></td>
<td style="width: 60pt;" width="80"></td>
<td style="width: 60pt;" width="80"></td>
<td style="width: 60pt;" width="80"></td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;"><b><br /></b></td>
<td><b>CRISPR/Cas9</b></td>
<td><b>TALEN</b></td>
<td><b>TALEN CRISPR/Cas9</b></td>
<td><b>ZFN</b></td>
<td>Total </td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;"><b>Cáncer hemático</b></td>
<td class="xl66"><b>3</b></td>
<td class="xl66"><b>1</b></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"><b>4</b></td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;">Not specified</td>
<td class="xl66">3</td>
<td class="xl66">1</td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66">4</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;"><b>Cáncer no hemático</b></td>
<td class="xl66"><b>9</b></td>
<td class="xl66"><b>1</b></td>
<td class="xl66"><b>1</b></td>
<td class="xl66"><b>1</b></td>
<td class="xl66"><b>12</b></td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;">mRNA electroporation</td>
<td class="xl66">1</td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66">1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;">Not specified</td>
<td class="xl66">8</td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66">1</td>
<td class="xl66">9</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;">Plasmid in gel</td>
<td class="xl66"></td>
<td class="xl66">1</td>
<td class="xl66">1</td>
<td class="xl66"></td>
<td class="xl66">2</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;"><b>Hemáticas</b></td>
<td class="xl66"><b>3</b></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"><b>1</b></td>
<td class="xl66"><b>4</b></td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;">AAV</td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66">1</td>
<td class="xl66">1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;">Not specified</td>
<td class="xl66">1</td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66">1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;">Ribonucleoprotein
electroporation</td>
<td class="xl66">2</td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66">2</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;"><b>HIV</b></td>
<td class="xl66"><b>1</b></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"><b>7</b></td>
<td class="xl66"><b>8</b></td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;">Adenoviral vector</td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66">3</td>
<td class="xl66">3</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;">mRNA electroporation</td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66">2</td>
<td class="xl66">2</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;">Not specified</td>
<td class="xl66">1</td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66">2</td>
<td class="xl66">3</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;"><b>Lisosomas</b></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"><b>2</b></td>
<td class="xl66"><b>2</b></td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;">AAV</td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66">2</td>
<td class="xl66">2</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;"><b>Visión</b></td>
<td class="xl66"><b>1</b></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"><b>1</b></td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;">AAV</td>
<td class="xl66">1</td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66"></td>
<td class="xl66">1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt;"><b>Total general</b></td>
<td class="xl66"><b>17</b></td>
<td class="xl66"><b>2</b></td>
<td class="xl66"><b>1</b></td>
<td class="xl66"><b>11</b></td>
<td class="xl66"><b>31</b></td>
</tr>
</tbody></table>
<br />
<br />
<table border="1" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 1030px;">
<colgroup><col style="mso-width-alt: 5851; mso-width-source: userset; width: 120pt;" width="160"></col>
<col span="6" style="width: 60pt;" width="80"></col>
<col style="mso-width-alt: 3291; mso-width-source: userset; width: 68pt;" width="90"></col>
</colgroup><tbody>
<tr height="20" style="height: 15.0pt;">
<td colspan="3" height="20" style="height: 15.0pt; mso-ignore: colspan; width: 240pt;" width="320"><b>DT¨s por Enfermedad (G), Nucleasa y Delivery</b></td>
<td style="width: 60pt;" width="80"></td>
<td style="width: 60pt;" width="80"></td>
<td style="width: 60pt;" width="80"></td>
<td style="width: 60pt;" width="80"></td>
<td style="width: 68pt;" width="90"></td>
</tr>
<tr height="80" style="height: 60.0pt;">
<td class="xl66" height="80" style="height: 60.0pt; width: 120pt;" width="160"></td>
<td class="xl66" style="width: 60pt;" width="80"><b>AAV</b></td>
<td class="xl66" style="width: 60pt;" width="80"><b>Adenoviral vector</b></td>
<td class="xl66" style="width: 60pt;" width="80"><b>mRNA electroporation</b></td>
<td class="xl66" style="width: 60pt;" width="80"><b>Not specified</b></td>
<td class="xl66" style="width: 60pt;" width="80"><b>Plasmid in gel</b></td>
<td class="xl66" style="width: 60pt;" width="80"><b>Ribonucleoprotein electroporation</b></td>
<td class="xl66" style="width: 68pt;" width="90"><b>Total general</b></td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl68" height="20" style="height: 15.0pt;"><b>Cáncer hemático</b></td>
<td class="xl69"></td>
<td class="xl69"></td>
<td class="xl69"></td>
<td class="xl69"><b>4</b></td>
<td class="xl69"></td>
<td class="xl69"></td>
<td class="xl69"><b>4</b></td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;">CRISPR/Cas9</td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67">3</td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67">3</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;">TALEN</td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67">1</td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67">1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl68" height="20" style="height: 15.0pt;"><b>Cáncer no hemático</b></td>
<td class="xl69"></td>
<td class="xl69"></td>
<td class="xl69"><b>1</b></td>
<td class="xl69"><b>9</b></td>
<td class="xl69"><b>2</b></td>
<td class="xl69"></td>
<td class="xl69"><b>12</b></td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;">CRISPR/Cas9</td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67">1</td>
<td class="xl67">8</td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67">9</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;">TALEN</td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67">1</td>
<td class="xl67"></td>
<td class="xl67">1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;">TALEN
CRISPR/Cas9</td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67">1</td>
<td class="xl67"></td>
<td class="xl67">1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;">ZFN</td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67">1</td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67">1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl68" height="20" style="height: 15.0pt;"><b>Hemáticas</b></td>
<td class="xl69"><b>1</b></td>
<td class="xl69"></td>
<td class="xl69"></td>
<td class="xl69"><b>1</b></td>
<td class="xl69"></td>
<td class="xl69"><b>2</b></td>
<td class="xl69"><b>4</b></td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;">CRISPR/Cas9</td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67">1</td>
<td class="xl67"></td>
<td class="xl67">2</td>
<td class="xl67">3</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;">ZFN</td>
<td class="xl67">1</td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67">1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl68" height="20" style="height: 15.0pt;"><b>HIV</b></td>
<td class="xl69"></td>
<td class="xl69"><b>3</b></td>
<td class="xl69"><b>2</b></td>
<td class="xl69"><b>3</b></td>
<td class="xl69"></td>
<td class="xl69"></td>
<td class="xl69"><b>8</b></td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;">CRISPR/Cas9</td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67">1</td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67">1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;">ZFN</td>
<td class="xl67"></td>
<td class="xl67">3</td>
<td class="xl67">2</td>
<td class="xl67">2</td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67">7</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl68" height="20" style="height: 15.0pt;"><b>Lisosomas</b></td>
<td class="xl69"><b>2</b></td>
<td class="xl69"></td>
<td class="xl69"></td>
<td class="xl69"></td>
<td class="xl69"></td>
<td class="xl69"></td>
<td class="xl69"><b>2</b></td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;">ZFN</td>
<td class="xl67">2</td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67">2</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl68" height="20" style="height: 15.0pt;"><b>Visión</b></td>
<td class="xl69"><b>1</b></td>
<td class="xl69"></td>
<td class="xl69"></td>
<td class="xl69"></td>
<td class="xl69"></td>
<td class="xl69"></td>
<td class="xl69"><b>1</b></td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;">CRISPR/Cas9</td>
<td class="xl67">1</td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67"></td>
<td class="xl67">1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl68" height="20" style="height: 15.0pt;"><b>Total general</b></td>
<td class="xl69"><b>4</b></td>
<td class="xl69"><b>3</b></td>
<td class="xl69"><b>3</b></td>
<td class="xl69"><b>17</b></td>
<td class="xl69"><b>2</b></td>
<td class="xl69"><b>2</b></td>
<td class="xl69"><b>31</b></td>
</tr>
</tbody></table>
<span style="color: red; mso-themecolor: dark2;"><br /></span>
<span style="color: red; mso-themecolor: dark2;"><span style="mso-spacerun: yes;"></span>Le ruego evalúe la presente entrada asignando un valor de 1 a 5, de peor a mejor valorada, usando la opción de comentarios
</span>JOSE Rhttp://www.blogger.com/profile/09318104344786439010noreply@blogger.com0tag:blogger.com,1999:blog-1952063008451683630.post-45275408710773576972020-01-09T19:05:00.000+01:002020-01-10T14:57:58.400+01:00Sangamo Therapeutics versus CRISPR Therapeutics <head><!-- Global site tag (gtag.js) - Google Analytics -->
<script async="" src="https://www.googletagmanager.com/gtag/js?id=UA-133555286-1"></script>
<script>
window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config', 'UA-133555286-1');
</script>
</head>
<br />
Tirando del hilo de las <a href="https://degenetica.blogspot.com/2019/12/avances-en-edicion-genica-addgene-y.html">tablas de CT´s de edición génica</a> he llegado a un interesante artículo de Cory Renauer: <a href="https://www.fool.com/investing/2019/03/28/better-buy-crispr-therapeutics-vs-sangamo-therapeu.aspx">Better Buy: CRISPR Therapeutics vs. Sangamo Therapeutics</a> en el que se plantea qué es mejor, comprar acciones de una empresa o de la otra.<br />
Sangamo Tx es el mayor esponsor de CT´s de edición génica recogidos en la tabla de Schacker (n=<strike>8</strike>, 7) y CRISPR Tx comparte con Vertex la esponsorización de otros dos CT´s. La primera empresa es una veterana con sus casi 35 años y la segunda es mucho más joven con 7 años de vida.<br />
En dos tablas, una referida a la empresa y otra a los productos, las comparo para ver qué compraríamos.<br />
<table border="1" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 623px;"><colgroup><col style="mso-width-alt: 5339; mso-width-source: userset; width: 110pt;" width="146"></col><col style="mso-width-alt: 10057; mso-width-source: userset; width: 206pt;" width="275"></col><col style="mso-width-alt: 7387; mso-width-source: userset; width: 152pt;" width="202"></col></colgroup><tbody>
<tr height="20" style="height: 15.0pt;"><td class="xl66" height="20" style="height: 15.0pt; width: 110pt;" width="146"></td>
<td class="xl67" style="width: 206pt;" width="275"><b>Sangamo Therapeutics</b></td>
<td class="xl67" style="width: 152pt;" width="202"><b>CRISPR Therapeutics</b></td>
</tr>
<tr height="19" style="height: 14.25pt; mso-height-source: userset;">
<td class="xl67" height="19" style="height: 14.25pt; width: 110pt;" width="146">Creación</td>
<td class="xl67" style="width: 206pt;" width="275"><a href="https://en.wikipedia.org/wiki/Sangamo_Therapeutics">1995</a></td>
<td class="xl67" style="width: 152pt;" width="202"><br />
<a href="https://golden.com/wiki/CRISPR_Therapeutics">2013</a><br />
<br /></td>
</tr>
<tr height="19" style="height: 14.25pt; mso-height-source: userset;">
<td class="xl67" height="19" style="height: 14.25pt; width: 110pt;" width="146">Valor en bolsa (6/1/2020). Ver abajo trayectoria bursátil</td>
<td class="xl67" style="width: 206pt;" width="275"><a href="https://www.google.com/search?q=value+sangamo+therapeutics&rlz=1C1GCEA_enES854ES854&oq=value+sangamo+th&aqs=chrome.1.69i57j33.8608j0j7&sourceid=chrome&ie=UTF-8">$ 954 million</a></td>
<td class="xl67" style="width: 152pt;" width="202"><br />
<a href="https://www.google.com/search?rlz=1C1GCEA_enES854ES854&sxsrf=ACYBGNSllyXWN3csg8qMNO3x5sCUO-vpNA%3A1578330889458&ei=CWsTXtCwG8nYaIyWusgF&q=value+crispr+therapeutics&oq=value+crispr+therapeutics&gs_l=psy-ab.3..0i8i30l2.432692.434846..437889...0.0..0.99.823.10......0....1..gws-wiz.......35i39j0i8i7i30j0i8i13i30.CM4MX49IrBQ&ved=0ahUKEwiQ2YPgvO_mAhVJLBoKHQyLDlkQ4dUDCAs&uact=5">$ 3566,65 million</a><br />
<br /></td>
</tr>
<tr height="23" style="height: 17.25pt; mso-height-source: userset;">
<td class="xl66" height="23" style="height: 17.25pt; width: 110pt;" width="146">Popes</td>
<td class="xl67" style="width: 205pt;" width="273"></td>
<td class="xl67" style="width: 152pt;" width="202">Carpentier</td>
</tr>
<tr height="39" style="height: 29.25pt; mso-height-source: userset;">
<td class="xl68" height="39" style="height: 29.25pt; width: 110pt;" width="146">Oficinas
centrales<span class="font5">: </span></td>
<td class="xl69" style="width: 205pt;" width="273"><a href="https://www.sangamo.com/about-us/contact">7000 Marina Blvd, Brisbane, CA 94005, EE. UU.</a></td>
<td class="xl68" style="width: 152pt;" width="202"><a href="http://www.crisprtx.com/about-us/contact">Baarerstrasse 14 ZUG V8 CH-6300 Switzerland</a></td>
</tr>
<tr height="39" style="height: 29.25pt; mso-height-source: userset;">
<td class="xl68" height="39" style="height: 29.25pt; width: 110pt;" width="146">Alianzas</td>
<td class="xl69" style="width: 205pt;" width="273">Pfizer, Kite, Takeda, Sanofi</td>
<td class="xl68" style="width: 152pt;" width="202">Vertex</td>
</tr>
</tbody></table>
<br />
<b>Productos</b><br />
De los pipelines de sus respectivas páginas web y de informes para inversores, <a href="https://investor.sangamo.com/static-files/36371e78-df57-486f-91b3-483b3feab2bf">en el caso de Sangamo</a> , he obtenido los datos de esta tabla.<br />
<table border="1" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 818px;">
<colgroup><col style="width: 60pt;" width="80"></col>
<col style="mso-width-alt: 11812; mso-width-source: userset; width: 242pt;" width="323"></col>
<col style="mso-width-alt: 15177; mso-width-source: userset; width: 311pt;" width="415"></col>
</colgroup><tbody>
<tr height="20" style="height: 15.0pt;">
<td class="xl65" height="20" style="height: 15.0pt; width: 60pt;" width="80">BLA (Biologics License Application de FDA)</td>
<td class="xl65" style="width: 242pt;" width="323">ninguno</td>
<td class="xl65" style="width: 311pt;" width="415">ninguno</td>
</tr>
<tr height="40" style="height: 30.0pt;">
<td class="xl65" height="40" style="height: 30.0pt; width: 60pt;" width="80">Fast Track´s de FDA</td>
<td class="xl65" style="width: 242pt;" width="323">4: SB-913 para MPS-2;<br />
SB-318 para MPS-1;<br />
SB-525 para Hemofilia A;<br />
SB-FIX para Hemofilia B<br />
<br />
<br />
<br /></td>
<td class="xl65" style="width: 311pt;" width="415">1: CTX001 para anemia falciforme</td>
</tr>
<tr height="255" style="height: 191.25pt; mso-height-source: userset;">
<td height="255" style="height: 191.25pt;">Pipeline preclínico</td>
<td class="xl66" style="width: 242pt;" width="323">PKU (ST-101) SANGAMO WHOLLY
OWNED<br />
<br />
IBD SANGAMO WHOLLY OWNED <br />
<br />
MS SANGAMO WHOLLY OWNED <br />
<br />
Oncology (Kite-037) PARTNER: Kite<br />
<br />
Solid Organ Transplant (TX200) SANGAMO WHOLLY OWNED<br />
<br />
α-Synucleiin (ST-502) SANGAMO WHOLLY OWNED<br />
<br />
ALS/FTD PARTNER: Pfizer <br />
<br />
Huntington’s Disease PARTNER: Takeda<br />
<br />
Tauopathies (ST-501) SANGAMO WHOLLY OWNED</td>
<td class="xl66" style="width: 311pt;" width="415">Immuno-Oncology<br />
<br />
CTX120 (IND-enabling) <br />
<br />
CTX130 (IND-enabling) <br />
<br />
Regenerative Medicine: Type I diabetes
mellitus (Research)<br />
InVivo Approaches:<br />
<br />
Glycogen storage disease type Ia (GSD Ia) (Research) <br />
<br />
Duchenne muscular dystrophy (DMD) (Research)<br />
<br />
Myotonic dystrophy type 1 (DM1) (Research) <br />
<br />
Cystic fibrosis (CF) (Research)</td>
</tr>
<tr height="39" style="height: 29.25pt; mso-height-source: userset;">
<td class="xl68" height="39" style="height: 29.25pt; width: 110pt;" width="146">Nucleasas</td>
<td class="xl69" style="width: 205pt;" width="273">ZFN</td>
<td class="xl68" style="width: 152pt;" width="202">CRISPR Cas9</td>
</tr>
<tr height="39" style="height: 29.25pt; mso-height-source: userset;">
<td class="xl68" height="39" style="height: 29.25pt; width: 110pt;" width="146">Observaciones</td>
<td class="xl69" style="width: 205pt;" width="273">NCT04046224, CT de producto contra enfermedad de Fabry, (ST-920) también está en fase clínica, luego serían 6 los en fase clínica. "Actual Study Start Date :<span style="white-space: pre;"> </span>July 23, 2019"</td>
<td class="xl68" style="width: 152pt;" width="202"><br /></td>
</tr>
</tbody></table>
<br />
<br />
<b>Trayectorias bursátiles</b><br />
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiaEzHE_XNpqdjrrawRu2Y4T6qqeFi5KmlXT-Yj6rYFZpj7WPkM5jkOdZWOJRNOeUaB9_bGwxJLp5QPCdNlmPdX8Jd-va_e-bBj1tJA2wvGUhl3Js5Go_dwny1ExRQxva52sny9PCcMjjaH/s1600/Sangamo+Cap+Burs.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="541" data-original-width="642" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiaEzHE_XNpqdjrrawRu2Y4T6qqeFi5KmlXT-Yj6rYFZpj7WPkM5jkOdZWOJRNOeUaB9_bGwxJLp5QPCdNlmPdX8Jd-va_e-bBj1tJA2wvGUhl3Js5Go_dwny1ExRQxva52sny9PCcMjjaH/s1600/Sangamo+Cap+Burs.gif" /></a>
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh-BAs8aWRKrxOJPSuKuN4i1iguwnaSXsFZENUa2sIdUqhHxN98aP9KgBmKZ0V7OjZ-WjhlqibJVqcnvceVb70hQQdHZvo1O8tkSPbWXZpZni6PkiSt-nMCWiN8BCDXOkkAcyPkdLPW4FXi/s1600/CRISPR+Tc+Cap+Burs.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="476" data-original-width="593" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh-BAs8aWRKrxOJPSuKuN4i1iguwnaSXsFZENUa2sIdUqhHxN98aP9KgBmKZ0V7OjZ-WjhlqibJVqcnvceVb70hQQdHZvo1O8tkSPbWXZpZni6PkiSt-nMCWiN8BCDXOkkAcyPkdLPW4FXi/s1600/CRISPR+Tc+Cap+Burs.gif" /></a></div>
<br />
<div class="separator" style="clear: both; text-align: center;">
</div>
<br />
Dice Renauer: <i>It's probably best to cheer for CRISPR from the sidelines, and put the better buy, Sangamo, in a diverse portfolio, </i><afirmaci 2019="" a="" abril="" actualizaci="" be="" corresponde="" de="" del="" en="" ltima="" n="" nbsp="" noviembre="" que="" supongo="" texto.="">CRISPR Therapeutics (NASDAQ: CRSP) y Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) publicaron la siguiente nota: <br />
<i> today announced positive, interim data from the first two patients with severe hemoglobinopathies treated with the investigational CRISPR/Cas9 gene-editing therapy CTX001 in ongoing Phase 1/2 clinical trials. One patient with transfusion-dependent beta thalassemia (TDT) received CTX001 in the first quarter of 2019 and data for this patient reflect nine months of safety and efficacy follow-up. One patient with severe sickle cell disease (SCD) received CTX001 in mid-2019 and data for this patient reflect four months of safety and efficacy follow-up. These studies are ongoing and patients will be followed for approximately two years following infusion. Several additional patients have been enrolled and have had drug product manufactured across the two studies.
</i><br />
Información, cuyo efecto en el valor de la acción, que nos parece ver reflejada en la gráfica que arriba se presenta.<br />
<span style="color: red; mso-themecolor: dark2;"><span style="mso-spacerun: yes;"></span>Le ruego evalúe la presente entrada asignando un valor de 1 a 5, de peor a mejor valorada, usando la opción de comentarios
</span></afirmaci>JOSE Rhttp://www.blogger.com/profile/09318104344786439010noreply@blogger.com0tag:blogger.com,1999:blog-1952063008451683630.post-86671387181975146052019-12-29T17:49:00.000+01:002019-12-29T17:49:52.284+01:00Avances en edición génica: Addgene y Biopharma Excellence<head><!-- Global site tag (gtag.js) - Google Analytics -->
<script async="" src="https://www.googletagmanager.com/gtag/js?id=UA-133555286-1"></script>
<script>
window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config', 'UA-133555286-1');
</script>
</head>
<br />
Tras publicar la <a href="https://degenetica.blogspot.com/2019/12/ensayos-clinicos-en-clinicaltrialsgov.html">entrada anterior</a> y <a href="https://degenetica.blogspot.com/2019/12/lvv-o-aavv-crispr-cas9.html">dos entradas atrás</a> sobre CRISPR, y en el camino de entender la dimensión de las posibilidades de esta herramienta, he encontrado una interesante iniciativa, que entre otras cosas tiene un repositorio de plásmidos: <a href="https://www.addgene.org/">Addgene</a><br />
<i>We distribute 81,207 plasmids on behalf of 4,062 labs from around the world. We also produce 446 ready-to-use viral vectors from our plasmid collection. Find what you need for your next experiment</i><br />
<i><br /></i>
He bajado su eBook <a href="https://info.addgene.org/download-addgenes-ebook-crispr-101-2nd-edition?_ga=2.123007947.1196022236.1577299421-300095457.1576429706"> Addgene's eBook: CRISPR 101</a> en el que se habla de numerosas herramientas de edición génica que están siendo, no sé si descubiertas ó inventadas, para muy diversos usos:<br />
<span class="fontstyle0"><i>Cpf1 family members contain a RuvC-like endonuclease domain, but they lack Cas9’s second HNH endonuclease domain. Cpf1 cleaves DNA in a staggered pattern and requires only one RNA rather than the two (tracrRNA and crRNA) needed by Cas9 for cleavage. </i></span><br />
En la línea de disminuir los off-target están la <b><span class="fontstyle0">eSpCas9</span> </b>y <span class="fontstyle0"><b>SpCas9-HF1.</b></span><br />
<br />
Buscando mejorar la tabla de la entrada anterior sobre los CT con CRISPR en Clinicaltrials.gov he encontrado el artículo <a href="https://link.springer.com/article/10.1186/s40169-019-0244-7">From fiction to science: clinical potentials and regulatory considerations of gene editing </a> El artículo de Schacker y Seimetz tiene una tabla con 31 CT de edición génica referenciados en clinicaltrial.gov a julio de 2019. Son CT en los que se usa ZF, TALEN y CRISPR. Están 18 que coinciden con los publicados en la entrada anterior de este blog - no están los de diagnóstico y de ciencia básica - más otros con ZF y TALEN. Me ha parecido genial. Copio la tabla 2 del artículo.<br />
<br />
<br />
<table style="background: rgb(255, 255, 255); border-collapse: collapse; border-spacing: 0px; border: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #333333; font-family: Georgia, serif; font-size: 17px; letter-spacing: 0.102px; margin: 0px; width: 1155.45px;"><thead style="box-sizing: border-box;">
<tr style="box-sizing: border-box;"><th style="background-color: #f2f2f2; border-bottom: 1px solid rgb(204, 204, 204); border-right: 1px solid rgb(204, 204, 204); box-sizing: border-box; padding: 8px 12px; text-align: left; vertical-align: top;"></th><th style="background-color: #f2f2f2; border-bottom: 1px solid rgb(204, 204, 204); border-right: 1px solid rgb(204, 204, 204); box-sizing: border-box; padding: 8px 12px; text-align: left; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; padding: 0px; vertical-align: top; word-break: normal;">
<span style="font-size: small;">NCT (status)</span></div>
</th><th style="background-color: #f2f2f2; border-bottom: 1px solid rgb(204, 204, 204); border-right: 1px solid rgb(204, 204, 204); box-sizing: border-box; padding: 8px 12px; text-align: left; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; padding: 0px; vertical-align: top; word-break: normal;">
<span style="font-size: small;">Country/region</span></div>
</th><th style="background-color: #f2f2f2; border-bottom: 1px solid rgb(204, 204, 204); border-right: 1px solid rgb(204, 204, 204); box-sizing: border-box; padding: 8px 12px; text-align: left; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; padding: 0px; vertical-align: top; word-break: normal;">
<span style="font-size: small;">Sponsor</span></div>
</th><th style="background-color: #f2f2f2; border-bottom: 1px solid rgb(204, 204, 204); border-right: 1px solid rgb(204, 204, 204); box-sizing: border-box; padding: 8px 12px; text-align: left; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; padding: 0px; vertical-align: top; word-break: normal;">
<span style="font-size: small;">Disease</span></div>
</th><th style="background-color: #f2f2f2; border-bottom: 1px solid rgb(204, 204, 204); border-right: 1px solid rgb(204, 204, 204); box-sizing: border-box; padding: 8px 12px; text-align: left; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; padding: 0px; vertical-align: top; word-break: normal;">
<span style="font-size: small;">Target/modification</span></div>
</th><th style="background-color: #f2f2f2; border-bottom: 1px solid rgb(204, 204, 204); border-right: 1px solid rgb(204, 204, 204); box-sizing: border-box; padding: 8px 12px; text-align: left; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; padding: 0px; vertical-align: top; word-break: normal;">
<span style="font-size: small;">Nuclease</span></div>
</th><th style="background-color: #f2f2f2; border-bottom: 1px solid rgb(204, 204, 204); border-right: 1px solid rgb(204, 204, 204); box-sizing: border-box; padding: 8px 12px; text-align: left; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; padding: 0px; vertical-align: top; word-break: normal;">
<span style="font-size: small;">Delivery</span></div>
</th></tr>
</thead><tbody style="box-sizing: border-box;">
<tr style="box-sizing: border-box;"><td rowspan="24" style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Ex vivo</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">NCT00842634 (completed)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">US</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Sangamo Therapeutics</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">HIV</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">CCR5 modified CD4+ T cells</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">ZFN</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Adenoviral vector</span></div>
</td></tr>
<tr style="box-sizing: border-box;"><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">NCT01044654 (completed)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">US</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Sangamo Therapeutics</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">HIV</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">CCR5 modified CD4+ T cells</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">ZFN</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Adenoviral vector</span></div>
</td></tr>
<tr style="box-sizing: border-box;"><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">NCT01252641 (completed)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">US</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Sangamo Therapeutics</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">HIV</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">CCR5 modified CD4+ T cells</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">ZFN</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Adenoviral vector</span></div>
</td></tr>
<tr style="box-sizing: border-box;"><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">NCT02388594 (completed)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">US</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">University of Pennsylvania</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">HIV</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">CCR5 modified CD34+ T cells</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">ZFN</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">mRNA electroporation</span></div>
</td></tr>
<tr style="box-sizing: border-box;"><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">NCT02500849 (active, not recruiting)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">US</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">City of Hope Medical Center</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">HIV</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">CCR5 modified CD34+ HSPCs</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">ZFN</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">mRNA electroporation</span></div>
</td></tr>
<tr style="box-sizing: border-box;"><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">NCT03617198 (not yet recruiting)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">US</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">University of Pennsylvania</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">HIV</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">CCR5 modified, C34-CXCR4, CD4 CAR T cells</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">ZFN</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Not specified</span></div>
</td></tr>
<tr style="box-sizing: border-box;"><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">NCT03666871 (not yet recruiting)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Not specified</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Case Western Reserve University</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">HIV</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">CCR5 modified CD4+ T cells</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">ZFN</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Not specified</span></div>
</td></tr>
<tr style="box-sizing: border-box;"><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">NCT03190278 (recruiting)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">US</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Cellectis S.A.</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Acute myeloid leukemia</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Allogeneic CAR T cells targeting CD123, TCR disruption</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">TALEN</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Not specified</span></div>
</td></tr>
<tr style="box-sizing: border-box;"><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">NCT03164135 (recruiting)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">China</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Affiliated Hospital to Academy of Military Medical Sciences (China)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">HIV-1</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">CCR5 modified CD34+ HSPCs (from donor)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">CRISPR/Cas</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Not specified</span></div>
</td></tr>
<tr style="box-sizing: border-box;"><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">NCT03655678 (recruiting)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Canada, Europe</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Vertex Pharmaceuticals Incorporated</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Beta Thalassemia</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Autologous CD34+ HSPCs modified at the enhancer of the BCL11A gene</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">CRISPR/Cas9</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Ribonucleoprotein electroporation</span></div>
</td></tr>
<tr style="box-sizing: border-box;"><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">NCT03728322 (not yet recruiting)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Not specified</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Allife Medical Science and Technology Co., Ltd</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Beta thalassemia</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">HBB gene correction in patient specific iHSCs</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">CRISPR/Cas9</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Not specified</span></div>
</td></tr>
<tr style="box-sizing: border-box;"><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">NCT03745287 (recruiting)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">US, Europe</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Vertex Pharmaceuticals Incorporated</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Sickle cell disease</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Autologous CD34+ HSPCs modified at the enhancer of the BCL11A gene</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">CRISPR/Cas9</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Ribonucleoprotein electroporation</span></div>
</td></tr>
<tr style="box-sizing: border-box;"><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">NCT03398967 (recruiting)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">China</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Chinese PLA General Hospital</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">B cell leukemia, B cell lymphoma</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Allogeneic CD19 and CD20/22 CAR T cells</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">CRISPR/Cas9</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Not specified</span></div>
</td></tr>
<tr style="box-sizing: border-box;"><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">NCT03166878 (recruiting)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">China</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Chinese PLA General Hospital</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">B cell leukemia, B cell lymphoma</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Allogeneic CD19-directed CAR T cells; TCR and B2 M disruption</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">CRISPR/Cas9</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Not specified</span></div>
</td></tr>
<tr style="box-sizing: border-box;"><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">NCT03399448 (recruiting)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">US</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">University of Pennsylvania</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Multiple Myeloma, Melanoma, Synovial Sarcoma, Myxoid/Round Cell Liposarcoma</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Autologous anti-NY-ESO CAR T cells, disruption of TCR and PD-1</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">CRISPR/Cas</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">mRNA electroporation</span></div>
</td></tr>
<tr style="box-sizing: border-box;"><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">NCT03690011 (not yet recruiting)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">US</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Baylor College of Medicine</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">T cell Acute Lymphoblastic Leukemia, T cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Anti-CD7 CAR T cells, CD7 KO</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">CRISPR/Cas9</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Not specified</span></div>
</td></tr>
<tr style="box-sizing: border-box;"><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">NCT03545815 (recruiting)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">China</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Chinese PLA General Hospital</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Solid tumor</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">PD-1 and TCR KO anti-mesothelin CAR T cells</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">CRISPR/Cas9</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Not specified</span></div>
</td></tr>
<tr style="box-sizing: border-box;"><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">NCT03747965 (recruiting)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">China</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Chinese PLA General Hospital</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Solid tumor</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Mesothelin-directed CAR T cells; PD-1 KO</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">CRISPR</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Not specified</span></div>
</td></tr>
<tr style="box-sizing: border-box;"><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">NCT03081715 (completed)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">China</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Hangzhou Cancer Hospital</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Esophageal cancer</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">PD-1 KO T cells</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">CRISPR/Cas9</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Not specified</span></div>
</td></tr>
<tr style="box-sizing: border-box;"><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">NCT02793856 (active, not recruiting)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">China</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Sichuan University</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Metastatic non-small cell lung cancer</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">PD-1 KO T cells</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">CRISPR/Cas9</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Not specified</span></div>
</td></tr>
<tr style="box-sizing: border-box;"><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">NCT03044743 (recruiting)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">China</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Yang Yang, Nanjing University Medical School</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">EBV positive advanced stage malignancies</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">PD-1 KO EBV-CTL cells</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">CRISPR/Cas9</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Not specified</span></div>
</td></tr>
<tr style="box-sizing: border-box;"><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">NCT02863913 (withdrawn—no funding)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">China</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Peking University</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Invasive Bladder Cancer Stage IV</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">PD-1 KO T cells</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">CRISPR/Cas9</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Not specified</span></div>
</td></tr>
<tr style="box-sizing: border-box;"><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">NCT02867345 (withdrawn—no funding)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">China</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Peking University</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Hormone Refractory Prostate Cancer</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">PD-1 KO T cells</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">CRISPR/Cas9</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Not specified</span></div>
</td></tr>
<tr style="box-sizing: border-box;"><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">NCT02867332 (withdrawn—no funding)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">China</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Peking University</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Metastatic renal cell carcinoma</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">PD-1 KO T cells</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">CRISPR/Cas9</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Not specified</span></div>
</td></tr>
<tr style="box-sizing: border-box;"><td rowspan="7" style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">In vivo</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">NCT03041324 (recruiting)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">US</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Sangamo Therapeutics</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Mucopolysaccharidosis II</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Insertion of corrected copy of Iduronate 2-Sulfatase gene into the Albumin locus</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">ZFN</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">AAV</span></div>
</td></tr>
<tr style="box-sizing: border-box;"><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">NCT02702115 (recruiting)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">US</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Sangamo Therapeutics</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Mucopolysaccharidosis I</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Insertion of corrected copy of α-<span class="EmphasisTypeSmallCaps " style="box-sizing: border-box; font-variant-caps: small-caps; font-variant-east-asian: normal; font-variant-numeric: normal;">l</span>-iduronidase gene into the Albumin locus</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">ZFN</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">AAV</span></div>
</td></tr>
<tr style="box-sizing: border-box;"><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">NCT02695160 (recruiting)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">US, Europe</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Sangamo Therapeutics</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Hemophilia B</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Insertion of a corrected copy of the factor 9 gene into the albumin locus</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">ZFN</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">AAV</span></div>
</td></tr>
<tr style="box-sizing: border-box;"><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">NCT02800369 (active, not recruiting)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">China</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Huazhong University of Science and Technology</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Human papillomavirus-Related malignant neoplasm</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">E7</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">ZFN</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Not specified</span></div>
</td></tr>
<tr style="box-sizing: border-box;"><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">NCT03226470 (not yet recruiting)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">China</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Huazhong University of Science and Technology</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Human papillomavirus-related malignant neoplasm</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">E6, E7</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">TALEN</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Plasmid in gel</span></div>
</td></tr>
<tr style="box-sizing: border-box;"><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">NCT03057912 (unknown)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">China</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">First Affiliated Hospital, Sun Yat-Sen University</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Human papillomavirus-Related malignant neoplasm</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">E6, E7</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; margin-bottom: 16px; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">TALEN</span></div>
<div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; margin-top: 16px; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">CRISPR/Cas9</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Plasmid in gel</span></div>
</td></tr>
<tr style="box-sizing: border-box;"><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">NCT03872479 (not yet recruiting)</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">US</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Allergan</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">Leber congenital amaurosis 10</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">CEP290</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">CRISPR/Cas9</span></div>
</td><td style="border-bottom: 1px solid rgb(204, 204, 204); box-sizing: border-box; color: #666666; padding: 8px 12px; vertical-align: top;"><div class="SimplePara" style="box-sizing: border-box; line-height: 1.5; overflow-wrap: normal; word-break: normal;">
<span style="font-size: small;">AAV</span></div>
</td></tr>
</tbody></table>
<br />
Agrupando los datos por países son: Canadá, Europa (1); China (14); not specified,(2); US (12) y US, Europe (2). China está dispuesta a ser una potencia también en edición génica.<br />
<br />
Agrupando los datos por patrocinador:<br />
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 657px;">
<colgroup><col style="mso-width-alt: 21504; mso-width-source: userset; width: 441pt;" width="588"></col>
<col style="mso-width-alt: 2523; mso-width-source: userset; width: 52pt;" width="69"></col>
</colgroup><tbody>
<tr height="24" style="height: 18.0pt;">
<td class="xl67" height="24" style="height: 18.0pt; width: 441pt;" width="588"><b>Sponsor</b></td>
<td class="xl67" style="width: 52pt;" width="69"><b>n</b></td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 341pt;" width="488">Affiliated Hospital to Academy of Military Medical
Sciences (China)</td>
<td class="xl66" style="border-top: none; width: 52pt;" width="69">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 441pt;" width="588">Allergan</td>
<td class="xl66" style="border-top: none; width: 52pt;" width="69">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 441pt;" width="588">Allife Medical Science and Technology Co., Ltd</td>
<td class="xl66" style="border-top: none; width: 52pt;" width="69">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 441pt;" width="588">Baylor College of Medicine</td>
<td class="xl66" style="border-top: none; width: 52pt;" width="69">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 441pt;" width="588">Case Western Reserve University</td>
<td class="xl66" style="border-top: none; width: 52pt;" width="69">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 441pt;" width="588">Cellectis S.A.</td>
<td class="xl66" style="border-top: none; width: 52pt;" width="69">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 441pt;" width="588">Chinese PLA General Hospital</td>
<td class="xl66" style="border-top: none; width: 52pt;" width="69">4</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 441pt;" width="588">City of Hope Medical Center</td>
<td class="xl66" style="border-top: none; width: 52pt;" width="69">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 441pt;" width="588">First Affiliated Hospital, Sun Yat-Sen University</td>
<td class="xl66" style="border-top: none; width: 52pt;" width="69">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 441pt;" width="588">Hangzhou Cancer Hospital</td>
<td class="xl66" style="border-top: none; width: 52pt;" width="69">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 441pt;" width="588">Huazhong University of Science and Technology</td>
<td class="xl66" style="border-top: none; width: 52pt;" width="69">2</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 441pt;" width="588">Peking University</td>
<td class="xl66" style="border-top: none; width: 52pt;" width="69">3</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 441pt;" width="588">Sangamo Therapeutics</td>
<td class="xl66" style="border-top: none; width: 52pt;" width="69">6</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 441pt;" width="588">Sichuan University</td>
<td class="xl66" style="border-top: none; width: 52pt;" width="69">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 441pt;" width="588">University of Pennsylvania</td>
<td class="xl66" style="border-top: none; width: 52pt;" width="69">3</td>
</tr>
<tr height="19" style="height: 14.25pt; mso-height-source: userset; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl72" height="19" style="height: 14.25pt; width: 441pt;" width="588">Vertex Pharmaceuticals Incorporated</td>
<td class="xl71" style="width: 52pt;" width="69">2</td>
</tr>
<tr height="22" style="height: 16.5pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl74" height="22" style="height: 16.5pt; width: 441pt;" width="588">Yang Yang, Nanjing University Medical School</td>
<td class="xl73" style="width: 52pt;" width="69">1</td>
</tr>
</tbody></table>
Sangamo (6), que es de US, aunque parezca de Japón, destaca en el número de CT´s<br />
<br />
Por la enfermedad a resolver:<br />
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 597px;">
<colgroup><col style="mso-width-alt: 16164; mso-width-source: userset; width: 332pt;" width="442"></col>
<col style="mso-width-alt: 5668; mso-width-source: userset; width: 116pt;" width="155"></col>
</colgroup><tbody>
<tr height="24" style="height: 18.0pt;">
<td class="xl67" height="24" style="height: 18.0pt; width: 332pt;" width="442"><b>Disease</b></td>
<td class="xl67" style="width: 116pt;" width="155"><b>n</b></td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 332pt;" width="442">Acute myeloid leukemia</td>
<td class="xl66" style="border-top: none; width: 116pt;" width="155">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 332pt;" width="442">B cell leukemia, B cell lymphoma</td>
<td class="xl66" style="border-top: none; width: 116pt;" width="155">2</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 332pt;" width="442">Beta thalassemia</td>
<td class="xl66" style="border-top: none; width: 116pt;" width="155">2</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 332pt;" width="442">EBV positive advanced stage malignancies</td>
<td class="xl66" style="border-top: none; width: 116pt;" width="155">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 332pt;" width="442">Esophageal cancer</td>
<td class="xl66" style="border-top: none; width: 116pt;" width="155">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 332pt;" width="442">Hemophilia B</td>
<td class="xl66" style="border-top: none; width: 116pt;" width="155">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 332pt;" width="442">HIV</td>
<td class="xl66" style="border-top: none; width: 116pt;" width="155">7</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 332pt;" width="442">HIV-1</td>
<td class="xl66" style="border-top: none; width: 116pt;" width="155">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 332pt;" width="442">Hormone Refractory Prostate Cancer</td>
<td class="xl66" style="border-top: none; width: 116pt;" width="155">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 332pt;" width="442">Human papillomavirus-Related malignant neoplasm</td>
<td class="xl66" style="border-top: none; width: 116pt;" width="155">3</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 332pt;" width="442">Invasive Bladder Cancer Stage IV</td>
<td class="xl66" style="border-top: none; width: 116pt;" width="155">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 332pt;" width="442">Leber congenital amaurosis 10</td>
<td class="xl66" style="border-top: none; width: 116pt;" width="155">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 332pt;" width="442">Metastatic non-small cell lung cancer</td>
<td class="xl66" style="border-top: none; width: 116pt;" width="155">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 332pt;" width="442">Metastatic renal cell carcinoma</td>
<td class="xl66" style="border-top: none; width: 116pt;" width="155">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 332pt;" width="442">Mucopolysaccharidosis I</td>
<td class="xl66" style="border-top: none; width: 116pt;" width="155">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 332pt;" width="442">Mucopolysaccharidosis II</td>
<td class="xl66" style="border-top: none; width: 116pt;" width="155">1</td>
</tr>
<tr height="45" style="height: 33.75pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="45" style="border-top: none; height: 33.75pt; width: 332pt;" width="442">Multiple Myeloma, Melanoma, Synovial Sarcoma,
Myxoid/Round Cell Liposarcoma</td>
<td class="xl66" style="border-top: none; width: 116pt;" width="155">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 332pt;" width="442">Sickle cell disease</td>
<td class="xl66" style="border-top: none; width: 116pt;" width="155">1</td>
</tr>
<tr height="22" style="height: 16.5pt; mso-height-source: userset; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl72" height="22" style="height: 16.5pt; width: 332pt;" width="442">Solid tumor</td>
<td class="xl71" style="width: 116pt;" width="155">2</td>
</tr>
<tr height="44" style="height: 33.0pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl74" height="44" style="height: 33.0pt; width: 332pt;" width="442">T
cell Acute Lymphoblastic Leukemia, T cell Acute Lymphoblastic Lymphoma,
T-non-Hodgkin Lymphoma</td>
<td class="xl73" style="width: 116pt;" width="155">1</td>
</tr>
</tbody></table>
<br />
Por el Target son:<br />
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 714px;">
<colgroup><col style="mso-width-alt: 21760; mso-width-source: userset; width: 446pt;" width="595"></col>
<col style="width: 89pt;" width="119"></col>
</colgroup><tbody>
<tr height="24" style="height: 18.0pt;">
<td class="xl68" height="24" style="height: 18.0pt; width: 446pt;" width="595"><b>Target/modification</b></td>
<td class="xl68" style="width: 89pt;" width="119"><b>n</b></td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl71" height="23" style="border-top: none; height: 17.25pt; width: 446pt;" width="595">Allogeneic CAR T cells targeting CD123, TCR disruption</td>
<td class="xl67" style="border-top: none; width: 89pt;" width="119">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl71" height="23" style="border-top: none; height: 17.25pt; width: 446pt;" width="595">Allogeneic CD19 and CD20/22 CAR T cells</td>
<td class="xl67" style="border-top: none; width: 89pt;" width="119">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl71" height="23" style="border-top: none; height: 17.25pt; width: 446pt;" width="595">Allogeneic CD19-directed CAR T cells; TCR and B2 M
disruption</td>
<td class="xl67" style="border-top: none; width: 89pt;" width="119">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl71" height="23" style="border-top: none; height: 17.25pt; width: 446pt;" width="595">Anti-CD7 CAR T cells, CD7 KO</td>
<td class="xl67" style="border-top: none; width: 89pt;" width="119">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl71" height="23" style="border-top: none; height: 17.25pt; width: 446pt;" width="595">Autologous anti-NY-ESO CAR T cells, disruption of TCR and
PD-1</td>
<td class="xl67" style="border-top: none; width: 89pt;" width="119">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl71" height="23" style="border-top: none; height: 17.25pt; width: 446pt;" width="595">Autologous CD34+ HSPCs modified at the enhancer of the
BCL11A gene</td>
<td class="xl67" style="border-top: none; width: 89pt;" width="119">2</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl71" height="23" style="border-top: none; height: 17.25pt; width: 446pt;" width="595">CCR5 modified CD34+ HSPCs</td>
<td class="xl67" style="border-top: none; width: 89pt;" width="119">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl71" height="23" style="border-top: none; height: 17.25pt; width: 446pt;" width="595">CCR5 modified CD34+ HSPCs (from donor)</td>
<td class="xl67" style="border-top: none; width: 89pt;" width="119">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl71" height="23" style="border-top: none; height: 17.25pt; width: 446pt;" width="595">CCR5 modified CD34+ T cells</td>
<td class="xl67" style="border-top: none; width: 89pt;" width="119">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl71" height="23" style="border-top: none; height: 17.25pt; width: 446pt;" width="595">CCR5 modified CD4+ T cells</td>
<td class="xl67" style="border-top: none; width: 89pt;" width="119">4</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl71" height="23" style="border-top: none; height: 17.25pt; width: 446pt;" width="595">CCR5 modified, C34-CXCR4, CD4 CAR T cells</td>
<td class="xl67" style="border-top: none; width: 89pt;" width="119">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl71" height="23" style="border-top: none; height: 17.25pt; width: 446pt;" width="595">CEP290</td>
<td class="xl67" style="border-top: none; width: 89pt;" width="119">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl71" height="23" style="border-top: none; height: 17.25pt; width: 446pt;" width="595">E6, E7</td>
<td class="xl67" style="border-top: none; width: 89pt;" width="119">2</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl71" height="23" style="border-top: none; height: 17.25pt; width: 446pt;" width="595">E7</td>
<td class="xl67" style="border-top: none; width: 89pt;" width="119">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl71" height="23" style="border-top: none; height: 17.25pt; width: 446pt;" width="595">HBB gene correction in patient specific iHSCs</td>
<td class="xl67" style="border-top: none; width: 89pt;" width="119">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl71" height="23" style="border-top: none; height: 17.25pt; width: 446pt;" width="595">Insertion of a corrected copy of the factor 9 gene into
the albumin locus</td>
<td class="xl67" style="border-top: none; width: 89pt;" width="119">1</td>
</tr>
<tr height="45" style="height: 23pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl71" height="23" style="border-top: none; height: 33.75pt; width: 446pt;" width="595">Insertion of corrected copy of Iduronate 2-Sulfatase gene
into the Albumin locus</td>
<td class="xl67" style="border-top: none; width: 89pt;" width="119">1</td>
</tr>
<tr height="45" style="height: 33.75pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl71" height="45" style="border-top: none; height: 33.75pt; width: 446pt;" width="595">Insertion of corrected copy of α-L-iduronidase gene into
the Albumin locus</td>
<td class="xl67" style="border-top: none; width: 89pt;" width="119">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl71" height="23" style="border-top: none; height: 17.25pt; width: 446pt;" width="595">Mesothelin-directed CAR T cells; PD-1 KO</td>
<td class="xl67" style="border-top: none; width: 89pt;" width="119">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl71" height="23" style="border-top: none; height: 17.25pt; width: 446pt;" width="595">PD-1 and TCR KO anti-mesothelin CAR T cells</td>
<td class="xl67" style="border-top: none; width: 89pt;" width="119">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl71" height="23" style="border-top: none; height: 17.25pt; width: 446pt;" width="595">PD-1 KO EBV-CTL cells</td>
<td class="xl67" style="border-top: none; width: 89pt;" width="119">1</td>
</tr>
<tr height="22" style="height: 16.5pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl73" height="22" style="height: 16.5pt; width: 446pt;" width="595">PD-1 KO T cells</td>
<td class="xl72" style="width: 89pt;" width="119">5</td>
</tr>
</tbody></table>
<br />
Por la nucleasa utilizada:<br />
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 266px;">
<colgroup><col style="width: 164pt;" width="318"></col>
<col style="mso-width-alt: 1755; mso-width-source: userset; width: 36pt;" width="48"></col>
</colgroup><tbody>
<tr height="24" style="height: 18.0pt;">
<td class="xl68" height="24" style="height: 18.0pt; width: 164pt;" width="218"><b>Nuclease</b></td>
<td class="xl69" style="width: 36pt;" width="48"><b>n</b></td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl76" height="23" style="border-top: none; height: 17.25pt; width: 164pt;" width="218">CRISPR</td>
<td class="xl70" style="border-top: none; width: 36pt;" width="48">1</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl76" height="23" style="border-top: none; height: 17.25pt; width: 164pt;" width="218">CRISPR/Cas</td>
<td class="xl70" style="border-top: none; width: 36pt;" width="48">2</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl76" height="23" style="border-top: none; height: 17.25pt; width: 164pt;" width="218">CRISPR/Cas9</td>
<td class="xl70" style="border-top: none; width: 36pt;" width="48">14</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl76" height="23" style="border-top: none; height: 17.25pt; width: 164pt;" width="218">TALEN</td>
<td class="xl70" style="border-top: none; width: 36pt;" width="48">2</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl76" height="23" style="border-top: none; height: 17.25pt; width: 164pt;" width="218">TALEN CRISPR/Cas9</td>
<td class="xl70" style="border-top: none; width: 36pt;" width="48">1</td>
</tr>
<tr height="22" style="height: 16.5pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl75" height="22" style="height: 16.5pt; width: 164pt;" width="218">ZFN</td>
<td class="xl74" style="width: 36pt;" width="48">11</td>
</tr>
</tbody></table>
<br />
Viendo en el tiempo a partir del NCT qué nucleasa se usaba más al inicio de los CT de edición génica ó en la actualidad, es decir viendo el dígito séptimo (millones, M) vemos que los ZFN tienen cierta estabilidad en el tiempo (1,2,5,3) mientras que los con CRISPR (he sumado los 3 tipos de CRISPR descritos CRISPR, CRISPR Cas y CRISPR Cas9) son del periodo más reciente (0,0,4,13). También los de TALEN, aunque en menor número son del periodo más reciente.<br />
<br />
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 302px;">
<colgroup><col style="mso-width-alt: 4644; mso-width-source: userset; width: 95pt;" width="227"></col>
<col span="5" style="width: 26pt;" width="35"></col>
</colgroup><tbody>
<tr height="20" style="height: 15.0pt;">
<td class="xl70" height="20" style="height: 15.0pt; width: 95pt;" width="127"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 369px;">
<colgroup><col style="mso-width-alt: 6400; mso-width-source: userset; width: 131pt;" width="175"></col>
<col style="mso-width-alt: 1974; mso-width-source: userset; width: 41pt;" width="54"></col>
<col span="4" style="width: 26pt;" width="35"></col>
</colgroup><tbody>
<tr height="24" style="height: 18.0pt; mso-height-source: userset;">
<td class="xl68" height="24" style="height: 18.0pt; width: 131pt;" width="175">Nuclease</td>
<td class="xl70" style="border-left: none; width: 41pt;" width="54">Total </td>
<td class="xl68" style="border-left: none; width: 26pt;" width="35">0</td>
<td class="xl68" style="border-left: none; width: 26pt;" width="35">1</td>
<td class="xl68" style="border-left: none; width: 26pt;" width="35">2</td>
<td class="xl68" style="border-left: none; width: 26pt;" width="35">3</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl71" height="20" style="height: 15.0pt; width: 131pt;" width="175">CRISPR</td>
<td class="xl67" style="border-left: none; width: 41pt;" width="54">17</td>
<td class="xl69" style="width: 26pt;" width="35"></td>
<td class="xl69" style="width: 26pt;" width="35"></td>
<td class="xl67" style="width: 26pt;" width="35">4</td>
<td class="xl67" style="border-left: none; width: 26pt;" width="35">13</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl67" height="20" style="border-top: none; height: 15.0pt; width: 131pt;" width="175">TALEN</td>
<td class="xl67" style="border-left: none; border-top: none; width: 41pt;" width="54">2</td>
<td class="xl69" style="width: 26pt;" width="35"></td>
<td class="xl69" style="width: 26pt;" width="35"></td>
<td class="xl69" style="width: 26pt;" width="35"></td>
<td class="xl67" style="border-top: none; width: 26pt;" width="35">2</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl67" height="20" style="border-top: none; height: 15.0pt; width: 131pt;" width="175">TALEN CRISPR/Cas9</td>
<td class="xl67" style="border-left: none; border-top: none; width: 41pt;" width="54">1</td>
<td class="xl69" style="width: 26pt;" width="35"></td>
<td class="xl69" style="width: 26pt;" width="35"></td>
<td class="xl69" style="width: 26pt;" width="35"></td>
<td class="xl67" style="border-top: none; width: 26pt;" width="35">1</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl67" height="20" style="border-top: none; height: 15.0pt; width: 131pt;" width="175">ZFN</td>
<td class="xl67" style="border-left: none; border-top: none; width: 41pt;" width="54">11</td>
<td class="xl67" style="border-left: none; width: 26pt;" width="35">1</td>
<td class="xl67" style="border-left: none; width: 26pt;" width="35">2</td>
<td class="xl67" style="border-left: none; width: 26pt;" width="35">5</td>
<td class="xl67" style="border-left: none; border-top: none; width: 26pt;" width="35">3</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td class="xl66" height="20" style="height: 15.0pt; width: 131pt;" width="175">Total</td>
<td class="xl66" style="width: 41pt;" width="54">31</td>
<td class="xl66" style="width: 26pt;" width="35">1</td>
<td class="xl66" style="width: 26pt;" width="35">2</td>
<td class="xl66" style="width: 26pt;" width="35">9</td>
<td class="xl66" style="width: 26pt;" width="35">19</td>
</tr>
</tbody></table>
<br /></td><td class="xl70" style="border-left: none; width: 26pt;" width="35"></td><td class="xl70" style="border-left: none; width: 26pt;" width="35"></td><td class="xl70" style="border-left: none; width: 26pt;" width="35"></td><td class="xl70" style="border-left: none; width: 26pt;" width="35"></td><td class="xl70" style="border-left: none; width: 26pt;" width="35"></td></tr>
</tbody></table>
Por el método de transfección no han podido encontrarlo en 17 de los CT<br />
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 414px;">
<colgroup><col style="mso-width-alt: 13750; mso-width-source: userset; width: 282pt;" width="376"></col>
<col style="mso-width-alt: 1389; mso-width-source: userset; width: 29pt;" width="38"></col>
</colgroup><tbody>
<tr height="24" style="height: 18.0pt;">
<td class="xl66" height="24" style="height: 18.0pt; width: 282pt;" width="376"><b>Delivery</b></td>
<td class="xl65" style="width: 29pt;" width="38"><b>n</b></td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 282pt;" width="376">AAV</td>
<td class="xl65" style="width: 29pt;" width="38">4</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 282pt;" width="376">Adenoviral vector</td>
<td class="xl65" style="width: 29pt;" width="38">3</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 282pt;" width="376">mRNA electroporation</td>
<td class="xl65" style="width: 29pt;" width="38">3</td>
</tr>
<tr height="23" style="height: 17.25pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl70" height="23" style="border-top: none; height: 17.25pt; width: 282pt;" width="376">Not specified</td>
<td class="xl65" style="width: 29pt;" width="38">17</td>
</tr>
<tr height="22" style="height: 16.5pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl71" height="22" style="border-top: none; height: 16.5pt; width: 282pt;" width="376">Plasmid in gel</td>
<td class="xl65" style="width: 29pt;" width="38">2</td>
</tr>
<tr height="22" style="height: 16.5pt; mso-outline-level: 1; mso-outline-parent: collapsed;">
<td class="xl72" height="22" style="height: 16.5pt; width: 282pt;" width="376">Ribonucleoprotein electroporation</td>
<td class="xl65" style="width: 29pt;" width="38">2</td>
</tr>
</tbody></table>
<br />
<br />
Sus autoras son Maria Schacker y Diane Seimetz de <a href="http://www.biopharma-excellence.com/">Biopharma Excellence</a>, una consultora para ayudar en las tramitaciones de los expedientes ante las agencias reguladoras.<br />
<br />
De su <a href="https://static1.squarespace.com/static/57d16156414fb5307d454a1d/t/595260b8414fb5a55ed70465/1498570942251/Biopharma+Excellence+Brochure.pdf">brochure </a>copiamos dos gráficas, una de tipos de productos<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiWhVu6BfKsmsQJNd9UCRS3BFBi2qW3UgF8gASxuTa8IObrswEFBCn-gSNM_8TSpCTeukoyFmHl_Jqbgf3nayN2b7P2QALfLgHtM-kV8tlhL_XWTGnGvwv2HE2EQeMWnEhA-06i6-n72Olh/s1600/Biopharma_product_classes.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="366" data-original-width="582" height="402" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiWhVu6BfKsmsQJNd9UCRS3BFBi2qW3UgF8gASxuTa8IObrswEFBCn-gSNM_8TSpCTeukoyFmHl_Jqbgf3nayN2b7P2QALfLgHtM-kV8tlhL_XWTGnGvwv2HE2EQeMWnEhA-06i6-n72Olh/s640/Biopharma_product_classes.gif" width="640" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
y otra de tipos de servicios</div>
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiW7fHfnqz4P7dT2tw4y8wo-jYKQao7gw0Z0Bni1wDtAy0rQR7wybbebnlmintgx90VIIUdcbzz7aQ4wenoMzbAhjrMDksuzRVfvNkJgUfFciaAr7hPtwfXTSi96T00tB1d798wK2LwczDS/s1600/Biopharma_services.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="317" data-original-width="572" height="354" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiW7fHfnqz4P7dT2tw4y8wo-jYKQao7gw0Z0Bni1wDtAy0rQR7wybbebnlmintgx90VIIUdcbzz7aQ4wenoMzbAhjrMDksuzRVfvNkJgUfFciaAr7hPtwfXTSi96T00tB1d798wK2LwczDS/s640/Biopharma_services.gif" width="640" /></a></div>
<br />
<br />
<span style="color: red; mso-themecolor: dark2;"><span style="mso-spacerun: yes;"></span>Le ruego evalúe la presente entrada asignando un valor de 1 a 5, de peor a mejor valorada, usando la opción de comentarios
</span>JOSE Rhttp://www.blogger.com/profile/09318104344786439010noreply@blogger.com0tag:blogger.com,1999:blog-1952063008451683630.post-37270121644383055542019-12-23T07:24:00.000+01:002019-12-23T16:27:09.843+01:00Ensayos clínicos en Clinicaltrials.gov con uso de CRISPR<head><!-- Global site tag (gtag.js) - Google Analytics -->
<script async="" src="https://www.googletagmanager.com/gtag/js?id=UA-133555286-1"></script>
<script>
window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config', 'UA-133555286-1');
</script>
</head>
<br />
Decía en la <a href="https://degenetica.blogspot.com/2019/12/lvv-o-aavv-crispr-cas9.html">ultima entrada</a> de los 31 ensayos clínicos de clinicaltrials.gov con la palabra CRISPR. Uno se retiró y de los 30 restantes he tenido referencia de resultados de los de CTX001 de anemia falciforme NCT03745287 y de betatalasemia NCT03655678 en <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512986/">Highly Efficient Therapeutic Gene Editing of Human Hematopoietic Stem Cells</a><br />
<br />
<br />
<table border="1" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 1526px;">
<colgroup><col style="width: 60pt;" width="80"></col>
<col style="mso-width-alt: 13385; mso-width-source: userset; width: 275pt;" width="366"></col>
<col style="mso-width-alt: 10459; mso-width-source: userset; width: 215pt;" width="286"></col>
<col style="mso-width-alt: 10861; mso-width-source: userset; width: 223pt;" width="297"></col>
<col style="mso-width-alt: 6838; mso-width-source: userset; width: 140pt;" width="187"></col>
<col span="2" style="mso-width-alt: 2889; mso-width-source: userset; width: 59pt;" width="79"></col>
<col style="mso-width-alt: 5558; mso-width-source: userset; width: 114pt;" width="152"></col>
</colgroup><tbody>
<tr height="68" style="height: 51.0pt; mso-height-source: userset;">
<td class="xl65" height="68" style="height: 51.0pt; width: 60pt;" width="80"><b>NCT Number</b></td>
<td class="xl65" style="width: 275pt;" width="366"><b>Title</b></td>
<td class="xl65" style="width: 215pt;" width="286"><b>Conditions</b></td>
<td class="xl65" style="width: 223pt;" width="297"><b>Interventions</b></td>
<td class="xl65" style="width: 140pt;" width="187"><b>Sponsor/Collaborators</b></td>
<td class="xl65" style="width: 59pt;" width="79"><b>Phases</b></td>
<td class="xl65" style="width: 59pt;" width="79"><b>Funded Bys</b></td>
<td class="xl65" style="width: 114pt;" width="152"><b>URL</b></td>
</tr>
<tr height="68" style="height: 51.0pt; mso-height-source: userset;">
<td class="xl65" height="68" style="height: 51.0pt; width: 60pt;" width="80">NCT03057912</td>
<td class="xl65" style="width: 275pt;" width="366">A Safety and Efficacy Study of
TALEN and CRISPR/Cas9 in the Treatment of HPV-related Cervical
Intraepithelial Neoplasia Ⅰ without invasion</td>
<td class="xl65" style="width: 215pt;" width="286">Human Papillomavirus-Related
Malignant Neoplasm</td>
<td class="xl65" style="width: 223pt;" width="297">Biological: TALEN , Biological:
CRISPR/Cas9</td>
<td class="xl65" style="width: 140pt;" width="187">First Affiliated Hospital, Sun
Yat-Sen University , Jingchu University of Technology</td>
<td class="xl65" style="width: 59pt;" width="79">Phase 1</td>
<td class="xl65" style="width: 59pt;" width="79">Other</td>
<td class="xl67" style="width: 114pt;" width="152"><a href="https://clinicaltrials.gov/show/NCT03057912">https://ClinicalTrials.gov/show/NCT03057912</a></td>
</tr>
<tr height="68" style="height: 51.0pt; mso-height-source: userset;">
<td class="xl65" height="68" style="height: 51.0pt; width: 60pt;" width="80">NCT04074369</td>
<td class="xl65" style="width: 275pt;" width="366">Evaluation of CRISPR-based Test
for the Rapid Identification of TB in Pulmonary Tuberculosis Suspects</td>
<td class="xl65" style="width: 215pt;" width="286">Tuberculosis, Pulmonary</td>
<td class="xl65" style="width: 223pt;" width="297">Diagnostic Test: CRISPR-based
Test</td>
<td class="xl65" style="width: 140pt;" width="187">Huashan Hospital , Wenzhou
Central Hospital , Hangzhou Red Cross Hospital</td>
<td class="xl65" style="width: 59pt;" width="79"></td>
<td class="xl65" style="width: 59pt;" width="79">Other</td>
<td class="xl67" style="width: 114pt;" width="152"><a href="https://clinicaltrials.gov/show/NCT04074369">https://ClinicalTrials.gov/show/NCT04074369</a></td>
</tr>
<tr height="68" style="height: 51.0pt; mso-height-source: userset;">
<td class="xl65" height="68" style="height: 51.0pt; width: 60pt;" width="80">NCT04178382</td>
<td class="xl65" style="width: 275pt;" width="366">Effect of PCR-CRISPR/Cas12a on
the Early Anti-infective Schemes in Patients With Open Air Pneumonia</td>
<td class="xl65" style="width: 215pt;" width="286">Severe Sepsis</td>
<td class="xl65" style="width: 223pt;" width="297">Diagnostic Test:
PCR-CRISPRï¼Cas12a detection</td>
<td class="xl65" style="width: 140pt;" width="187">Chinese Medical Association</td>
<td class="xl65" style="width: 59pt;" width="79">Not Applicable</td>
<td class="xl65" style="width: 59pt;" width="79">Other</td>
<td class="xl67" style="width: 114pt;" width="152"><a href="https://clinicaltrials.gov/show/NCT04178382">https://ClinicalTrials.gov/show/NCT04178382</a></td>
</tr>
<tr height="93" style="height: 69.75pt; mso-height-source: userset;">
<td class="xl65" height="93" style="height: 69.75pt; width: 60pt;" width="80">NCT03164135</td>
<td class="xl65" style="width: 275pt;" width="366">Safety of Transplantation of
CRISPR CCR5 Modified CD34+ Cells in HIV-infected Subjects With Hematological
Malignances</td>
<td class="xl65" style="width: 215pt;" width="286">HIV-1-infection</td>
<td class="xl65" style="width: 223pt;" width="297">Genetic: CCR5 gene modification</td>
<td class="xl65" style="width: 140pt;" width="187">Affiliated Hospital to Academy
of Military Medical Sciences , Peking University , Capital Medical University</td>
<td class="xl65" style="width: 59pt;" width="79">Not Applicable</td>
<td class="xl65" style="width: 59pt;" width="79">Other</td>
<td class="xl67" style="width: 114pt;" width="152"><a href="https://clinicaltrials.gov/show/NCT03164135">https://ClinicalTrials.gov/show/NCT03164135</a></td>
</tr>
<tr height="68" style="height: 51.0pt; mso-height-source: userset;">
<td class="xl65" height="68" style="height: 51.0pt; width: 60pt;" width="80">NCT03545815</td>
<td class="xl65" style="width: 275pt;" width="366">Study of CRISPR-Cas9 Mediated
PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients
With Mesothelin Positive Multiple Solid Tumors.</td>
<td class="xl65" style="width: 215pt;" width="286">Solid Tumor, Adult</td>
<td class="xl65" style="width: 223pt;" width="297">Biological: anti-mesothelin
CAR-T cells</td>
<td class="xl65" style="width: 140pt;" width="187">Chinese PLA General Hospital</td>
<td class="xl65" style="width: 59pt;" width="79">Phase 1</td>
<td class="xl65" style="width: 59pt;" width="79">Other</td>
<td class="xl67" style="width: 114pt;" width="152"><a href="https://clinicaltrials.gov/show/NCT03545815">https://ClinicalTrials.gov/show/NCT03545815</a></td>
</tr>
<tr height="68" style="height: 51.0pt; mso-height-source: userset;">
<td class="xl65" height="68" style="height: 51.0pt; width: 60pt;" width="80">NCT03655678</td>
<td class="xl65" style="width: 275pt;" width="366">A Safety and Efficacy Study
Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia</td>
<td class="xl65" style="width: 215pt;" width="286">Beta-Thalassemia , Thalassemia ,
Genetic Diseases, Inborn , Hematologic Diseases , Hemoglobinopathies</td>
<td class="xl65" style="width: 223pt;" width="297">Biological: CTX001</td>
<td class="xl65" style="width: 140pt;" width="187">Vertex Pharmaceuticals
Incorporated , CRISPR Therapeutics</td>
<td class="xl65" style="width: 59pt;" width="79">Phase 1 , Phase 2</td>
<td class="xl65" style="width: 59pt;" width="79">Industry</td>
<td class="xl67" style="width: 114pt;" width="152"><a href="https://clinicaltrials.gov/show/NCT03655678">https://ClinicalTrials.gov/show/NCT03655678</a></td>
</tr>
<tr height="88" style="height: 66.0pt; mso-height-source: userset;">
<td class="xl65" height="88" style="height: 66.0pt; width: 60pt;" width="80">NCT03399448</td>
<td class="xl65" style="width: 275pt;" width="366">NY-ESO-1-redirected CRISPR
(TCRendo and PD1) Edited T Cells (NYCE T Cells)</td>
<td class="xl65" style="width: 215pt;" width="286">Multiple Myeloma , Melanoma ,
Synovial Sarcoma , Myxoid/Round Cell Liposarcoma</td>
<td class="xl65" style="width: 223pt;" width="297">Biological: NY-ESO-1 redirected
autologous T cells with CRISPR edited endogenous TCR and PD-1 , Drug:
Cyclophosphamide , Drug: Fludarabine , Device: NY-ESO-1 expression testing</td>
<td class="xl65" style="width: 140pt;" width="187">University of Pennsylvania ,
Parker Institute for Cancer Immunotherapy , Tmunity Therapeutics</td>
<td class="xl65" style="width: 59pt;" width="79">Phase 1</td>
<td class="xl65" style="width: 59pt;" width="79">Other , Industry</td>
<td class="xl65" style="width: 114pt;" width="152"></td>
</tr>
<tr height="68" style="height: 51.0pt; mso-height-source: userset;">
<td class="xl65" height="68" style="height: 51.0pt; width: 60pt;" width="80">NCT04037566</td>
<td class="xl65" style="width: 275pt;" width="366">CRISPR (HPK1) Edited
CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.</td>
<td class="xl65" style="width: 215pt;" width="286">Leukemia Lymphocytic Acute (ALL)
in Relapse , Leukemia Lymphocytic Acute (All) Refractory , Lymphoma, B-Cell ,
CD19 Positive</td>
<td class="xl65" style="width: 223pt;" width="297">Genetic: XYF19 CAR-T cell ,
Drug: Cyclophosphamide , Drug: Fludarabine</td>
<td class="xl65" style="width: 140pt;" width="187">Xijing Hospital , Xi'An Yufan
Biotechnology Co.,Ltd</td>
<td class="xl65" style="width: 59pt;" width="79">Phase 1</td>
<td class="xl65" style="width: 59pt;" width="79">Other</td>
<td class="xl67" style="width: 114pt;" width="152"><a href="https://clinicaltrials.gov/show/NCT04037566">https://ClinicalTrials.gov/show/NCT04037566</a></td>
</tr>
<tr height="68" style="height: 51.0pt; mso-height-source: userset;">
<td class="xl65" height="68" style="height: 51.0pt; width: 60pt;" width="80">NCT03745287</td>
<td class="xl65" style="width: 275pt;" width="366">A Safety and Efficacy Study
Evaluating CTX001 in Subjects With Severe Sickle Cell Disease</td>
<td class="xl65" style="width: 215pt;" width="286">Sickle Cell Disease ,
Hematological Diseases , Hemoglobinopathies</td>
<td class="xl65" style="width: 223pt;" width="297">Biological: CTX001</td>
<td class="xl65" style="width: 140pt;" width="187">Vertex Pharmaceuticals
Incorporated , CRISPR Therapeutics</td>
<td class="xl65" style="width: 59pt;" width="79">Phase 1 , Phase 2</td>
<td class="xl65" style="width: 59pt;" width="79">Industry</td>
<td class="xl67" style="width: 114pt;" width="152"><a href="https://clinicaltrials.gov/show/NCT03745287">https://ClinicalTrials.gov/show/NCT03745287</a></td>
</tr>
<tr height="68" style="height: 51.0pt; mso-height-source: userset;">
<td class="xl65" height="68" style="height: 51.0pt; width: 60pt;" width="80">NCT04035434</td>
<td class="xl65" style="width: 275pt;" width="366">A Safety and Efficacy Study
Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies</td>
<td class="xl65" style="width: 215pt;" width="286">B-cell Malignancy , Non-Hodgkin
Lymphoma , B-cell Lymphoma</td>
<td class="xl65" style="width: 223pt;" width="297">Biological: CTX110</td>
<td class="xl65" style="width: 140pt;" width="187">CRISPR Therapeutics AG , CRISPR
Therapeutics</td>
<td class="xl65" style="width: 59pt;" width="79">Phase 1 , Phase 2</td>
<td class="xl65" style="width: 59pt;" width="79">Industry</td>
<td class="xl67" style="width: 114pt;" width="152"><a href="https://clinicaltrials.gov/show/NCT04035434">https://ClinicalTrials.gov/show/NCT04035434</a></td>
</tr>
<tr height="68" style="height: 51.0pt; mso-height-source: userset;">
<td class="xl65" height="68" style="height: 51.0pt; width: 60pt;" width="80">NCT03538613</td>
<td class="xl65" style="width: 275pt;" width="366">Study of People With Metastatic
Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating
Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the
CRISPR/Cas9 System</td>
<td class="xl65" style="width: 215pt;" width="286">Gastrointestinal Epithelial
Cancer , Gastrointestinal Neoplasm , Cancer of Gastrointestinal Tract ,
Cancer, Gastrointestinal</td>
<td class="xl65" style="width: 223pt;" width="297">Drug: Cyclophosphamide , Drug:
Fludarabine , Drug: Aldesleukin , Biological: CISH inactivated TIL</td>
<td class="xl65" style="width: 140pt;" width="187">National Cancer Institute (NCI)
, National Institutes of Health Clinical Center (CC)</td>
<td class="xl65" style="width: 59pt;" width="79">Phase 1 , Phase 2</td>
<td class="xl65" style="width: 59pt;" width="79">NIH</td>
<td class="xl67" style="width: 114pt;" width="152"><a href="https://clinicaltrials.gov/show/NCT03538613">https://ClinicalTrials.gov/show/NCT03538613</a></td>
</tr>
<tr height="68" style="height: 51.0pt; mso-height-source: userset;">
<td class="xl65" height="68" style="height: 51.0pt; width: 60pt;" width="80">NCT03728322</td>
<td class="xl65" style="width: 275pt;" width="366">iHSCs With the Gene Correction
of HBB Intervent Subjests With β-thalassemia Mutations</td>
<td class="xl65" style="width: 215pt;" width="286">Thalassemia</td>
<td class="xl65" style="width: 223pt;" width="297">Biological: iHSCs treatment
group</td>
<td class="xl65" style="width: 140pt;" width="187">Allife Medical Science and
Technology Co., Ltd.</td>
<td class="xl65" style="width: 59pt;" width="79">Early Phase 1</td>
<td class="xl65" style="width: 59pt;" width="79">Industry</td>
<td class="xl67" style="width: 114pt;" width="152"><a href="https://clinicaltrials.gov/show/NCT03728322">https://ClinicalTrials.gov/show/NCT03728322</a></td>
</tr>
<tr height="68" style="height: 51.0pt; mso-height-source: userset;">
<td class="xl65" height="68" style="height: 51.0pt; width: 60pt;" width="80">NCT03747965</td>
<td class="xl65" style="width: 275pt;" width="366">Study of PD-1 Gene-knocked Out
Mesothelin-directed CAR-T Cells With the Conditioning of PC in Mesothelin
Positive Multiple Solid Tumors</td>
<td class="xl65" style="width: 215pt;" width="286">Solid Tumor, Adult</td>
<td class="xl65" style="width: 223pt;" width="297">Biological: Mesothelin-directed
CAR-T cells</td>
<td class="xl65" style="width: 140pt;" width="187">Chinese PLA General Hospital</td>
<td class="xl65" style="width: 59pt;" width="79">Phase 1</td>
<td class="xl65" style="width: 59pt;" width="79">Other</td>
<td class="xl67" style="width: 114pt;" width="152"><a href="https://clinicaltrials.gov/show/NCT03747965">https://ClinicalTrials.gov/show/NCT03747965</a></td>
</tr>
<tr height="68" style="height: 51.0pt; mso-height-source: userset;">
<td class="xl65" height="68" style="height: 51.0pt; width: 60pt;" width="80">NCT03855631</td>
<td class="xl65" style="width: 275pt;" width="366">Exploiting Epigenome Editing in
Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders</td>
<td class="xl65" style="width: 215pt;" width="286">Kabuki Syndrome 1</td>
<td class="xl65" style="width: 223pt;" width="297">Genetic: Intervention on primary
cultured cells</td>
<td class="xl65" style="width: 140pt;" width="187">University Hospital, Montpellier
, Association Française contre les Myopathies Telethon</td>
<td class="xl65" style="width: 59pt;" width="79"></td>
<td class="xl65" style="width: 59pt;" width="79">Other</td>
<td class="xl67" style="width: 114pt;" width="152"><a href="https://clinicaltrials.gov/show/NCT03855631">https://ClinicalTrials.gov/show/NCT03855631</a></td>
</tr>
<tr height="68" style="height: 51.0pt; mso-height-source: userset;">
<td class="xl65" height="68" style="height: 51.0pt; width: 60pt;" width="80">NCT03342547</td>
<td class="xl65" style="width: 275pt;" width="366">Identification of Host Factors
of Norovirus Infections in Mini-Gut Model</td>
<td class="xl65" style="width: 215pt;" width="286">Gastrointestinal Infection</td>
<td class="xl65" style="width: 223pt;" width="297">Procedure: Duodenal biopsy ,
Procedure: Saliva</td>
<td class="xl65" style="width: 140pt;" width="187">Chinese University of Hong Kong</td>
<td class="xl65" style="width: 59pt;" width="79">Not Applicable</td>
<td class="xl65" style="width: 59pt;" width="79">Other</td>
<td class="xl67" style="width: 114pt;" width="152"><a href="https://clinicaltrials.gov/show/NCT03342547">https://ClinicalTrials.gov/show/NCT03342547</a></td>
</tr>
<tr height="68" style="height: 51.0pt; mso-height-source: userset;">
<td class="xl65" height="68" style="height: 51.0pt; width: 60pt;" width="80">NCT03166878</td>
<td class="xl65" style="width: 275pt;" width="366">A Study Evaluating UCART019 in
Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma</td>
<td class="xl65" style="width: 215pt;" width="286">B Cell Leukemia , B Cell
Lymphoma</td>
<td class="xl65" style="width: 223pt;" width="297">Biological: UCART019</td>
<td class="xl65" style="width: 140pt;" width="187">Chinese PLA General Hospital</td>
<td class="xl65" style="width: 59pt;" width="79">Phase 1 , Phase 2</td>
<td class="xl65" style="width: 59pt;" width="79">Other</td>
<td class="xl65" style="width: 114pt;" width="152">https://ClinicalTrials.gov/show/NCT03166878</td>
</tr>
<tr height="197" style="height: 147.75pt; mso-height-source: userset;">
<td class="xl65" height="197" style="height: 147.75pt; width: 60pt;" width="80">NCT03606486</td>
<td class="xl65" style="width: 275pt;" width="366">Lavage of the Uterine Cavity for
Diagnosis of Ovarian Cancer</td>
<td class="xl65" style="width: 215pt;" width="286">High Grade Ovarian Serous
Adenocarcinoma , Stage III Ovarian Cancer AJCC v8 , Stage IIIA Ovarian Cancer
AJCC v8 , Stage IIIA1 Ovarian Cancer AJCC v8 , Stage IIIA2 Ovarian Cancer
AJCC v8 , Stage IIIB Ovarian Cancer AJCC v8 , Stage IIIC Ovarian Cancer AJCC
v8 , Stage IV Ovarian Cancer AJCC v8 , Stage IVA Ovarian Cancer AJCC v8 ,
Stage IVB Ovarian Cancer AJCC v8</td>
<td class="xl65" style="width: 223pt;" width="297">Other: Biospecimen Collection ,
Other: Laboratory Biomarker Analysis , Other: Lavage , Other: Pap Smear</td>
<td class="xl65" style="width: 140pt;" width="187">University of Washington ,
National Cancer Institute (NCI) , Minnesota Ovarian Cancer Alliance</td>
<td class="xl65" style="width: 59pt;" width="79">Not Applicable</td>
<td class="xl65" style="width: 59pt;" width="79">Other , NIH</td>
<td class="xl67" style="width: 114pt;" width="152"><a href="https://clinicaltrials.gov/show/NCT03606486">https://ClinicalTrials.gov/show/NCT03606486</a></td>
</tr>
<tr height="68" style="height: 51.0pt; mso-height-source: userset;">
<td class="xl65" height="68" style="height: 51.0pt; width: 60pt;" width="80">NCT03398967</td>
<td class="xl65" style="width: 275pt;" width="366">A Feasibility and Safety Study
of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy
for Relapsed or Refractory Leukemia and Lymphoma</td>
<td class="xl65" style="width: 215pt;" width="286">B Cell Leukemia , B Cell
Lymphoma</td>
<td class="xl65" style="width: 223pt;" width="297">Biological: Universal Dual
Specificity CD19 and CD20 or CD22 CAR-T Cells</td>
<td class="xl65" style="width: 140pt;" width="187">Chinese PLA General Hospital</td>
<td class="xl65" style="width: 59pt;" width="79">Phase 1 , Phase 2</td>
<td class="xl65" style="width: 59pt;" width="79">Other</td>
<td class="xl67" style="width: 114pt;" width="152"><a href="https://clinicaltrials.gov/show/NCT03398967">https://ClinicalTrials.gov/show/NCT03398967</a></td>
</tr>
<tr height="68" style="height: 51.0pt; mso-height-source: userset;">
<td class="xl65" height="68" style="height: 51.0pt; width: 60pt;" width="80">NCT03081715</td>
<td class="xl65" style="width: 275pt;" width="366">PD-1 Knockout Engineered T Cells
for Advanced Esophageal Cancer</td>
<td class="xl65" style="width: 215pt;" width="286">Esophageal Cancer</td>
<td class="xl65" style="width: 223pt;" width="297">Other: PD-1 Knockout T Cells</td>
<td class="xl65" style="width: 140pt;" width="187">Hangzhou Cancer Hospital , Anhui
Kedgene Biotechnology Co.,Ltd</td>
<td class="xl65" style="width: 59pt;" width="79">Not Applicable</td>
<td class="xl65" style="width: 59pt;" width="79">Other</td>
<td class="xl67" style="width: 114pt;" width="152"><a href="https://clinicaltrials.gov/show/NCT03081715">https://ClinicalTrials.gov/show/NCT03081715</a></td>
</tr>
<tr height="68" style="height: 51.0pt; mso-height-source: userset;">
<td class="xl65" height="68" style="height: 51.0pt; width: 60pt;" width="80">NCT03332030</td>
<td class="xl65" style="width: 275pt;" width="366">Stem Cells in NF1 Patients With
Tumors of the Central Nervous System</td>
<td class="xl65" style="width: 215pt;" width="286">Neurofibromatosis Type 1 ,
Tumors of the Central Nervous System</td>
<td class="xl65" style="width: 223pt;" width="297">Diagnostic Test: Collection of
Stem Cells</td>
<td class="xl65" style="width: 140pt;" width="187">Children's Research Institute</td>
<td class="xl65" style="width: 59pt;" width="79"></td>
<td class="xl65" style="width: 59pt;" width="79">Other</td>
<td class="xl67" style="width: 114pt;" width="152"><a href="https://clinicaltrials.gov/show/NCT03332030">https://ClinicalTrials.gov/show/NCT03332030</a></td>
</tr>
<tr height="68" style="height: 51.0pt; mso-height-source: userset;">
<td class="xl65" height="68" style="height: 51.0pt; width: 60pt;" width="80">NCT03690011</td>
<td class="xl65" style="width: 275pt;" width="366">Cell Therapy for High Risk
T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells</td>
<td class="xl65" style="width: 215pt;" width="286">T-cell Acute Lymphoblastic
Leukemia , T-cell Acute Lymphoblastic Lymphoma , T-non-Hodgkin Lymphoma</td>
<td class="xl65" style="width: 223pt;" width="297">Genetic: CD7.CAR/28zeta CAR T
cells , Drug: Fludarabine , Drug: Cytoxan</td>
<td class="xl65" style="width: 140pt;" width="187">Baylor College of Medicine , The
Methodist Hospital System , Texas Children's Hospital , Center for Cell and
Gene Therapy, Baylor College of Medicine</td>
<td class="xl65" style="width: 59pt;" width="79">Phase 1</td>
<td class="xl65" style="width: 59pt;" width="79">Other</td>
<td class="xl67" style="width: 114pt;" width="152"><a href="https://clinicaltrials.gov/show/NCT03690011">https://ClinicalTrials.gov/show/NCT03690011</a></td>
</tr>
<tr height="68" style="height: 51.0pt; mso-height-source: userset;">
<td class="xl65" height="68" style="height: 51.0pt; width: 60pt;" width="80">NCT03681951</td>
<td class="xl65" style="width: 275pt;" width="366">First-time-in-human (FTIH) Study
of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults
With Advanced Solid Tumors</td>
<td class="xl65" style="width: 215pt;" width="286">Neoplasms, Pancreatic</td>
<td class="xl65" style="width: 223pt;" width="297">Drug: GSK3145095 , Drug:
Pembrolizumab</td>
<td class="xl65" style="width: 140pt;" width="187">GlaxoSmithKline , Parexel</td>
<td class="xl65" style="width: 59pt;" width="79">Phase 2</td>
<td class="xl65" style="width: 59pt;" width="79">Industry</td>
<td class="xl67" style="width: 114pt;" width="152"><a href="https://clinicaltrials.gov/show/NCT03681951">https://ClinicalTrials.gov/show/NCT03681951</a></td>
</tr>
<tr height="68" style="height: 51.0pt; mso-height-source: userset;">
<td class="xl65" height="68" style="height: 51.0pt; width: 60pt;" width="80">NCT02863913</td>
<td class="xl65" style="width: 275pt;" width="366">PD-1 Knockout Engineered T Cells
for Muscle-invasive Bladder Cancer</td>
<td class="xl65" style="width: 215pt;" width="286">Invasive Bladder Cancer Stage IV</td>
<td class="xl65" style="width: 223pt;" width="297">Biological: PD-1 Knockout T
Cells , Drug: Cyclophosphamide , Drug: IL-2</td>
<td class="xl65" style="width: 140pt;" width="187">Peking University</td>
<td class="xl65" style="width: 59pt;" width="79">Phase 1</td>
<td class="xl65" style="width: 59pt;" width="79">Other</td>
<td class="xl67" style="width: 114pt;" width="152"><a href="https://clinicaltrials.gov/show/NCT02863913">https://ClinicalTrials.gov/show/NCT02863913</a></td>
</tr>
<tr height="68" style="height: 51.0pt; mso-height-source: userset;">
<td class="xl65" height="68" style="height: 51.0pt; width: 60pt;" width="80">NCT02867345</td>
<td class="xl65" style="width: 275pt;" width="366">PD-1 Knockout Engineered T Cells
for Castration Resistant Prostate Cancer</td>
<td class="xl65" style="width: 215pt;" width="286">Hormone Refractory Prostate
Cancer</td>
<td class="xl65" style="width: 223pt;" width="297">Biological: PD-1 Knockout T
Cells , Drug: Cyclophosphamide , Drug: IL-2</td>
<td class="xl65" style="width: 140pt;" width="187">Peking University</td>
<td class="xl65" style="width: 59pt;" width="79"></td>
<td class="xl65" style="width: 59pt;" width="79">Other</td>
<td class="xl67" style="width: 114pt;" width="152"><a href="https://clinicaltrials.gov/show/NCT02867345">https://ClinicalTrials.gov/show/NCT02867345</a></td>
</tr>
<tr height="68" style="height: 51.0pt; mso-height-source: userset;">
<td class="xl65" height="68" style="height: 51.0pt; width: 60pt;" width="80">NCT02867332</td>
<td class="xl65" style="width: 275pt;" width="366">PD-1 Knockout Engineered T Cells
for Metastatic Renal Cell Carcinoma.</td>
<td class="xl65" style="width: 215pt;" width="286">Metastatic Renal Cell Carcinoma</td>
<td class="xl65" style="width: 223pt;" width="297">Biological: PD-1 Knockout T
Cells , Drug: Cyclophosphamide , Drug: IL-2</td>
<td class="xl65" style="width: 140pt;" width="187">Peking University</td>
<td class="xl65" style="width: 59pt;" width="79">Phase 1</td>
<td class="xl65" style="width: 59pt;" width="79">Other</td>
<td class="xl67" style="width: 114pt;" width="152"><a href="https://clinicaltrials.gov/show/NCT02867332">https://ClinicalTrials.gov/show/NCT02867332</a></td>
</tr>
<tr height="68" style="height: 51.0pt; mso-height-source: userset;">
<td class="xl65" height="68" style="height: 51.0pt; width: 60pt;" width="80">NCT02793856</td>
<td class="xl65" style="width: 275pt;" width="366">PD-1 Knockout Engineered T Cells
for Metastatic Non-small Cell Lung Cancer</td>
<td class="xl65" style="width: 215pt;" width="286">Metastatic Non-small Cell Lung
Cancer</td>
<td class="xl65" style="width: 223pt;" width="297">Drug: Cyclophosphamide , Other:
PD-1 Knockout T Cells</td>
<td class="xl65" style="width: 140pt;" width="187">Sichuan University , Chengdu
MedGenCell, Co., Ltd.</td>
<td class="xl65" style="width: 59pt;" width="79">Phase 1</td>
<td class="xl65" style="width: 59pt;" width="79">Other , Industry</td>
<td class="xl67" style="width: 114pt;" width="152"><a href="https://clinicaltrials.gov/show/NCT02793856">https://ClinicalTrials.gov/show/NCT02793856</a></td>
</tr>
<tr height="105" style="height: 78.75pt; mso-height-source: userset;">
<td class="xl65" height="105" style="height: 78.75pt; width: 60pt;" width="80">NCT03044743</td>
<td class="xl65" style="width: 275pt;" width="366">PD-1 Knockout EBV-CTLs for
Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies</td>
<td class="xl65" style="width: 215pt;" width="286">Stage IV Gastric Carcinoma ,
Stage IV Nasopharyngeal Carcinoma , T-Cell Lymphoma Stage IV , Stage IV Adult
Hodgkin Lymphoma , Stage IV Diffuse Large B-Cell Lymphoma</td>
<td class="xl65" style="width: 223pt;" width="297">Drug: Fludarabine , Drug:
Cyclophosphamide , Drug: Interleukin-2</td>
<td class="xl65" style="width: 140pt;" width="187">Yang Yang , The Affiliated
Nanjing Drum Tower Hospital of Nanjing University Medical School</td>
<td class="xl65" style="width: 59pt;" width="79">Phase 1 , Phase 2</td>
<td class="xl65" style="width: 59pt;" width="79">Other</td>
<td class="xl67" style="width: 114pt;" width="152"><a href="https://clinicaltrials.gov/show/NCT03044743">https://ClinicalTrials.gov/show/NCT03044743</a></td>
</tr>
<tr height="113" style="height: 84.75pt; mso-height-source: userset;">
<td class="xl65" height="113" style="height: 84.75pt; width: 60pt;" width="80">NCT03872479</td>
<td class="xl65" style="width: 275pt;" width="366">Single Ascending Dose Study in
Participants With LCA10</td>
<td class="xl65" style="width: 215pt;" width="286">Blindness , Leber Congenital
Amaurosis 10 , Vision Disorders , Eye Diseases , Eye Diseases, Hereditary ,
Eye Disorders Congenital , Retinal Disease , Retinal Degeneration</td>
<td class="xl65" style="width: 223pt;" width="297">Drug: AGN-151587</td>
<td class="xl65" style="width: 140pt;" width="187">Allergan , Editas Medicine, Inc.</td>
<td class="xl65" style="width: 59pt;" width="79">Phase 1 , Phase 2</td>
<td class="xl65" style="width: 59pt;" width="79">Industry</td>
<td class="xl67" style="width: 114pt;" width="152"><a href="https://clinicaltrials.gov/show/NCT03872479">https://ClinicalTrials.gov/show/NCT03872479</a></td>
</tr>
<tr height="142" style="height: 106.5pt; mso-height-source: userset;">
<td class="xl65" height="142" style="height: 106.5pt; width: 60pt;" width="80">NCT04122742</td>
<td class="xl65" style="width: 275pt;" width="366">Diagnosis of RSTS:
Identification of the Acetylation Profiles as Epigenetic Markers for
Assessing Causality of CREBBP Variants.</td>
<td class="xl65" style="width: 215pt;" width="286">Rubinstein-Taybi Syndrome</td>
<td class="xl65" style="width: 223pt;" width="297">Procedure: skin biopsy for the
primary fibroblast culture and a 15 ml blood sample (3 unnamed samples of
5ml) in each of the 4 SRT patients included. , Other: Generation of Induced
Pluripotent Stem Cells (iPSC) from fibroblasts obtained by skin biopsy , Other:
Histone acetylation profiles of cells of SRT patients with CREBBP mutations ,
Other: Functional involvement of identified epigenetic alterations ,
Biological: Culture of lymphoblastoid line from blood sample</td>
<td class="xl65" style="width: 140pt;" width="187">University Hospital, Bordeaux</td>
<td class="xl65" style="width: 59pt;" width="79"></td>
<td class="xl65" style="width: 59pt;" width="79">Other</td>
<td class="xl67" style="width: 114pt;" width="152"><a href="https://clinicaltrials.gov/show/NCT04122742">https://ClinicalTrials.gov/show/NCT04122742</a></td>
</tr>
<tr height="68" style="height: 51.0pt; mso-height-source: userset;">
<td class="xl65" height="68" style="height: 51.0pt; width: 60pt;" width="80">NCT02964481</td>
<td class="xl65" style="width: 275pt;" width="366">Malignant Hyperthermia Registry
and Genetic Testing</td>
<td class="xl65" style="width: 215pt;" width="286">Malignant Hyperthermia</td>
<td class="xl65" style="width: 223pt;" width="297"></td>
<td class="xl65" style="width: 140pt;" width="187">Children's Hospital Medical
Center, Cincinnati</td>
<td class="xl65" style="width: 59pt;" width="79"></td>
<td class="xl65" style="width: 59pt;" width="79">Other</td>
<td class="xl67" style="width: 114pt;" width="152"><a href="https://clinicaltrials.gov/show/NCT02964481">https://ClinicalTrials.gov/show/NCT02964481</a></td>
</tr>
</tbody></table>
<span style="color: red; mso-themecolor: dark2;"><span style="mso-spacerun: yes;"></span>Le ruego evalúe la presente entrada asignando un valor de 1 a 5, de peor a mejor valorada, usando la opción de comentarios
</span>JOSE Rhttp://www.blogger.com/profile/09318104344786439010noreply@blogger.com0tag:blogger.com,1999:blog-1952063008451683630.post-1284213837055723712019-12-10T15:21:00.000+01:002019-12-15T12:29:35.777+01:00Sobre los LVV y otras cosas<head><!-- Global site tag (gtag.js) - Google Analytics -->
<script async="" src="https://www.googletagmanager.com/gtag/js?id=UA-133555286-1"></script>
<script>
window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config', 'UA-133555286-1');
</script>
</head>
<br />
<br />
<br />
En estos meses de sequía en la emisión de Autorizaciones de comercialización por parte de la EMA, ya que <a href="https://degenetica.blogspot.com/2019/06/autorizado-un-nuevo-atmp-zynteglo.html">desde junio que se produjo la autorización de Zynteglo</a> la única novedad ha sido la <a href="https://degenetica.blogspot.com/2019/10/molmed-retira-la-autorizacion-de.html">retirada por parte de Molmed de Zalmoxis</a>, he intentado mejorar mi conocimiento de los vectores virales.<br />
En el artículo de F Delgado, 2011, <a href="https://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28-articulo-caracteristicas-virologicas-del-vih-S0213005X10004040">Características virológicas del VIH</a>, veo de la estructura génica del virus VIH-1. a partir del cual se han obtenido los vectores lentivirales.<br />
<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhtAXIi-JnyfICMnXbXxNN5y8-2rlozvt6MwG_1A_MPII7GTSg9TTozi0UrGT4AM4kGaJqgdBqqMnVjjQJSuFzm6IWxzJ1bCBj_U-_heSfZ6-oH6s66OFIsgf-5uoHBl0t2yj8e20802cML/s1600/Genes+VIH-1+Delgado+Fig+5.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="674" data-original-width="949" height="454" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhtAXIi-JnyfICMnXbXxNN5y8-2rlozvt6MwG_1A_MPII7GTSg9TTozi0UrGT4AM4kGaJqgdBqqMnVjjQJSuFzm6IWxzJ1bCBj_U-_heSfZ6-oH6s66OFIsgf-5uoHBl0t2yj8e20802cML/s640/Genes+VIH-1+Delgado+Fig+5.gif" width="640" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
Veo se la estructura del genoma del virus y lista de proteínas que a partir de él se generan<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEglaYUOgvO5Rwm0snK50Fng29AaUoKkU4_0_77LHbVuomdopJav7ghWfxJ6AmiOusA51qSjH_cbahAAY80gMIwLx05kZSDcn7Pedd_rCRyfgzaPvKWDbNGUSN0wuhr7q97vtSljJHwz1r2f/s1600/Genes+VIH-1.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="675" data-original-width="905" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEglaYUOgvO5Rwm0snK50Fng29AaUoKkU4_0_77LHbVuomdopJav7ghWfxJ6AmiOusA51qSjH_cbahAAY80gMIwLx05kZSDcn7Pedd_rCRyfgzaPvKWDbNGUSN0wuhr7q97vtSljJHwz1r2f/s1600/Genes+VIH-1.gif" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
En este artículo <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4779296/">Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the βA(T87Q)-Globin Gene </a> en la gráfica 3, veo la estructura del vector viral HPV569 b-globin a partir de la que se ha obtenido el vector BB305 utilizado por bluebird bio en la elaboración de Zynteglo.<br />
<br />
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhCe8-X9WjE8Syhi3D8DBu_cuLLkH6Qwlp4J5qW6cQWQL6HNfr2IxpgilUvWUyPLIjP0-lHhiCWOcF8hECb745l1eX6uNdb-z8u2xVi6tGpTndMpPMet4Lv2quSTmZGlMaVpy-fVzGKnJG7/s1600/Estructura+HPV569+LVV.gif" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" data-original-height="523" data-original-width="1080" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhCe8-X9WjE8Syhi3D8DBu_cuLLkH6Qwlp4J5qW6cQWQL6HNfr2IxpgilUvWUyPLIjP0-lHhiCWOcF8hECb745l1eX6uNdb-z8u2xVi6tGpTndMpPMet4Lv2quSTmZGlMaVpy-fVzGKnJG7/s1600/Estructura+HPV569+LVV.gif" /></a><br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
En <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568014/">A Guide to Approaching Regulatory Considerations for Lentiviral-Mediated Gene Therapies</a> en la Figura 2 veo el esquema de elaboración del vector<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
</div>
<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjndG2Rscnzt7hHYGsN8IgZ7F_8IXeBoR49W9gPOhZN6L7wtuP5YkmcrczbcgFCJSCiTl3T42BTxj2LfWXnPreO8yTVXo58mea2r4Ppwt36pZGmUP5HQzJPwoBZMm0Wy6E2WYQA0Z9u6CSa/s1600/Proceso+elaboracion+BB305.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="585" data-original-width="728" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjndG2Rscnzt7hHYGsN8IgZ7F_8IXeBoR49W9gPOhZN6L7wtuP5YkmcrczbcgFCJSCiTl3T42BTxj2LfWXnPreO8yTVXo58mea2r4Ppwt36pZGmUP5HQzJPwoBZMm0Wy6E2WYQA0Z9u6CSa/s1600/Proceso+elaboracion+BB305.gif" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: left;">
Y el esquema del vector para ser utilizado en la elaboración de diversas soluciones para modificación génica, similar al
de dos gráficas más arriba.
</div>
<div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;">
<span style="font-family: "times new roman" , serif; font-size: 12.0pt;"><o:p></o:p></span></div>
<br />
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhdncb3UZDaJVJhtbUnuylYkl8hm80ZlBkOxpsH6c2LQ85BZFvILXwqqbYZwk_NiNespWjxjRUasUoCLPbrBYsgaaS_vCyjpC3RonlRDFEjKMys1qWrp2gMdn40LTMsLUrqz7DMmYsoIMsm/s1600/BB305+en+White.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="375" data-original-width="708" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhdncb3UZDaJVJhtbUnuylYkl8hm80ZlBkOxpsH6c2LQ85BZFvILXwqqbYZwk_NiNespWjxjRUasUoCLPbrBYsgaaS_vCyjpC3RonlRDFEjKMys1qWrp2gMdn40LTMsLUrqz7DMmYsoIMsm/s1600/BB305+en+White.gif" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhdncb3UZDaJVJhtbUnuylYkl8hm80ZlBkOxpsH6c2LQ85BZFvILXwqqbYZwk_NiNespWjxjRUasUoCLPbrBYsgaaS_vCyjpC3RonlRDFEjKMys1qWrp2gMdn40LTMsLUrqz7DMmYsoIMsm/s1600/BB305+en+White.gif" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><br /></a><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhdncb3UZDaJVJhtbUnuylYkl8hm80ZlBkOxpsH6c2LQ85BZFvILXwqqbYZwk_NiNespWjxjRUasUoCLPbrBYsgaaS_vCyjpC3RonlRDFEjKMys1qWrp2gMdn40LTMsLUrqz7DMmYsoIMsm/s1600/BB305+en+White.gif" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><br /></a><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhdncb3UZDaJVJhtbUnuylYkl8hm80ZlBkOxpsH6c2LQ85BZFvILXwqqbYZwk_NiNespWjxjRUasUoCLPbrBYsgaaS_vCyjpC3RonlRDFEjKMys1qWrp2gMdn40LTMsLUrqz7DMmYsoIMsm/s1600/BB305+en+White.gif" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><br /></a><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhdncb3UZDaJVJhtbUnuylYkl8hm80ZlBkOxpsH6c2LQ85BZFvILXwqqbYZwk_NiNespWjxjRUasUoCLPbrBYsgaaS_vCyjpC3RonlRDFEjKMys1qWrp2gMdn40LTMsLUrqz7DMmYsoIMsm/s1600/BB305+en+White.gif" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><br /></a><br />
Me planteo ¿qué tecnología está siendo objeto de más investigación, el uso de LVV ó el de AAVV? Y le pregunto a Pubmed, restringido a humanos, ("lentiviral virus vector" 3911 resultados ; "adeno associated virus vector": 4336 resultados ). Obtengo los datos y elaboro la gráfica que viene a continuación que habla por sí sola: la investigación sobre AAVV comenzó antes, el uso de LVV lo ha superado en interés y en los últimos años ambas técnicas están siendo objeto de menor interés.<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgpVK3yhVUpcW4IA695BOrTGS9wRHBIpHz6Fc7u2U6nsvPHuBCskxgzl1kGM7IWpnkAGpujmZhDRv4dBlIg4jR9rofufSeOjOnf-zSVxeoKsVOkYc6tTwbn_E13yAlDGrXJxl_ZxiniKltf/s1600/LVV_AAVV_Humanos.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="467" data-original-width="754" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgpVK3yhVUpcW4IA695BOrTGS9wRHBIpHz6Fc7u2U6nsvPHuBCskxgzl1kGM7IWpnkAGpujmZhDRv4dBlIg4jR9rofufSeOjOnf-zSVxeoKsVOkYc6tTwbn_E13yAlDGrXJxl_ZxiniKltf/s1600/LVV_AAVV_Humanos.gif" /></a></div>
<br />
Teniendo claro que LVV y AAVV son técnicas para hacer llegar el ADN modificado al interior del núcleo celular y CRISPR Cas9 una herramienta de edición génica y por tanto dos herramientas distintas y complementarias. ¿puede ser el interés por CRISPR Cas9 la causa del menor interés en estas técnicas? Pregunto a Pubmed por CRISPR Cas9, en humanos, (4272 resultados) y genero esta nueva gráfica, que también habla por sí sola.<br />
<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh8mqNqm1B-GFWNjP2qlN5KHdW16U9o-cVhesX0xG9XIoUbRb6asc5ykypWBVgNmo2x-aUtgb1bNAV2c30Rs0Zz0jsamtGddgGrr7hKTtEDIAihD1sfW6KOaUZDICdWRWIcUdeZKtFpEj2Q/s1600/LVV_AAVV_CRISPR+Cas9_Humanos.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="467" data-original-width="754" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh8mqNqm1B-GFWNjP2qlN5KHdW16U9o-cVhesX0xG9XIoUbRb6asc5ykypWBVgNmo2x-aUtgb1bNAV2c30Rs0Zz0jsamtGddgGrr7hKTtEDIAihD1sfW6KOaUZDICdWRWIcUdeZKtFpEj2Q/s1600/LVV_AAVV_CRISPR+Cas9_Humanos.gif" /></a></div>
<br />
<div class="separator" style="clear: both; text-align: center;">
</div>
En las preguntas a Pubmed no se presenta datos de 2019 para comparar años completos. Posiblemente actualicemos la gráfica cuando finalice el año 2019.<br />
<br />
Si buscamos ensayos clínicos en los dos principales registros (EUDRA: clinicaltrialsregister.eu y clinicaltrials.gov) los resultados son:<br />
<br />
<br />
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 320px;">
<colgroup><col span="4" style="width: 60pt;" width="80"></col>
</colgroup><tbody>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt; width: 60pt;" width="80"></td>
<td style="width: 60pt;" width="80">AAVV</td>
<td style="width: 60pt;" width="80">LVV</td>
<td style="width: 60pt;" width="80">CRISPR</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;">EUDRACT</td>
<td align="right">26</td>
<td align="right">49</td>
<td align="right">0</td>
</tr>
<tr height="20" style="height: 15.0pt;">
<td height="20" style="height: 15.0pt;">CT.GOV</td>
<td align="right">46</td>
<td align="right">46</td>
<td align="right">31</td>
</tr>
</tbody></table>
<br />
<span style="color: red; mso-themecolor: dark2;"><span style="mso-spacerun: yes;"></span>Le ruego evalúe la presente entrada asignando un valor de 1 a 5, de peor a mejor valorada, usando la opción de comentarios
</span>JOSE Rhttp://www.blogger.com/profile/09318104344786439010noreply@blogger.com0tag:blogger.com,1999:blog-1952063008451683630.post-54387787147161473352019-12-06T04:53:00.000+01:002019-12-06T04:55:52.642+01:00PeriCord: incorporación del primer paciente a un ensayo clínico en Fase I.<head><!-- Global site tag (gtag.js) - Google Analytics -->
<script async="" src="https://www.googletagmanager.com/gtag/js?id=UA-133555286-1"></script>
<script>
window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config', 'UA-133555286-1');
</script>
</head>
Veo en diversa prensa profesional y generalista que en el Hospital Germans Trial i Pujol se ha comenzado a utilizar un nuevo medicamento (PeriCord) consistente en una lámina de pericardio con células de cordón umbilical para tratar el infarto de miocardio.<br />
<a href="http://www.germanstrias.org/noticias/175/a-team-at-germans-trias-treat-a-patient-with-a-new-bio-implant-to-repair-heart-tissue-after-a-heart-attack">Dice la web del Hospital Germans Trial i Pujol</a>: <i>Un equipo de Germans Trias trata el primer paciente con un nuevo bioimplante para reparar el tejido del corazón después de un infarto.</i><br />
En ningún lugar del texto se habla de que se trata de un ensayo clínico y se habla de la autorización de la AEMPS.<br />
Creo que estaría bien decir que se está hablando de la incorporación del primer paciente, allá por mayo de 2019, al<a href="http://reec.aemps.es/reec/estudio/2018-001964-49"> ensayo clínico, en Fase I, recogido en el Registro Español de Estudios clínicos ( REEC) con <b>Identificador</b> 2018-001964-49 y con <b>Código Protocolo</b> ICOR-2016-02.</a><br />
Consiste el producto en una lámina de pericardio humano descelularizado y enriquecido con células de cordón umbilical para tratar el infarto de miocardio, que nos recuerda a <a href="https://degenetica.blogspot.com/2018/06/maci-un-medicamento-que-fue-y-ya-no-es.html">MACI </a>en su estructura, aunque no en su indicación, claro. No es lo mismo un corazón que una rodilla.<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjLJ3b4E8yUGCiaUMXqWAWWJwIIzELpX6Eyo12Rch_zWAMI4sMnB5GT0ieQGJXcFFKhCK83NcIgb-zafYzlN6g2v_cxYBephOdujvYqUmPMDEBKCmeBSXoagS0lVxusf0vFJBgRqvrannSS/s1600/Pericord1.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="523" data-original-width="1013" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjLJ3b4E8yUGCiaUMXqWAWWJwIIzELpX6Eyo12Rch_zWAMI4sMnB5GT0ieQGJXcFFKhCK83NcIgb-zafYzlN6g2v_cxYBephOdujvYqUmPMDEBKCmeBSXoagS0lVxusf0vFJBgRqvrannSS/s1600/Pericord1.gif" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhnLRJM5XmVrrUf_O4ZVp47mkSr8c4J7GnM9G1Kr2TZo2NqJhznA162aubfKqeJRJnFDHqYRLpIeMxM71lzigokPDnfqPnn2u3rBz1CUqdWFZc83Kvsf1tqXf-0rkkCaVt61Wv2rfgdaNKM/s1600/Pericord21.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="545" data-original-width="871" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhnLRJM5XmVrrUf_O4ZVp47mkSr8c4J7GnM9G1Kr2TZo2NqJhznA162aubfKqeJRJnFDHqYRLpIeMxM71lzigokPDnfqPnn2u3rBz1CUqdWFZc83Kvsf1tqXf-0rkkCaVt61Wv2rfgdaNKM/s1600/Pericord21.gif" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgMdJt2GvfjKnqxp_x2EvfkwEoV5umCAQUtTtcD3vIdnVNkwFkYPFgIYLzByCpi-MDPThrGrAW7mosi4TRkwgaYTG9G0g_AZhF6ECI5J0-Lrgl0NbZ3xP-wnD_X6AhYUFVqVtzYwD0ORk5r/s1600/Pericord3.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="523" data-original-width="884" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgMdJt2GvfjKnqxp_x2EvfkwEoV5umCAQUtTtcD3vIdnVNkwFkYPFgIYLzByCpi-MDPThrGrAW7mosi4TRkwgaYTG9G0g_AZhF6ECI5J0-Lrgl0NbZ3xP-wnD_X6AhYUFVqVtzYwD0ORk5r/s1600/Pericord3.gif" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgvF0CPZWhpjUKWWJ53Q5_XusxNst41inRNlRtT3S33_MiEXTyuQiJHw0DOlC6GOBsxOGKi7-gjnZuKjWkpJU5HNEyePJu21zWd1ldVeNNzkgXRkU1NEaYf_Nj9b-kHPy2cqX9KI6rqmHw_/s1600/Pericord4.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="523" data-original-width="953" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgvF0CPZWhpjUKWWJ53Q5_XusxNst41inRNlRtT3S33_MiEXTyuQiJHw0DOlC6GOBsxOGKi7-gjnZuKjWkpJU5HNEyePJu21zWd1ldVeNNzkgXRkU1NEaYf_Nj9b-kHPy2cqX9KI6rqmHw_/s1600/Pericord4.gif" /></a></div>
<br />
<br />
<span style="color: red; mso-themecolor: dark2;"><span style="mso-spacerun: yes;"></span>Le ruego evalúe la presente entrada asignando un valor de 1 a 5, de peor a mejor valorada, usando la opción de comentarios
</span>JOSE Rhttp://www.blogger.com/profile/09318104344786439010noreply@blogger.com0tag:blogger.com,1999:blog-1952063008451683630.post-56987189013175191042019-11-30T16:39:00.000+01:002019-12-06T04:58:03.226+01:00Diario Médico entrega sus premios a las Mejores Ideas 2019<head><!-- Global site tag (gtag.js) - Google Analytics -->
<script async="" src="https://www.googletagmanager.com/gtag/js?id=UA-133555286-1"></script>
<script>
window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config', 'UA-133555286-1');
</script>
</head>
<br />
Médico ha concedido sus premios a las <a href="https://www.diariomedico.com/especiales/mejores-ideas/mejores-ideas-2019-todas-las-iniciativas-premiadas.html">Mejores Ideas 2019</a> , y como no podía ser de otra manera, varios de los premios recaen en
medicamentos o iniciativas de las que nos hemos ocupado en este blog. En concreto son dos medicamentos - Yescarta y Alofisel - y el MAPA DE COMUNIDADES de MEDICINA PERSONALIZADA DE PRECISIÓN del Instituto Roche.<br />
<div class="MsoNormal">
Yescarta son las
CART<span style="mso-spacerun: yes;"> </span>de Gilead/Kite que las<a href="https://degenetica.blogspot.com/2018/09/los-dos-car-t-ya-tienen-el-epar-de-la.html"> autorizo la
EMA</a><span style="mso-spacerun: yes;"><a href="https://degenetica.blogspot.com/2018/09/los-dos-car-t-ya-tienen-el-epar-de-la.html"> </a> </span>el mismo día que las CART<span style="mso-spacerun: yes;"> </span>de Novartis (Kymriah). Estructuralmente son
similares aunque diferentes, sus respectivas composiciones son:</div>
<div class="MsoNormal">
<b>Kymriah</b>: El CAR-T tiene una
cadena específica para el CD19, seguida de un codo y transmembrana CD8
que se fusiona con 4-1BB (CD137) y CD3<br />
<b>Yescarta</b>: que comprende un fragmento variable de cadena única (scFv) anti-CD19 murino unido a los dominios coestimuladores CD28 y CD3-zeta.</div>
<div class="MsoNormal">
</div>
<div class="MsoNormal">
Y sus indicaciones son:<br />
Las de Kymriah: </div>
<div class="MsoNormal">
<ul>
<li>Pacientes pediátricos y adultos menores de 25 años con Leucemia
Linfoblastica Aguda refractoria al tratamiento, en recaída post
trasplante o en segunda o posterior recaída.</li>
</ul>
<ul>
<li>Adultos con linfoma difuso
de celulas B grandes (DLBCL en inglés) después de dos ó más líneas de
tratamiento sistémico.</li>
</ul>
La de Yescarta:<br />
<br />
<br />
<ul>
<li>Adultos con linfoma difuso de celulas B grandes (DLBCL en inglés) después de dos ó más líneas de tratamiento sistémico</li>
</ul>
<br />
No sabemos por qué se premia a una y no a otra, pero
suponemos que alguna razón habrá.
</div>
<div class="MsoNormal">
<br />
El otro medicamento premiado es <b>Alofisel </b>denominado como "Primer fármaco desarrollado en España basado en células madre alogénicas" del que nos hemos ocupado específicamente en:<a href="https://degenetica.blogspot.com/2018/04/autorizado-un-producto-de-terapia.html">Autorizado un producto de terapia génica de origen español: Alofisel, </a> en abril de 2018 y en <a href="https://degenetica.blogspot.com/2019/10/acuerdo-de-la-comision-interministerial.html">Acuerdo de la COMISIÓN INTERMINISTERIAL DE PRECIOS DE LOS MEDICAMENTOS sobre Alofisel</a> en octubre de 2019. Este medicamento es propiedad de la japonesa Takeda a través de la adquisición de Tijenix, quien a su vez adquirió la inicialmente española Cellerix.</div>
<div class="MsoNormal">
<br />
Y el tercer asunto premiado por Diario Médico, del que nos ocupamos en este blog en abril de 2019 es el<a href="https://degenetica.blogspot.com/2019/04/mapa-de-comunidades-de-medicina.html">.MAPA DE COMUNIDADES de MEDICINA PERSONALIZADA DE PRECISIÓN del Instituto Roche.</a><br />
<br />
Enhorabuena a los premiados.<br />
<br />
<br /></div>
<span style="color: red; mso-themecolor: dark2;"><span style="mso-spacerun: yes;"></span>Le ruego evalúe la presente entrada asignando un valor de 1 a 5, de peor a mejor valorada, usando la opción de comentarios
</span>JOSE Rhttp://www.blogger.com/profile/09318104344786439010noreply@blogger.com0tag:blogger.com,1999:blog-1952063008451683630.post-66031819253426642532019-11-23T21:41:00.000+01:002019-11-23T22:03:09.508+01:00Damià Tormo, Columbus Venture Partners y otros<head><!-- Global site tag (gtag.js) - Google Analytics -->
<script async="" src="https://www.googletagmanager.com/gtag/js?id=UA-133555286-1"></script>
<script>
window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config', 'UA-133555286-1');
</script>
</head>
<br />
Estos días he sabido de la <a href="https://valenciaplaza.com/el-mundo-que-viene-el-futuro-de-la-salud">celebración en Valencia de una mesa redonda de emprendedores del ámbito biotech </a> patrocinada por <a href="https://hubempresa.bancsabadell.com/">Hub Empresa de Banco Sabadell</a> en el que ha participado un conocido de hace mucho tiempo, Frederic Llordachs, cofundador de Doctoralia. También han participado Ángela Pérez, CEO de Imegen, Óscar Lozano, CEO de Rithmi y un desconocido para mí, Damiá Tormo (DT)<br />
Respecto al curriculum de DT me remito a su perfil en <a href="https://www.linkedin.com/in/damiatormo/">Linkedin</a> y añado que su formación inicial es un grado en biología por la Universidad de Valencia y ha sido <a href="https://es.fpdgi.org/proyectos/premios-fpdgi/premiados/empresa/damia-tormo-carulla-premio-fundacion-princesa-de-girona-empresa-2017/">Premio Fundación Princesa de Girona Empresa 2017</a><br />
<a href="http://www.empresia.es/persona/tormo-carulla-damia/">DT es consejero de Columbus Venture Partners (CVP) y directivo, según Empresia.es </a> de:<br />
<br />
<div class="dashboard-item" style="background-color: white; border-left: 1px solid rgb(221, 221, 221); box-sizing: border-box; color: #555555; display: inline; float: left; font-family: "Open Sans", sans-serif; font-size: 14.44px; margin: 0px 5px 1.5em 0px; min-width: 20%; padding: 1em 0.75em 3em;">
<div class="title" style="box-sizing: border-box; color: #777777; font-size: 11.552px; text-transform: uppercase;">
CARGOS ACTIVOS</div>
<div class="data " id="divCargosActivos" style="box-sizing: border-box; font-family: "Open Sans", "Helvetica Neue", Helvetica, Arial, sans-serif; font-size: 43.32px; font-weight: bold; height: 20px; line-height: 1em;">
<span id="spanCargosActivos" style="box-sizing: border-box;"><a href="https://www.blogger.com/null" style="background-color: transparent; box-sizing: border-box; color: #2c61a7; text-decoration-line: underline;">11</a> <span aria-hidden="true" class="fa fa-question-circle" data-original-title="Nombramientos activos de Damia Tormo Carulla publicados en el BORME desde el 1 de Enero de 2009" data-placement="right" data-toggle="tooltip" style="box-sizing: border-box; display: inline-block; font-family: "fontawesome"; font-size: 36.822px; font-stretch: normal; font-weight: normal; line-height: 1;" title=""></span></span></div>
</div>
<div class="dashboard-item" style="background-color: white; border-left: 1px solid rgb(221, 221, 221); box-sizing: border-box; color: #555555; display: inline; float: left; font-family: "Open Sans", sans-serif; font-size: 14.44px; margin: 0px 5px 1.5em 0px; min-width: 20%; padding: 1em 0.75em 3em;">
<div class="title" style="box-sizing: border-box; color: #777777; font-size: 11.552px; text-transform: uppercase;">
CARGOS HISTÓRICOS</div>
<div class="data " id="divCargosInActivos" style="box-sizing: border-box; font-family: "Open Sans", "Helvetica Neue", Helvetica, Arial, sans-serif; font-size: 43.32px; font-weight: bold; height: 20px; line-height: 1em;">
<span id="spanCargosInActivos" style="box-sizing: border-box;"><a href="https://www.blogger.com/null" style="background-color: transparent; box-sizing: border-box; color: #2c61a7; text-decoration-line: underline;">5</a> <span aria-hidden="true" class="fa fa-question-circle" data-original-title="Cargos anteriores de Damia Tormo Carulla publicados en el BORME desde el 1 de Enero de 2009" data-placement="right" data-toggle="tooltip" style="box-sizing: border-box; display: inline-block; font-family: "fontawesome"; font-size: 36.822px; font-stretch: normal; font-weight: normal; line-height: 1;" title=""></span></span></div>
</div>
<div class="dashboard-item" style="background-color: white; border-left: 1px solid rgb(221, 221, 221); box-sizing: border-box; color: #555555; display: inline; float: left; font-family: "Open Sans", sans-serif; font-size: 14.44px; margin: 0px 5px 1.5em 0px; min-width: 20%; padding: 1em 0.75em 3em;">
<div class="title" style="box-sizing: border-box; color: #777777; font-size: 11.552px; text-transform: uppercase;">
TOTAL EMPRESAS</div>
<div class="data " id="divTotalEmpresas" style="box-sizing: border-box; font-family: "Open Sans", "Helvetica Neue", Helvetica, Arial, sans-serif; font-size: 43.32px; font-weight: bold; height: 20px; line-height: 1em;">
<span id="spanTotalEmpresas" style="box-sizing: border-box;"><a href="https://www.blogger.com/null" style="background-color: transparent; box-sizing: border-box; color: #2c61a7; text-decoration-line: underline;">9</a> <span aria-hidden="true" class="fa fa-question-circle" data-original-title="Total empresas en las que figura Damia Tormo Carulla" data-placement="right" data-toggle="tooltip" style="box-sizing: border-box; display: inline-block; font-family: "fontawesome"; font-size: 36.822px; font-stretch: normal; font-weight: normal; line-height: 1;" title=""></span></span></div>
</div>
<br />
<br />
<br />
<br />
<br />
<br />
<a href="https://www.cnmv.es/portal/Consultas/ECR/Gestora.aspx?nif=A87354007&vista=41&fs=22/11/2019">COLUMBUS VENTURE PARTNERS, SGEIC, S.A</a>. gestiona dos fondos, tal como puede verse, tanto en la propia web de la SGEIC, como en la CNMV:<br />
<ul>
<li>Columbus INNVIERTE Life Science </li>
<i>
Columbus lanzó su primer fondo en abril de 2016 (Columbus INNVIERTE Life Science, FCR) de 41M€, invertidos en 5 compañías: PTS, Radioterapia de Protones, Vivet Therapeutics, Aura Biosciences y Viralgen Vector Core.</i> (De la web de CVP)</ul>
<ul>
<li>Columbus Life Science Fund II,</li>
<i>
El fondo </i>(de 70M)<i> financiará hasta siete proyectos en terapias avanzadas con productos, plataformas o tecnologías disruptivas que abordan necesidades médicas no cubiertas. (De la web de CVP)</i><br />
<br />
Por su parte, en el portfolio actual de CVP hay 9 sociedades.</ul>
<table border="1" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 1303px;">
<colgroup><col style="mso-width-alt: 4278; mso-width-source: userset; width: 88pt;" width="117"></col>
<col style="mso-width-alt: 10422; mso-width-source: userset; width: 214pt;" width="285"></col>
<col style="mso-width-alt: 13787; mso-width-source: userset; width: 283pt;" width="377"></col>
<col style="mso-width-alt: 4169; mso-width-source: userset; width: 86pt;" width="114"></col>
<col style="mso-width-alt: 14994; mso-width-source: userset; width: 308pt;" width="410"></col>
</colgroup><tbody>
<tr height="20" style="height: 15.0pt;">
<td class="xl73" height="20" style="height: 15.0pt; width: 88pt;" width="117"><b>Sociedad</b></td>
<td class="xl73" style="width: 214pt;" width="285"><b>Objetivo</b></td>
<td class="xl73" style="width: 283pt;" width="377"><b>Producto/Pipeline</b></td>
<td class="xl73" style="width: 86pt;" width="114"><b>Sede/s</b></td>
<td class="xl73" style="width: 308pt;" width="410"><b>Partners</b></td>
</tr>
<tr height="40" style="height: 30.0pt;">
<td class="xl67" height="40" style="height: 30.0pt; width: 88pt;" width="117"><a href="http://www.viralgenvc.com/">Viralgen Viral Core</a></td>
<td class="xl68" style="width: 214pt;" width="285"> elaboracion de AAV´s </td>
<td class="xl68" style="width: 283pt;" width="377"></td>
<td class="xl68" style="width: 86pt;" width="114">S Sebastián</td>
<td class="xl68" style="width: 308pt;" width="410">AskBio, ColumbusVP</td>
</tr>
<tr height="69" style="height: 51.75pt; mso-height-source: userset;">
<td class="xl67" height="69" style="height: 51.75pt; width: 88pt;" width="117"><a href="http://www.bioncotech.com/">Bioncotech</a></td>
<td class="xl65" style="width: 214pt;" width="285"> <i>We develop cutting-edge
RNA-based therapies against validated and novel targets in cancer and immune
cells.</i></td>
<td class="xl66" style="width: 283pt;" width="377"> <i>BO-112, Bioncotech’s lead product, is a
synthetic dsRNA complex targeting cytosolic helicases MDA5 and RIG-I as well
as toll-like receptor TLR3. </i></td>
<td class="xl68" style="width: 86pt;" width="114">Valencia y Madrid</td>
<td class="xl68" style="width: 308pt;" width="410">ColumbusVP, Droia</td>
</tr>
<tr height="100" style="height: 75.0pt;">
<td class="xl67" height="100" style="height: 75.0pt; width: 88pt;" width="117"><a href="http://www.vivet-therapeutics.com/">Vivet Therapeutics</a></td>
<td class="xl69" style="width: 214pt;" width="285"><i>Vivet Therapeutics is committed
to developing an innovative liver-directed gene therapy platform for the
treatment of rare and severe inherited metabolic disorders</i></td>
<td class="xl71" style="width: 283pt;" width="377"><a href="https://www.vivet-therapeutics.com/en/pipeline">Pipeline</a></td>
<td class="xl68" style="width: 86pt;" width="114">Francia</td>
<td class="xl68" style="width: 308pt;" width="410">ColumbusVP, CIMA</td>
</tr>
<tr height="100" style="height: 75.0pt;">
<td class="xl67" height="100" style="height: 75.0pt; width: 88pt;" width="117"><a href="https://www.sanifit.com/">Sanifit</a></td>
<td class="xl68" style="width: 214pt;" width="285">treatments for calciphylaxis</td>
<td class="xl68" style="width: 283pt;" width="377">SNF472</td>
<td class="xl68" style="width: 86pt;" width="114">Palma y San Diego (CA)</td>
<td class="xl68" style="width: 308pt;" width="410">ColumbusVP, La Caixa Capital Risc, MGA Business
Consulting, Health Equity, Ysios Capital, Lundbeckfond Ventures, Forbion,
Gilde Healthcare, Edmond de Rothschild Investment Partners, Baxter Ventures,
Alta Life Sciences</td>
</tr>
<tr height="40" style="height: 30.0pt;">
<td class="xl67" height="40" style="height: 30.0pt; width: 88pt;" width="117"><a href="https://www.quironsalud.es/es/protonterapia">Centro de Protonterapia</a></td>
<td class="xl68" style="width: 214pt;" width="285">terapia de protones</td>
<td class="xl68" style="width: 283pt;" width="377"></td>
<td class="xl68" style="width: 86pt;" width="114">Madrid</td>
<td class="xl68" style="width: 308pt;" width="410">QuirónSalud, ColumbusVP</td>
</tr>
<tr height="80" style="height: 60.0pt;">
<td class="xl67" height="80" style="height: 60.0pt; width: 88pt;" width="117"><a href="http://www.aurabiosciences.com/">Aura Biosciences</a></td>
<td class="xl72" style="width: 214pt;" width="285">AU-011</td>
<td class="xl66" style="width: 283pt;" width="377"> <i>"first-in-class therapy for ocular
melanoma and other ocular cancers based on a novel viral nanoparticle
technology, with the potential to eliminate the tumor without harming
surrounding ocular tissue."</i></td>
<td class="xl68" style="width: 86pt;" width="114">Cambrige (MA) </td>
<td class="xl68" style="width: 308pt;" width="410">ColumbusVP</td>
</tr>
<tr height="86" style="height: 64.5pt; mso-height-source: userset;">
<td class="xl67" height="86" style="height: 64.5pt; width: 88pt;" width="117"><a href="https://pts-polypeptides.com/">Polypeptide therapeutic solutions</a></td>
<td class="xl70" style="width: 214pt;" width="285"><i>We bring a unique solution
offering well-defined functional architectures, accurate target polypeptide
chain length, narrow molecular weight distributions, batch-to-batch
reproducibility, scale-up to multi-kilogram production, analytical
development and cGMP quality.</i></td>
<td class="xl67" style="width: 283pt;" width="377"><a href="https://pts-polypeptides.com/solutions">Solutions</a></td>
<td class="xl68" style="width: 86pt;" width="114">Valencia</td>
<td class="xl68" style="width: 308pt;" width="410">ColumbusVP, Universidad Jaume I,
IIS La Fe, Cidetec, Isochem, Iris, Centro de Investigación Principe Felipe</td>
</tr>
<tr height="120" style="height: 90.0pt;">
<td class="xl67" height="120" style="height: 90.0pt; width: 88pt;" width="117"><a href="http://www.askbio.com/">Asklepio Biopharmaceuticals </a></td>
<td class="xl68" style="width: 214pt;" width="285">Elaborar terapias génicas
basadas en AAV´s</td>
<td class="xl67" style="width: 283pt;" width="377"><a href="https://www.askbio.com/product-pipeline/">Pipeline</a></td>
<td class="xl68" style="width: 86pt;" width="114">Duke (NC)</td>
<td class="xl68" style="width: 308pt;" width="410"> ALS Therapy Development Institute,
Nationwide Children’s Hospital, The Muscular Dystrophy Association,
Musculoskeletal Transplant Foundation, North Carolina Biotechnology Center,
North Carolina Board of Science & Technology, Parent Project Muscular
Dystrophy, and UNC Gene Therapy Centre.
ColumbusVP</td>
</tr>
<tr height="160" style="height: 120.0pt;">
<td class="xl68" height="160" style="height: 120.0pt; width: 88pt;" width="117">Touchlight
adeno Asociated Virus SL</td>
<td class="xl68" style="width: 214pt;" width="285">La producción de adn sintético
para uso terapéutico, incluyendo también entre otras actividades, la
investigación y desarrollo (i+d) en dicho ámbito biotecnológico, la
comercialización, la distribución, investigación, desarrollo, innovación,
consultoría, ingeniería, producción, fabricación, etc.,. (Empresia.es)</td>
<td class="xl68" style="width: 283pt;" width="377"></td>
<td class="xl68" style="width: 86pt;" width="114">S Sebastián</td>
<td class="xl68" style="width: 308pt;" width="410"></td>
</tr>
</tbody></table>
<span style="color: red; mso-themecolor: dark2;"><span style="mso-spacerun: yes;"></span>Le ruego evalúe la presente entrada asignando un valor de 1 a 5, de peor a mejor valorada, usando la opción de comentarios
</span>
JOSE Rhttp://www.blogger.com/profile/09318104344786439010noreply@blogger.com0tag:blogger.com,1999:blog-1952063008451683630.post-82072935211639678302019-10-29T16:11:00.000+01:002019-11-01T07:10:47.520+01:00Entrada 100 en degenetica.blogspot.com<head><!-- Global site tag (gtag.js) - Google Analytics -->
<script async="" src="https://www.googletagmanager.com/gtag/js?id=UA-133555286-1"></script>
<script>
window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config', 'UA-133555286-1');
</script>
</head>
<br />
Con motivo de la entrada 100, presento el listado de las 99 entradas
anteriores. Han
transcurrido 588 días desde la primera publicación, que son 84 semanas,
es decir salimos a más de una publicación por semana. Gracias por acompañarnos en este camino de descubrimientos fantásticos.<br />
<ul>
<li><a href="https://degenetica.blogspot.com/2018/02/que-quiere-ser-esto.html">¿Que quiere ser ésto?</a></li>
<li><a href="https://degenetica.blogspot.com/2018/02/quien-hace-genetica-humana-en-espana.html">¿Donde se hace genética humana en España?</a></li>
<li><a href="https://degenetica.blogspot.com/2018/02/que-hay-autorizado-de-terapia-genica.html">¿Qué hay autorizado de terapia génica?</a></li>
<li><a href="https://degenetica.blogspot.com/2018/03/que-es-el-uk-biobank.html">¿Qué es el UK BIOBANK?</a></li>
<li><a href="https://degenetica.blogspot.com/2018/03/los-car-t-1.html">Los CAR-T (1)</a></li>
<li><a href="https://degenetica.blogspot.com/2018/03/los-car-t-2.html">Los CAR-T (2)</a></li>
<li><a href="https://degenetica.blogspot.com/2018/03/que-es-un-gwas.html">¿Qué es un GWAS?</a></li>
<li><a href="https://degenetica.blogspot.com/2018/03/health-in-code.html">Health in Code</a></li>
<li><a href="https://degenetica.blogspot.com/2018/03/hoy-hace-un-ano.html">Hoy hace un año</a></li>
<li><a href="https://degenetica.blogspot.com/2018/03/embo-embl-ebi-emblem.html">EMBO, EMBL, EBI, EMBLEM</a></li>
<li><a href="https://degenetica.blogspot.com/2018/04/otro-autorizado-por-la-ema-strimvelis.html">Otro autorizado por la EMA: STRIMVELIS, producto y productores</a></li>
<li><a href="https://degenetica.blogspot.com/2018/04/siguiendo-con-los-autorizados-imlygic.html">Siguiendo con los autorizados: IMLYGIC</a></li>
<li><a href="https://degenetica.blogspot.com/2018/04/autorizados-si-pero-financiados.html">Autorizados sí, ¿pero financiados?</a></li>
<li><a href="https://degenetica.blogspot.com/2018/04/autorizado-un-producto-de-terapia.html">Autorizado un producto de terapia génica de origen español: Alofisel</a></li>
<li><a href="https://degenetica.blogspot.com/2018/04/biotech-espanol-segun-labiotecheu.html">Biotech español según Labiotech.eu</a></li>
<li><a href="https://degenetica.blogspot.com/2018/04/un-interesante-autorizado-por-la-fda.html">Un interesante autorizado por la FDA: LUXTURNA</a></li>
<li><a href="https://degenetica.blogspot.com/2018/05/los-virus-protagonistas-en-algunas.html">Los virus, protagonistas en algunas soluciones</a></li>
<li><a href="https://degenetica.blogspot.com/2018/05/visita-un-laboratorio-de-la-facultad-de.html">Visita a un laboratorio de la Facultad de Ciencias de la salud de la UJI.</a></li>
<li><a href="https://degenetica.blogspot.com/2018/05/actualidad-sobre-los-car-t-autorizados.html">Actualidad sobre los CAR-T autorizados por la FDA</a></li>
<li><a href="https://degenetica.blogspot.com/2018/05/zalmoxis-otro-italiano-autorizado-por.html">Zalmoxis, otro italiano autorizado por la EMA</a></li>
<li><a href="https://degenetica.blogspot.com/2018/05/de-las-car-t-en-la-eu.html">De las CAR-T en la EU</a></li>
<li><a href="https://degenetica.blogspot.com/2018/05/medicamentos-de-terapias-avanzadas.html">Medicamentos de terapias avanzadas vistos desde la normativa</a></li>
<li><a href="https://degenetica.blogspot.com/2018/06/sobre-molmed-spa.html">Sobre Molmed SpA</a></li>
<li><a href="https://degenetica.blogspot.com/2018/06/maci-un-medicamento-que-fue-y-ya-no-es.html">MACI: un medicamento que fue y ya no es.</a></li>
<li><a href="https://degenetica.blogspot.com/2018/06/clinical-trials-de-car-t-en-eudra.html">Clinical Trials de CAR-T en Eudra</a></li>
<li><a href="https://degenetica.blogspot.com/2018/06/sobre-holoclar.html">Sobre Holoclar</a></li>
<li><a href="https://degenetica.blogspot.com/2018/06/lo-mas-reciente-de-la-fda-andexxa-y.html">Lo más reciente de la FDA: ANDEXXA y Plasma Cryoprecipitate (For Further Manufacturing Use)</a></li>
<li><a href="https://degenetica.blogspot.com/2018/06/la-vacuna-rtssas01-contra-la-malaria.html">La vacuna RTS,S/AS01 contra la malaria.</a></li>
<li><a href="https://degenetica.blogspot.com/2018/06/informe-favorable-de-ema-kymriah-y.html">Informe favorable de EMA a Kymriah y Yescarta a través de PRIME</a></li>
<li><a href="https://degenetica.blogspot.com/2018/07/actividades-sociales-entorno-los.html">Actividades "sociales" entorno a los Medicamentos de Terapias Avanzadas y Edición Génica.</a></li>
<li><a href="https://degenetica.blogspot.com/2018/07/importancia-de-car-t-en-asco-y-pubmed.html">Importancia de CAR-T en ASCO y PUBMED</a></li>
<li><a href="https://degenetica.blogspot.com/2018/07/los-clinical-trials-de-kite-gilead_9.html">Los Clinical Trials de Kite-Gilead sobre los CAR-T de las CD19</a></li>
<li><a href="https://degenetica.blogspot.com/2018/07/ucart-no-estan-autorizadas-pero-estan.html">UCART: no están autorizadas pero están en ello</a></li>
<li><a href="https://degenetica.blogspot.com/2018/07/resultados-economicos-de-los-cart-en.html">Resultados económicos de los CART en 2018</a></li>
<li><a href="https://degenetica.blogspot.com/2018/08/resultados-del-primer-semestre-de-2018.html">Resultados del primer semestre de 2018 de MolMed</a></li>
<li><a href="https://degenetica.blogspot.com/2018/09/el-nice-ingles-y-kymriah.html">El NICE inglés y Yescarta. </a></li>
<li><a href="https://degenetica.blogspot.com/2018/09/dice-novartis-tener-la-autorizacion-de.html">Dice Novartis tener la autorización de la EC para Kymriah</a></li>
<li><a href="https://degenetica.blogspot.com/2018/09/los-dos-car-t-ya-tienen-el-epar-de-la.html">Los dos CAR-T ya tienen el EPAR de la EMA</a></li>
<li><a href="https://degenetica.blogspot.com/2018/09/charla-en-la-uji.html">Charla en la UJI sobre ATMP´s autorizados por la EMA</a></li>
<li><a href="https://degenetica.blogspot.com/2018/10/anticuerpos-monoclonales-mab_59.html">Anticuerpos monoclonales (mAB) autorizados por la EMA (1)</a></li>
<li><a href="https://degenetica.blogspot.com/2018/10/anticuerpos-monoclonales-mab_15.html">Anticuerpos monoclonales (mAB) autorizados por la EMA (2)</a></li>
<li><a href="https://degenetica.blogspot.com/2018/10/human-cell-atlas-otra-tarea-colosal.html">Human Cell Atlas: otra tarea colosal</a></li>
<li><a href="https://degenetica.blogspot.com/2018/10/r-de-gsk-hacia-donde-van.html">R&D de GSK: ¿hacia donde van?</a></li>
<li><a href="https://degenetica.blogspot.com/2018/11/unos-apuntes-sobre-23andme.html">Unos apuntes sobre 23andme</a></li>
<li><a href="https://degenetica.blogspot.com/2018/11/cuantas-celulas-constituyen-la-vida-de.html">¿Cuantas células constituyen la vida de una persona?</a></li>
<li><a href="https://degenetica.blogspot.com/2018/11/quien-donde-y-en-que-se-investiga-en.html">¿Quién, donde y en qué se investiga en España en ATMP´s?</a></li>
<li><a href="https://degenetica.blogspot.com/2018/11/normativa-de-omgs.html">Normativa de OMG´s</a></li>
<li><a href="https://degenetica.blogspot.com/2018/12/allen-institute-for-cell-science-otra.html">Allen Institute for Cell Science, otra iniciativa de base celular a seguir.</a></li>
<li><a href="https://degenetica.blogspot.com/2018/12/los-ensayos-clinicos-con-ipsc-en.html">Los ensayos clínicos con iPSC en enfermos.</a></li>
<li><a href="https://degenetica.blogspot.com/2018/12/una-entrada-diferente-una-interesante.html">Una entrada diferente: una interesante comida</a></li>
<li><a href="https://degenetica.blogspot.com/2018/12/los-car-t-en-el-sistema-nacional-de.html">Los CAR-T en el Sistema Nacional de Salud español.</a></li>
<li><a href="https://degenetica.blogspot.com/2018/12/notificaciones-de-liberacion-de-omgs.html">Notificaciones de liberación de OMG´s por institución</a></li>
<li><a href="https://degenetica.blogspot.com/2018/12/cosas-resolver-por-el-2019.html">Cosas a resolver por el 2019</a></li>
<li><a href="https://degenetica.blogspot.com/2019/01/ponencia-de-estudio-sobre-genomica.html">Ponencia de estudio sobre genómica, constituida en el seno de la Comisión de Sanidad, Consumo y Bienestar Social, del Senado, conclusiones en pocas semanas.</a></li>
<li><a href="https://degenetica.blogspot.com/2019/01/recomendaciones-para-una-estrategia.html">Recomendaciones para una Estrategia Estatal de Medicina Personalizada de Precisión del Instituto Roche</a></li>
<li><a href="https://degenetica.blogspot.com/2019/01/la-ema-emite-la-epar-de-luxturna.html">La EMA emite la EPAR de Luxturna (Voretigén neparvovec)</a></li>
<li><a href="https://degenetica.blogspot.com/2019/01/resumen-de-atmps-autorizados-por-la-ema.html">Resumen de ATMP´s autorizados por la EMA</a></li>
<li><a href="https://degenetica.blogspot.com/2019/01/sobre-provenge-un-atmp-retirado-por-el.html">Sobre Provenge, un ATMP retirado por el titular</a></li>
<li><a href="https://degenetica.blogspot.com/2019/02/paneles-de-miocardiopatia-hipertrofica.html">Paneles de miocardiopatía hipertrófica</a></li>
<li><a href="https://degenetica.blogspot.com/2019/02/despliegue-informativo-en-diario-medico.html">Despliegue informativo en Diario Medico sobre las CAR-T</a></li>
<li><a href="https://degenetica.blogspot.com/2019/02/onpattro-patisiran-y-tegsedi-inotersen.html">Onpattro (Patisiran) y Tegsedi (Inotersen): dos NO ATMP´s aunque pudieran parecerlo</a></li>
<li><a href="https://degenetica.blogspot.com/2019/02/publicado-en-el-boletin-de-las-cortes.html">Publicado en el Boletín Oficial de las Cortes Generales el Informe de la Ponencia sob</a></li>
<li><a href="https://degenetica.blogspot.com/2019/02/primer-anivesario-de.html">Primer aniversario de degenetica.blogpspot.com</a></li>
<li><a href="https://degenetica.blogspot.com/2019/02/sobre-tegsedi-inotersen-y-su.html">Sobre Tegsedi (Inotersén) y su autorización por la EMA</a></li>
<li><a href="https://degenetica.blogspot.com/2019/03/ya-hay-varios-hospitales-para.html">Ya hay varios hospitales para administrar las CAR-T en España</a></li>
<li><a href="https://degenetica.blogspot.com/2019/03/spinraza-nusinersen-el-primer-aso-de-la.html">Spinraza (Nusinersen) fue el primer ASO de la EMA</a></li>
<li><a href="https://degenetica.blogspot.com/2019/03/zolgensma-de-novartis-posible-para-mayo.html">Zolgensma, de Novartis, posible para mayo en la FDA</a></li>
<li><a href="https://degenetica.blogspot.com/2019/03/actualizacion-de-los-ermas-del-miteco.html">Actualizacion de los ERMA´s del MITECO.</a></li>
<li><a href="https://degenetica.blogspot.com/2019/03/segundo-aniversario-del-fallecimiento.html">Segundo aniversario del fallecimiento de Guillermo Negre (Peñeta)</a></li>
<li><a href="https://degenetica.blogspot.com/2019/03/las-retinopatias-hereditarias-y-las.html">Las Retinopatias Hereditarias y las soluciones: Luxturna y EDIT-101/AGN-151587</a></li>
<li><a href="https://degenetica.blogspot.com/2019/03/un-proximo-nuevo-atmp-zynteglo.html">Un próximo nuevo ATMP: Zynteglo</a></li>
<li><a href="https://degenetica.blogspot.com/2019/04/de-las-cart-academicas-en-barcelona.html">De las CART académicas en Barcelona</a></li>
<li><a href="https://degenetica.blogspot.com/2019/04/mapa-de-comunidades-de-medicina.html">MAPA DE COMUNIDADES de MEDICINA PERSONALIZADA DE PRECISIÓN del Instituto Roche</a></li>
<li><a href="https://degenetica.blogspot.com/2019/04/nc1-terapia-celular-academica-del.html">NC1: terapia celular "académica" del Hospital Universitario Puerta de Hierro Majadahonda</a></li>
<li><a href="https://degenetica.blogspot.com/2019/04/que-es-de-la-ucart-de-allogene.html">¿Qué es de las UCART de Allogene Therapeutics?</a></li>
<li><a href="https://degenetica.blogspot.com/2019/05/resultados-kymria-y-yescarta-q1-2019.html">Resultados económicos de Kymria y Yescarta Q1 2019</a></li>
<li><a href="https://degenetica.blogspot.com/2019/05/designados-por-el-ministerio-de-sanidad.html">Designados por el Ministerio de Sanidad los hospitales para las CAR-T</a></li>
<li><a href="https://degenetica.blogspot.com/2019/05/celulas-hc016-de-histocell-para-lesion.html">Células HC016 de Histocell para Lesión medular aguda</a></li>
<li><a href="https://degenetica.blogspot.com/2019/05/informe-final-de-icer-sobre-zolgensma.html">Informe final de ICER sobre Zolgensma</a></li>
<li><a href="https://degenetica.blogspot.com/2019/05/aprobado-zolgensma-por-la-fda-su-precio.html">Aprobado Zolgensma por la FDA. Su precio USD 2.1M </a></li>
<li><a href="https://degenetica.blogspot.com/2019/06/high-specialised-tecnologies-hst-of.html">High Specialised Tecnologies (HST) of National Institute for Health and Care Excelence (NICE)</a></li>
<li><a href="https://degenetica.blogspot.com/2019/06/autorizado-un-nuevo-atmp-zynteglo.html">Autorizado un nuevo ATMP: ZYNTEGLO</a></li>
<li><a href="https://degenetica.blogspot.com/2019/06/actualizacion-datos-atmps-junio-de-2019.html">Actualización datos ATMP´s a Junio de 2019</a></li>
<li><a href="https://degenetica.blogspot.com/2019/06/actualizacion-de-la-informacion-sobre.html">Actualización de la información sobre Evaluaciones de Riesgo Medioambiental del Ministerio de transición ecológica</a></li>
<li><a href="https://degenetica.blogspot.com/2019/06/de-los-virus-en-los-atmps-y-la.html">De los virus en los ATMP´S y la clasificación de estos en la EMA, FDA y ARM</a></li>
<li><a href="https://degenetica.blogspot.com/2019/07/de-los-avances-en-financiacion-de-los.html">De los avances en financiación de los ATMP´s autorizados</a></li>
<li><a href="https://degenetica.blogspot.com/2019/07/clasificacion-topografica-de-los-atmps.html">Clasificación topográfica de las indicaciones de los ATMP´s</a></li>
<li><a href="https://degenetica.blogspot.com/2019/07/abundante-e-interesante-literatura.html">Abundante e interesante literatura sobre ATMP´s</a></li>
<li><a href="https://degenetica.blogspot.com/2019/09/el-nice-dara-en-breve-el-ok-luxturna.html">El NICE dará en breve el OK a Luxturna</a></li>
<li><a href="https://degenetica.blogspot.com/2019/09/patriotismo-de-posibles-medicamentos.html">Patriotismo de posibles medicamentos: Omomyc y VTX-801</a></li>
<li><a href="https://degenetica.blogspot.com/2019/09/informacion-sobre-car-ts-en-la-web-del.html">Información sobre CAR-T´s en la web del Ministerio de Sanidad, Consumo y Bienestar Social (MSCBS)</a></li>
<li><a href="https://degenetica.blogspot.com/2019/09/de-nuevo-charla-en-la-universidad-jaime.html">De nuevo charla en la Universidad Jaime I (UJI) sobre ATMP´s autorizados por la EMA.</a></li>
<li><a href="https://degenetica.blogspot.com/2019/09/the-centers-for-medicare-medicaid.html">The Centers for Medicare & Medicaid Services (CMS) establecen la cobertura sobre las CAR-T</a>
<a href="https://degenetica.blogspot.com/2019/09/cigna-asume-el-pago-de-luxturna-y.html">Cigna asume el pago de Luxturna y Zolgensma</a></li>
<li><a href="https://degenetica.blogspot.com/2019/10/patentes-y-biotecnologia.html">Patentes y biotecnologia en CAR-T`s</a></li>
<li><a href="https://degenetica.blogspot.com/2019/10/molmed-retira-la-autorizacion-de.html">Molmed retira la autorización de Zalmoxis</a></li>
<li><a href="https://degenetica.blogspot.com/2019/10/el-consejo-interterritorial-y-el-nc1.html">El Consejo Interterritorial y el NC1 del Hospital Puerta de Hierro</a>
<a href="https://degenetica.blogspot.com/2019/10/acuerdo-de-la-comision-interministerial.html">A</a></li>
<li><a href="https://degenetica.blogspot.com/2019/10/acuerdo-de-la-comision-interministerial.html">Acuerdo de la COMISIÓN INTERMINISTERIAL DE PRECIOS DE LOS MEDICAMENTOS sobre Alofisel</a></li>
<li><a href="https://degenetica.blogspot.com/2019/10/resultados-economicos-de-las-cart-hasta.html">Resultados económicos de las CART hasta Q3 del 2019, y sobre Zolgensma y sus circunstancias.</a></li>
</ul>
<br />
<span style="color: red;">Le ruego evalúe la presente entrada asignando un valor de 1 a 5, de peor a mejor valorada, usando la opción de comentarios</span>JOSE Rhttp://www.blogger.com/profile/09318104344786439010noreply@blogger.com0tag:blogger.com,1999:blog-1952063008451683630.post-73118144572151318972019-10-26T21:43:00.000+02:002019-10-26T21:43:07.922+02:00Resultados económicos de las CART hasta Q3 del 2019, y sobre Zolgensma y sus circunstancias.Actualizamos los datos de resultados económicos de Novartis y Kite/Gilead para sus respectivos CART: KYMRIAH y YESCARTA obtenidos de las páginas web de las empresas.<br />
<br />
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 680px;"><colgroup><col span="5" style="width: 64pt;" width="85"></col><col span="3" style="width: 64pt;" width="85"></col></colgroup><tbody>
<tr height="20" style="height: 15pt;"><td class="xl65" colspan="6" height="20" style="height: 15pt; width: 384pt;" width="510"><b>Datos de ingresos generados por los CART autorizados (millones de dólares)</b></td><td class="xl65" style="width: 64pt;" width="85"></td><td class="xl65" style="width: 64pt;" width="85"></td></tr>
<tr height="20" style="height: 15pt;"><td class="xl65" height="20" style="height: 15pt;"></td><td class="xl65">2018</td><td class="xl65"></td><td class="xl65"></td><td class="xl65"></td><td class="xl65">2019</td><td class="xl65"></td><td class="xl65"></td></tr>
<tr height="20" style="height: 15pt;"><td class="xl65" height="20" style="height: 15pt;"></td><td class="xl65">Q1</td><td class="xl65">Q2</td><td class="xl65">Q3</td><td class="xl65">Q4</td><td class="xl65">Q1</td><td class="xl65">Q2</td><td class="xl65">Q3</td></tr>
<tr height="20" style="height: 15pt;"><td class="xl65" height="20" style="height: 15pt;">Kymriah</td><td class="xl66"><a href="https://labiotech.eu/medical/kymriah-car-t-therapy-novartis-sales/">12</a></td><td class="xl66"><a href="https://www.novartis.com/sites/www.novartis.com/files/q2-2018-ir-presentation.pdf">16</a></td><td class="xl66"><a href="https://www.novartis.com/news/media-releases/novartis-delivered-strong-growth-and-innovation-during-third-quarter-including-progressing-advanced-therapy-platforms-drive-future-growth">20</a></td><td class="xl66"><a href="https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2018-en.pdf">28</a></td><td class="xl66"><a href="https://www.novartis.com/sites/www.novartis.com/files/q1-2019-media-release-en.pdf">45</a></td><td class="xl66"><a href="https://www.novartis.com/sites/www.novartis.com/files/q2-2019-media-release-en.pdf">58</a></td><td class="xl66"><a href="https://www.novartis.com/sites/www.novartis.com/files/q3-2019-media-release-en.pdf">79</a></td></tr>
<tr height="20" style="height: 15pt;"><td class="xl65" height="20" style="height: 15pt;">Yescarta</td><td class="xl66"><a href="http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=2346042">40</a></td><td class="xl66"><a href="http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=2359992">68</a></td><td class="xl66"><a href="http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=2373553">75</a></td><td class="xl66"><a href="http://investors.gilead.com/news-releases/news-release-details/gilead-sciences-announces-fourth-quarter-and-full-year-2018">81</a></td><td class="xl66"><a href="http://investors.gilead.com/static-files/ead8235f-ab4e-4d0e-b354-453b3d6820a2">96</a></td><td class="xl66"><a href="http://investors.gilead.com/news-releases/news-release-details/gilead-sciences-announces-second-quarter-2019-financial-results">120</a></td><td class="xl66"><a href="http://investors.gilead.com/news-releases/news-release-details/gilead-sciences-announces-third-quarter-2019-financial-results">118</a></td></tr>
</tbody></table>
<br />
Yescarta sigue superando a Kymriah, pero ha disminuido respecto del anterior trimestre.<br />
<br />
Sobre la actividad de aplicación de CART´s en España,<a href="https://www.redaccionmedica.com/secciones/hematologia-y-hemoterapia/ramon-garcia-sanz-ocho-centros-cart-para-todo-el-pais-son-insuficientes--4935"> en una entrevista a Ramón García Sanz, nuevo Presidente de la SEHH:</a><br />
"Obviamente, los ocho centros que hay ahora mismo para todo el país se está viendo que son insuficientes. En este momento ya hay varios centros que están haciendo un CART por semana, lo que puede empezar a exceder de la capacidad de los distintos centros. Esto hace que sean muy probable que necesitemos más en el futuro."<br />
<br />
Con respecto a Zolgensma de Novartis, que no está aún autorizada por la EMA y se prevé su autorización en el primer trimestre de 2020, la FDA lo autorizó el 24 de mayo de 2019 y el día 22 de octubre el laboratorio ha presentado <a href="https://www.novartis.com/sites/www.novartis.com/files/q3-2019-media-release-en.pdf">resultados de las ventas del grupo</a> y entre muchos datos los específicos de las ventas de Zolgensma.<br />
<br />
<i>Zolgensma sales of USD 160 million, strong launch including broad access
</i><br />
<a href="https://www.fiercepharma.com/pharma/novartis-zolgensma-beats-data-woe-payer-resistance-strong-and-high-interest-ceo">Parece ser que las expectativas del mercado eran inferiores a los resultados obtenidos en unos días de mayo y junio.</a><br />
<i><br /></i>
Desde su aprobación en mayo diversas malas noticias sobre el producto se han venido produciendo:<br />
-fallecimiento de un paciente en un ensayo clínico que la empresa ha dicho no tiene que ver con el tratamiento sin con la evolución de la propia enfermedad.<br />
- un asunto de posible falsificación de datos sobre la evaluación de un ratón en un estudio que ha llevado a la expulsión de dos directivos de la AveXis, la empresa que Novartis compró inicial fabricante del medicamento.<br />
<br />
La empresa aporta datos de posibles nuevas indicaciones:<br />
<i> Zolgensma new data were presented at EPNS continuing to show significant therapeutic benefit in
prolonging event-free survival now up to 5 years of age in patients with SMA type I. Data from the
STRONG trial in SMA type II patients was presented at WMS showing a mean increase of 5.9 points
from baseline in HFMSE scores in patients 2 to 5 years of age following treatment with AVXS-101 IT,
nearly double the clinically meaningful threshold. </i><br />
<br />
<br />JOSE Rhttp://www.blogger.com/profile/09318104344786439010noreply@blogger.com0